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ABSTRACT
Genetic mapping, positional cloning and reverse genetics provide an alternative to 
the biochemical and molecular approaches used to date, to determine the basis of 
arsenical resistance in Trypanosoma brucei. Genetic mapping of loci determining 
phenotypes of relevance to diseases has proved to be a powerful approach in a 
number of organisms including humans and Plasmodium falciparum, particularly 
when coupled with a full genome sequence. In this thesis, this approach has been 
established in T brucei by determining the genetic basis of naturally occurring 
arsenical resistance and undertaking linkage analysis using our recently developed 
genetic map.
I adapted a simple, verified screening assay for assessing drug sensitivity based on 
the use of AlamarBlue. Three stocks used as parents in genetic crosses differed in 
drug sensitivity; STIB 247-8ensitive, STIB 386-Resistant and TREU 927-Resistant. 
Genetic linkage analysis using 101 polymorphic markers identified from the 
extensive sequence available from the genome project was then used to examine 
inheritance of the drug resistance phenotype in T. brucei. From this, the co- 
segregation (into FI progeny) of markers and the resistance phenotype was 
determined using crosses, 247 x 386 and 247 x 927. Inheritance of resistance in 
both crosses was compatible with a simple single locus genetic model with one 
dominant allele determining resistance. Linkage analysis showed that the locus 
conferring resistance lay within an -25 kilobase region on Chromosome II, which 
contains 6 open reading frames (ORFs).
A reverse genetic approach was then used to disrupt alleles for each of the six 
ORFs in turn. An allele of one gene, Tb927.2.2380, was shown to determine 
resistance and this was confirmed by transfecting the resistance allele into a drug 
sensitive stock to generate an arsenical resistant line. This gene also determines 
cross-resistance to the major veterinary trypanocide, diminazene aceturate and has 
been named the arsenical and diamidine (ard) resistance gene.
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Chapter 1 General Introduction
CHAPTER 1 
GENERAL INTRODUCTION
1.1 TRYPANOSOMES
The family Trypanosomatidae contain important pathogens of humans and domestic 
animais. The diseases caused by these protozoa are endemic or enzootic in different 
areas of the world and are responsible for serious medical and economic problems. 
Trypanosomatids are unicellular obligate parasites found in a wide variety of 
invertebrate and vertebrate hosts in nature. A number of these flagellates have 
monogenetic (one host) life cycles, but most of the notorious members of the family are 
the digenetic (two host) species responsible for the vector borne diseases including 
leishmaniasis and trypanosomiasis, which affect humans and domestic livestock in the 
tropical and sub-tropical areas of the world (Gibson and Stevens, 1999).
There are many species of Trypanosoma that live in their host without causing any 
disease, however there are a number of species that represent a disease complex, 
commonly referred to as trypanosomiasis. Those which cause most concern to man are 
the tsetse transmitted trypanosomes of Sub-Saharan Africa and the reduviid transmitted 
trypanosomes of South America. Chagas’ disease caused by Trypanosoma cruzi 
occurs throughout Latin America and in terms of human infectivity it is by far the most 
important species, causing disease in approximately 20 million people annually in 
Central and South America. In contrast, African trypanosome infection in humans is 
markedly lower. Although there is an estimated 60 million people living in 300 disease
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foci in Africa that are at risk to infection, about 500,000 individuals are infected each 
year, with approximately 50,000 deaths (Barrett et a/., 2003).
The range of African trypanosomiasis is restricted by the distribution of its tsetse fly 
vector (Glossina spp) and of its animal reservoirs. The tsetse fly vector infests 11 million 
km  ^ south of the Sahara, transmitting trypanosomes to livestock, causing the disease 
"Nagana”; and to humans, causing sleeping sickness. Nagana is a result of infection 
from the species T. brucei, T. congolense and T. vivax. Wildlife including warthog, 
buffalo and bush pig are the natural hosts of these parasites. Most wildlife species and 
some indigenous livestock breeds can tolerate infection without major adverse 
consequences and some even recover spontaneously without any treatment. Fly 
infection rates vary but are generally around 10-15% for T. congolense and T. vivax but 
much lower for T. bnicei. Once a tsetse becomes infected, it remains infective for the 
rest of its life. Tsetse flies inhabit a broad range of habitats from the semi-arid margins 
of the Sahel, through tropical rainforests to the sub-tropical savannas of S.Africa. 
Twenty two species and various sub-species of tsetse are recognised and these are 
divided into three groups: (1) Forest tsetse- fusca group, (2) Riverine tsetse- palpalls 
group and (3) Savanna tsetse- morsltans group (Bourn et a/., 2001). Animal 
trypanosomiasis has a detrimental effect on the African economy and, as a 
consequence, indirectly on the population. Animals kept in areas of moderate risk have 
lower calving rates, lower milk yields and higher rates of calf mortality. In tsetse-infested 
areas trypanosomiasis can reduce the offtake of meat and milk by at least 50% 
(Swallow, 2000).
Chapter 1 General Introduction
Human sleeping sickness is a result of infection by subspecies of T. brucei termed T. b. 
rhodesiense and T. b. gambiense. The former causes an acute illness in East Africa 
and the latter causes a chronic illness predominantly found in West and Central Africa. 
T. b. brucei is identical morphologically and biologically to these two subspecies in 
every aspect of its life cycle differing only in that Infection is not transmissible to humans 
(Tait, 2000). Two further trypanosome species deserve mention, which are pathogenic 
to livestock and both are closely related to T. brucei but are not transmitted by tsetse 
flies. T. equiperdum is transmitted venereally between horses and T. evansi, which is 
transmitted by tabaniid flies (Tait, 2000).
The mode of transmission from the insect vector to the new host has been used to 
subdivide the genus into two groups: the Salivaria and Stercoraria. The difference 
between the two groups is defined in terms of the mode of transmission with the former 
occurring via the saliva of the insect and in the latter via the faeces. T. cruzi is a 
member of the stercoraria, the metacyclic stage being expelled with the faeces when 
the reduviid bug takes a blood meal, thereby gaining entry to the mammalian host by 
contamination of the bite site (Vickerman, 1985). A wider range of trypanosomes belong 
to the Salivaria group, T. b. rhodesiense, T. b. gambiense, T. vivax and T. congolense, 
where transmission occurs when the insect vector bites the host and discharges saliva 
containing metacyclics into the wound (Tait, 2000).
Within the tsetse fly, development of the trypanosome varies substantially between the 
three Salivarian species. In T. congolense development occurs in the midgut of the
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tsetse, and then in to the mouths parts. In T. brucei, development In the midgut is 
followed by development in the salivary glands, while development of T. vivax occurs 
solely in the fly's proboscis (Vickerman et a!., 1991). In this study the emphasis will be 
on T. brucei.
1.2 GEOGRAPHICAL DISTRIBUTION
The distribution of sleeping sickness occurs in endemic foci. The parasites also infect 
wild and domestic animals that serve as reservoir hosts. For example, T. b. gambiense 
is common in pigs and T. b. rhodesiense is found in cattle and game. The current 
epidemics of the disease are caused by T. b. gambiense, in countries ranging from 
southern Sudan, northem Uganda, the Democratic Republic of Congo, Congo, Central 
African Republic and Angola (Fig 1.1). The severity of many of these epidemics has 
been heightened by the fact that due to political instability there has been a breakdown 
in primary health care. Trypanosomiasis is endemic in 36 of the 52 African countries. 
Approximately half a million people carry the disease today and in some villages 50% of 
the inhabitants are infected. The WHO has reported that deaths due to sleeping 
sickness in two provinces of the Democratic Republic of Congo at least equal those of 
AIDS (Masiga and Barrett, 2000). The foci of T. b. rhodesiense infections are in eastern 
and southern Africa with an epidemic in Uganda and drug resistance to Melarsoprol, the 
only drug available for treatment of late stage T. b. rhodesiense infection reported in 
Kenya and Uganda (Matovu et a!., 2001).
Chapter 1 General Introduction
EfWenilc mgh andanrHc 
EmOWMC Ai r«*A
Fig 1.1: Map showing countries of Africa where trypanosomiasis is prevaient. Figure reproduced 
from httD://www.ala.ac.uk/ibls/ii/mbp/resint.htm. (Dr M.B.P Barrett).
1.3 LIFE CYCLE
The life cycle of T.brucei has been thoroughly described (Vickerman, 1985). The 
parasite undergoes many changes as it is transmitted between the blood of a 
mammalian host and the gut of the tsetse fly, these being required for adaptation to the 
very different environmental conditions encountered (Hendrick et al., 2000). In 
particular, the parasite undergoes metabolic development in order to successfully move 
from the glucose-rich bloodstream to the tsetse midgut, where proline is the main 
energy source (Priest and Hajduk, 1994). The trypanosome also changes the major 
proteins that comprise its surface coat and undergoes morphological development from 
the bloodstream trypomastigote to the tsetse procyclic stage (Brown et a!., 1973). The 
successive stages in the life cycle of T.brucei reveal that, underlying the obvious 
morphological alterations more complex changes in the parasite's structure are taking 
place. The major changes take place in the mitochondrial system and at the surface
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membrane. These changes are both linked to the survival mechanisms, the former is 
related to the to adaptive changes in energy metabolism, the latter needed for evasion 
of the mammalian host's non-specific and specific defence mechanisms. It is also 
important to note that during the developmental cycle the trypanosome switches 
between proliferative phases in which it undergoes binary fission, which is linked with 
establishing the parasite in a new environment, and non proliferative phases in which it 
is incapable of division, and connected with major changes in the environment when it 
moves between the insect vector and the mammalian host (Vickerman, 1985).
T. brucei has six distinct stages in its life cycle. Slender form bloodstream parasites 
multiply by binary fission thus increasing numbers in the blood. Slender forms also 
transform, firstly into intermediate bloodstream forms and then to stumpy forms that are 
infective to a tsetse fly. In the slender forms, the mitochondrion is inactive but begins to 
become active in the stumpy forms. In the midgut of the tsetse fly, the trypanosomes 
undergo a further transformation to procyclic forms. The procyclic forms differentiate 
into non-dividing mesocyclic forms and migrate to the salivary glands. These then 
differentiate into epimastigotes, which then undergo extensive division. The cycle is 
complete when the epimastigotes, which are unable to survive in the mammalian host, 
differentiate into the non-dividing metacyclic forms (Figure 1.2). These metacyclics are 
found free in the saliva of the vector and are able to withstand the host's defences 
having acquired the variable surface glycoprotein (VSG) on their surface (Vickerman, 
1985; Matthews, 1999).
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The VSG coat is present only in the mammalian stages of the parasite and is lost once 
cyclical development in the tsetse fly begins, until the metacyclic stage in the tsetse fly 
is reached when recoating occurs. As well as providing a barrier to natural host 
defences, the VSG coat also enables the parasite to evade the host’s immune 
response, by changing its surface coat and therefore the host cannot mount an 
adequate antibody response quickly enough the kill the parasites. Antigenic variation 
involves the replacement of one VSG coat by another, however what initiates this switch 
is uncertain (Vickerman, 1985).
The parasites multiply by binary fission as long slender trypomastigotes with a doubling 
time of approximately 6 hr. The parasitaemia fluctuates owing to evasion of the host’s 
immune response by antigenic variation on the part of the parasite. The slender forms, 
referred to as “homotype” as they primarily express a single homogeneous surface 
antigen, form the major part of the population. When the host mounts an IgM immune 
response to the surface antigen homotype, the levels of parasitaemia go into remission 
due to the destruction of trypanosomes by the action of antibody and complement 
(corresponding to the variable antigen type (VAT)). In addition to the homotype (VAT) a 
trypanosome population also contains minor VATs or “heterotypes” which continue to 
multiply during the remission phase. One of these VATs overgrows the others to give 
rise to a recrudesence of the parasitaemia in which it becomes the homotype. This in 
turn leads to an increase in parasitaemia, induction of antibodies to the VAT and then 
remission. It is this process which gives rise to the characteristic fluctuations in
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parasitaemia observed in human sleeping sickness. Each VAT is determined by a 
specific VSG (Vickerman, 1985).
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Fig 1.2: The life cycle of T. brucei.
Figure reproduced from http://www.gla.ac.uk/centres/wcmp/research/baiTv/research.htmt#1. 
(Professor D. Barry and Dr R. McCulloch)
1.4 PATHOLOGY OF SLEEPING SICKNESS
Human sleeping sickness is an extremely debilitating disease, which is categorised into 
two distinct phases: early and late. On biting the mammalian host, the tsetse fly 
deposits metacyclic trypanosomes in the dermal connective tissue leading to a localised 
inflammatory response, which culminates in the development of a “chancre”. From the
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chancre the parasites spread to the draining lymph nodes and bloodstream, initiating 
the haemolymphatic early phase of the disease, characterised by general malaise, 
headache, fever, peripheral odema and anaemia (Masiga and Barrett, 2000). 
Symptoms of this early stage are relatively non-specific and can be easily confused with 
those of other diseases such as influenza and malaria. The important thing is the blood- 
brain barrier. The parasites cross it at multiple sites, including the choroid plexus and 
supra-chiasmatic nucleus into the brain and the cerebrospinal fluid (CSF) resulting in 
the late stage of the infection (Vickerman, 1985). This usually occurs within the first 
month post infection by T. b. rhodesiense, but over a period from several months to 
years after infection with T. b. gambiense (Masiga and Barrett, 2000). Subsequent 
neural damage and host reaction cause the more specific symptoms associated with 
sleeping sickness, namely, severe headaches, unusual sleep patterns, loss of 
concentration and coordination, leading to brain function deterioration which, if left 
untreated inevitably leads to coma and death (Bentivaglio et al, 1994).
1.5 CHEMOTHERAPY
The development of antimicrobial arsenical drugs stems from the first studies on 
chemotherapy conducted by Paul Ehrlich and his colleagues in 1909. In most clinical 
situations, the use of such compounds has been superseded by the development of 
more selective agents (Fairlamb et al., 1989). Only a limited number of drugs are 
currently available for treatment of African trypanosomiasis. Ehrlichs early work 
established the vital general principles of chemotherapy, which subsequently led via 
arsenoxide to the synthesis of arsenobenzol, the first antitrypanosomal drug, followed
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by the current less toxic counterparts. The discovery of suramin in the 1920s and 
pentamidine in the 1930s were mainly as a result of Ehrlich s earlier work on 
trypanosomal compounds (Gutteridge, 1985). For nearly 60 years there were no further 
advances in the development of novel compounds for treatment, until the 1980’s, when 
it was discovered that eflornithine (DFMO) had trypanocidal properties (Wang, 1997).
Antimicrobial drugs are used in three distinct ways: prophylaxis, treatment and 
prevention of transmission from the blood. Currently chemotherapy of African 
trypanosomiasis centres around four main drugs: pentamidine for early stage treatment, 
suramin for the treatment of the early stages of infection, while DFMO and melarsoprol 
are effective for the treatment of late stage infection when the trypanosome have 
entered the CNS (Gutteridge, 1985).
The drugs listed above are plagued by numerous problems, ranging from oral 
inabsorption, acute toxicity, short duration of action and unfortunately the emergence of 
drug resistance. The ideal drug for the treatment of sleeping sickness would have the 
following properties: it would have high oral availability, be administered in a single dose 
or a limited number of doses over a short period of time, have minimal side effects but 
yet be active against all stages of the course of infection and all strains and species of 
trypanosome which are responsible for disease. The lack of oral activity and severe side 
effects cause enormous logistical problems. The former is most critical for a 
chemoprophylactic due to fact that mass administration is much more difficult if an 
injectable formulation has to be used. The successful treatment of African
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trypanosomiasis often requires a stay in hospital, up to a month for people with late 
stage disease, as a consequence of the potentially dangerous side effects of treatment. 
However the most important limitation of current chemotherapy is the lack of drugs with 
a broad spectrum of activity against all stages of the disease and species of parasite. In 
particular, there is a lack of drugs available with activity against stages involving the 
CNS, and activity against T. b. rhodesiense is as a rule lower than that seen in T. b. 
gambiense (Gutteridge, 1985). Mechanisms of antitrypanosomal action of these drugs 
are largely unknown, except DFMO, which is a suicide inhibitor of ornithine 
decarboxylase (Carter and Fairlamb, 1993).
1.6 DRUG DESCRIPION AND MODE OF ACTION
1.6.1 Mefaminophenyl arsenlcals
Melarsoprol (MelB) contains a trivalent arsenic element with a highly reactive 
arsenoxide group (Fig 1.3). It is the presence of the arsenoxide group that allows 
passage of MelB across the blood brain barrier (BBB) as it confers the physical property 
of lipid solubility. The transport of MelB into the trypanosome is via a purine transporter 
(Carter and Fairlamb, 1993). This transporter, P2, whose role is the uptake of the 6-  
aminopurines adenine and adenosine, recognises a motif that is present on these 
substrates and also the melamine moiety of melarsoprol (Fig 1.3) (Carter et a!., 1999). 
Trypanosomes have a highly developed transport system due to the fact that they are 
unable to synthesise purines and so must acquire them from their host. MelB acts, 
therefore, as a competing ligand for the purine site on the transport protein (Carter and 
Fairlamb, 1993). This could also explain it’s selective mode of action against the j
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trypanosome as a result of P2 transport leading to accumulation of high levels of drug 
within the trypanosome.
Modification of the MelB melamine ring has generated other analogous compounds. A 
number of trivalent arsenlcals have been developed as a result of the modification of 
MelB namely, Melarsen oxide (MelOx), Phenylarsine oxide (PhenOx), Cymelarsan 
(MelCy) and Trimelarsan (MelW). MelB is a prodrug and the active metabolite in the 
body is MelOx (Fig 1.3). It is thought that enzymatic processes in vivo contribute to the 
conversion of MelB to MelOx (Nok, 2003). It is thought that arsenlcals inhibit a range of 
enzyme activities in vitro but it is unknown what the primary target is.
MelCy (Melarsamine hydrochloride) and MelW are both trivalent derivatives of MelB 
both having the melamine ring (Fig 1.3). Cymelarsan has been developed with activity 
against trypanosomes of the T. brucei sub-group and has been licenced for use in 
camels and has proved effective against T. evansi both in animal infections and in vitro 
(Ross and Barns, 1996).
1.6.2 Pentamidine
Pentamidine has been the first line drug for the treatment of early stage T. b. gambiense 
infection (de Koning, 2001A). This drug is an aromatic diamidine and a di -  cationic 
molecule and as a result diffuses slowly across biological membranes (de Koning, 
2001B). Its mode of action remains a matter of debate. However, it is generally 
accepted that this diamidine has a limited activity towards host cells (Denise and
12
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Barrett, 2001). The uptake of the drug seems to involve the P2 transporter, which, has 
also been associated with the uptake of the melaminophenyl arsenicals (Carter and 
Fairlamb, 1993). A biochemical reason for the transport of diverse molecules such as 
Pentamidine, MelB and adenosine by the same transporter is suggested by the 
identification of a substrate recognition motif for P2 for both classes of drugs (Fig 1.3) 
(Barrett and Fairlamb, 1999). Two further transporters have been shown to be involved 
in Pentamidine uptake, LAPT1 (low affinity pentamidine transporter) and HAPT1 (high 
affinity pentamidine transporter) (de Koning, 2001A).
1.6.3 Suramin
This sulphated naphthylamine was first introduced in 1922. It is generally considered 
the drug of choice for the treatment of early stage trypanosomiasis, especially T. b. 
rhodesiense. Due to its chemical structure and high negative charge suramin is not 
effective against the late stage of infection, as it cannot traverse the blood brain barrier 
(Wang, 1995).
Suramin has been found to bind to albumin and low density lipoproteins (LDL) in serum. 
Therefore, it is likely that suramin binds to a variety of serum proteins that enter the 
trypanosomes initially by receptor mediated endocytosis of some of the serum proteins 
(Wang, 1995). Suramin is a member of the sulfonated aromatic compounds found to 
bind to the active sites of dehydrogenases and kinases (Hawking, 1978). It has been 
found that in T. brucei suramin is a potent inhibitor of all the glycolytic enzymes in T. 
brucei (Nok, 2003).
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It is possible that suramin may bind to the glycolytic enzymes and interfere with the 
import of these enzymes into the glycosomes (Clayton, 1987). Thus, inhibition of 
glycosomal protein import may lead to a gradual decrease of enzyme concentration in 
the glycosome and as a result a slowing down of energy metabolism in suramin treated 
trypanosomes (Wang, 1995).
1.6.4 Efiornithine
The clinical name for DL-a-difluoromethylornithine (DFMO) is efiornithine, a fluorinated 
derivative of ornithine that was first synthesised as a potential suicide inhibitor of 
ornithine decarboxylase (GDC). GDC is the key enzyme in the pathway leading to the 
biosynthesis of polyamines; putrescine, spermidine and spermine and these are 
essential for proliferation of prokaryotic and eukaryotic cells. DFMG has good 
antitrypanosomal activity for the treatment of both early and late stages of T. b. 
gambiense infections but unfortunately it is relatively ineffective against T. b. 
rhodesiense infections (Wang, 1995).
DFMG acts by inhibiting trypanosomal GDC. Due to the low rate of in vivo turnover of 
GDC in the trypanosomes, DFMG can effectively inhibit the enzyme activity and deplete 
the intracellular polyamines to bring the cells into a dormant GO phase, which is 
destroyed by the host immune response. The trypanosomes are capable of taking up 
polyamines, but the polyamine level in mammalian plasma is extremely low due to the 
presence of very high levels of polyamine oxidase. This low polyamine level in the 
environment helps explain why, among the many species of parasitic protozoa, the
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African trypanosomes are the only ones susceptible to DFMO treatment. This is due to 
the fact that they stay in the bloodstream of mammalian hosts where the level of 
polyamines is low (Wang, 1995).
1.7 VETERINARY TRYPANOCIDES
1.7.1 Berenil
Berenil, like Pentamidine is an aromatic diamidine and a di -  cationic molecule and as a 
result diffuses slowly across biological membranes (de Koning, 2001 Bj. Berenil is 
widely used for the treatment of T. brucei infections in cattle. It is transported in T. b. 
brucei by P2, but not by HAPT1 or LAPT1. It is also an effective drug against T. 
congolense infection even though this trypanosome lacks detectable P2 transporter 
activity (de Koning, 2001B).
1.7.2 Isometamidium
Isometamidium cloride (Samorin) is used both prophylactically and therapeutically for 
the treatment of animal trypanosomiasis. It is a conjugate of homidium and part of the 
Berenil molecule. It is thought that the action of isometamidium in T. congolense is 
dependent on two sets of transporters: facilitated diffusion in the plasma membrane and 
active transporters in the mitochondrial membrane. In T. b. brucei, the P2 transporter 
may be responsible, in part, for drug uptake as it inhibits P2-mediated adenosine 
uptake. However, adenosine does not significantly inhibit isometamidium uptake 
suggesting its role is not an important one (de Koning, 2001B).
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1.7.3 Homidium
Homidium otherwise known as ethidium, was first found to have trypanocidal activity 
over 50 years ago. It is a potent mutagenic agent with many non-discriminating 
biochemical reactivities. Its mechanism as a trypanocidal agent is poorly understood. It 
has been shown to interfere with the glycosomal functions, trypanothione metabolism 
and replication of kinetoplast minicircles in the trypanosomes. Homidium was 
extensively used in the 1960s and 1970s, but its usefulness has been greatly reduced 
owing to widespread trypanosomal resistance. The mechanism of this resistance is 
unknown (Wang, 1995).
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Fig 1.3: Structures of the the P2 substrate adenosine, melaminophenyl arsenicals, diamidines, 
phenylarsine oxide, efiornithine and suramin.
NH
N
N
OH
OH OH
Adenosine
m
As
OH
Melarsoprol
NHHN
NH
0
Pentamidine
17
Fig 1.3 cont
Melarsen oxide
Chapter 1 General Introduction
NH
As
NH
NH
N—N=N
NH
Berenil
NH ^ C H z
H,
Cymelarsan
18
Chapter 1 General Introduction
Fig 1.3 cont
OK
PK
As
Trimelarsan
Phenylarsine oxide
COOH
HgN (C H2)3 ■ C -  NH2
\ h F 2
DFMO
19
Chapter 1 General Introduction
0 .S
H O
SOo- N -C
O H
CHo H3C
C =0
N' 'N
Suramin
Fig 1.3 The P2 transporters whose normal physiological roie is the uptake of 6-aminopurines adenine 
and adenosine recognises a motif which is present on these substrates and the melamine moiety 
of MelB, MelCy, MelOx, MelW, Berenil and Pentamidine (de Koning and Jarvis, 1999). This 
recognition motif is circled in blue. The arsenoxide group that confers the physiochemical ability of 
lipid solubility thus allowing passage across the blood brain barrier (Pepin and Milford, 1994) is 
present on MelB, PhenOx and MelOx and is circled in red. Models of drug structures were kind 
gifts from Harry de Koning.
1.8 DRUG RESISTANCE IN T. BRUCEi
Drug resistance Is only one of the many possibilities that may be linked to drug 
treatment failure with trypanocides in the field. Even if drugs are accurately 
administered, it would have to be demonstrated that the parasites have developed 
resistance to the drug as often other reasons for treatment failure are found, such as the 
accessibility of drug to trypanosomes in host tissues where the required concentration 
may not be attained (Burri et al., 2000). The World Health Organisation laid down a 
definition in 1963 stating that, “The difference between drug resistance and treatment 
failure is that drug resistance inevitably leads to treatment failure, whereas treatment 
failure dose not necessarily indicate drug resistance. "
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Chemotherapeutic intervention is continuously faced with increasing occurrence of drug 
resistance because all of the drugs currently used for treatment have been used for 
many decades. Consequently, resistance in all T. brucei sub-species from different 
areas of Africa has been reported (Table 1.1). There have been reports of treatment 
failure for patients treated with MelB, particularly in Sudan, Angola, Uganda and the 
Democratic Republic of Congo (Fig 1.4). It has been reported that, even after some of 
these patients were given subsequent treatment with the same drug no effect on the 
progression of the disease was observed (Matovu et a/., 2001).
Country Trypanosome species Resistance to
Nigeria
Kenya
Uganda
D. R. Congo
T. brucei 
T. b. rhodesiense 
T. b. rhodesiense 
T. brucei 
T. b. gambiense
Berenil 
Melarsoprol 
Melarsoprol and DFMO 
Berenil 
Melarsoprol
Table 1.1: Reports of drug resistance In T. brucei. The reports were generated from isolated small- 
scale surveys and could be an under estimate of the problem (Matovu et al., 2001 ).
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CTNagant
Fig 1.4: Distribution of drug resistant trypanosomes in Africa. As can be seen resistance is more 
widespread amongst animal trypanosome infection (Nagana), whilst human African 
trypanosomiasis is concentrated along the belt from Angola to the Sudan (Figure reproduced 
from Matovu etal., 2001).
It has been suggested that the mechanism of resistance to all melaminophenyl 
arsenicals is the same and occurs as a consequence of an alteration in a specific 
adenosine transporter (P2) that is able to recognise the melaminophenyl moiety of 
these trypanocides as similar to that of the purine ring of adenosine (Fig 1.3) (Carter 
and Fairlamb, 1993). Transport kinetic studies have shown that an arsenical-sensitive T. 
brucei line contains two high affinity transport systems for adenosine capable of 
scavenging the low concentration of nucleosides in the mammalian bloodstream (Carter 
and Fairlamb, 1993). The two adenosine transporters were identified: the PI which 
transports adenosine, inosine and other nucleosides and the P2 which transports 
adenosine, adenine and melarsoprol (Fig 1.5). A melaminophenyl arsenical resistant 
T.brucei line (RU15) was shown to have a greatly reduced initial rate of P2 mediated
22
Chapter 1 General Introduction
adenosine uptake. The arsenical resistance phenotype was associated with a loss of or 
alteration to the P2 transporter responsible for uptake of the melaminophenyl arsenical 
involved (Carter and Fairlamb, 1993). However, there have been several findings that 
suggest that alteration of the P2 transporter is not the only route by which drug 
resistance arises. One such investigation showed that resistance to MelCy was 
expressed in procyclic forms (Scott et al., 1996), but it is known that the P2 transporter 
is not expressed in procyclic forms (de Koning and Jarvis, 1998).
Molecular and transfections studies have been carried out to determine the basis of 
Melarsoprol resistance in T. brucei. The gene encoding the P2 transporter, T. brucei 
adenosine transporter 1 (TbATI), has been identified and expressed in Saccharomyces 
cerevisiae and was used to assess the potential of substrates to inhibit TbATI mediated 
transport (Matovu et al., 2003). A gene knock-out of TbATI in T. brucei has been 
performed and its effect on drug uptake and resistance determined. It was found that as 
a result of deleting this gene, there was only a small reduction in the sensitivity of the 
trypanosomes to MelB, MelOx, MelCy and Pentamidine compared to the wild-type 
strain (Maser et al., 1999). However, resistance to Berenil increased quite significantly 
in comparison to the other drugs (Matovu et al., 2003). The TbATI gene from a drug 
sensitive clone (STIB 777s) and a drug resistant clone (STIB 777r) was cloned and 
sequenced and it was found that the gene from the resistant line had 10 nucleotide
differences, six of which manifested themselves at the amino acid level. These findings, I
1therefore, provide evidence that TbATI encodes an adenosine transporter, which 
mediates the uptake of, and thus susceptibility to, melaminophenyl arsenicals and that j
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mutations or deletions of TbAT 1 contribute to arsenical resistance in T. brucei (Mâser et 
al., 1999). This result further indicates that other routes are involved in conferring the 
drug resistance phenotype.
1 runsport ol trypunocidc
hf / n i i i  f o r  c r ( r \ \ - r c \ ! \ } a } n  (
Arsenicals
Berenil
Pen! ainidiiie
Propamidine
Stilbamidine
Isometainidiiim;
Pentamidine 
Prop ami dine
K inetoplast
Isometamidium If
t^enlami dine
Formycin A 
Formycin B
Fig 1.5: Overview of the uptake mechanisms involved in drug uptake in T. brucei. Indicated are the 
P1 and P2 transporters whose normal physiological function is the salvage of 6-aminopurines; 
P1 is specific for adenosine and inosine and P2, for adenosine and adenine. But the P2 
transporter also mediates the uptake of arsenicals and diamidines, as shown, because of the 
structural similarities between the drugs and adenosine. The HAPT1 and 1_APT1 are two 
additional transporters, which are involved in the uptake of Pentamidine (de Koning, 2001). 
HAPT 1, high affinity pentamidine transporter; LAPT1, low affinity pentamidine transporter. Figure 
reproduced from: vvw w .qIa.ac.uk/jb ls/ii/a ifs/purm Q deI.Q ff. (Dr H. de Koning)
Most of the arsenical resistant strains analysed to date show cross resistance to all 
related compounds having a melaminyl moiety. However, these strains are found to be
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susceptible to the lipid soluble compound phenylarsine oxide that lacks the melaminyl 
ring. These observations suggest that resistance is based on the melaminyl part of the 
molecule (Carter and Fairlamb, 1993). It has also been demonstrated that while there is 
cross-resistance between the melaminophenyl arsenicals and the diamidine Berenil, 
there is a lower level of resistance to Pentamidine (de Koning, 2001A). This has led to 
the proposal, first suggested 10 years ago, that Pentamidine is either taken up by a 
different transporter or has an altered affinity for the transporter (Fig 1.5) (Fairlamb et 
al., 1992). Two additional transporters, specific for Pentamidine transport, have more 
recently been identified: the high-affinity pentamidine transporter HAPT1 and the low- 
affinity pentamidine transporter LAPT1; both of these transporters are adenosine 
insensitive (de Koning, 20Q1A). Although Berenil is structurally related to Pentamidine 
(Fig 1.3), it is not an effective substrate for HAPT1 or LAPT1, and cannot enter 
trypanosomes by routes other than the P2 transporter (de Koning and Jarvis, 2001). 
This may explain why resistance to Berenil in the field is more widespread while 
resistance to Pentamidine is much less common (Matovu et al., 2001).
A separate study showed that a T. equiperdum line selected for a 36 fold resistance to 
Berenil also showed a four fold resistance to cymelarsan (Barrett and Fairlamb, 1999). 
The wild type line had an adenosine transport system similar to that of T.brucei. The 
resistant line still had both PI and P2 activity, however the substrate affinity and uptake 
capacity of P2 was greatly reduced. It was concluded, therefore, that a mutation in the 
P2 transporter caused the parasite to become resistant to Berenil but with low cross­
resistance to cymelarsan (Barrett and Fairlamb, 1999).
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It has also been shown that that arsenical resistance is a stable phenotype during tsetse 
transmission, and this could have serious implications leading to the spread of drug 
resistance in the field (Scott et al., 1996). In all examples of cross-resistance between 
arsenicals and diamidines, transport via the P2 transporter is altered in such a way that 
it leads to a diminished accumulation of drug and therefore confers resistance (Barrett 
and Fairlamb, 1999).
Resistance to Suramin does not seem to be as a result of metabolism and unlike the 
arsenicals and diamidines it is unlikely that the mechanism leading to resistance is a 
result of diminished uptake (Nok, 2003). The reason for this is that LDL uptake is 
essential for proliferation in T. b. brucei, which is unable to synthesis fatty acids and 
cholesterol de novo (de Koning, 2001B). A recent study has shown that suramin entry 
into the cell is not mediated via an LDL specific receptor and that the suramin receptor 
is a distinct entity. The study also showed that suramin uptake relies on prior binding to 
serum compounds and is by an energy-dependent mechanism that has yet to be 
identified (Pal etal., 2002).
T. b. rhodesiense is thought to attain resistance to DFMO either by altering the 
properties of target enzymes or by regulating drug transport across the cell membrane 
(Nok, 2003). A study carried out using a DFMO resistant mutant determined that altered 
drug accumulation was the only mechanism that could explain the observed resistance. 
The drug resistant strain did not enhance its ODC activity or lower the sensitivity of its 
ODC toward DFMO inhibition. Also, it had the normal rate of converting exogenous
26
Chapter 1 General Introduction
ornithine to endogenous polyamines. However, the mutant strain had an altered 
capability of taking up exogenous DFMO, accumulating it to only a very low level in the 
cell. This low drug concentration within the cell prevented DFMO from exerting its 
inhibitory effect on growth of the cells (Phillips and Wang, 1987). The possible 
involvement of a specific transporter protein, however has not been ruled out for DFMO 
uptake (Nok, 2003). Obviously more studies will need to be carried out before the 
mechanism of DFMO action and resistance can be fully understood.
Advances in trypanosoma! chemotherapy are not very optimistic. Among the limited 
number of drugs currently available, each has its particular disadvantages and 
drawbacks and several have severe side effects. The only new drug, DFMO, displays 
excellent efficacy against T. b. gambiense, the problem is the amount of drug needed, 
and the requirement for hospitalisation. As yet the mechanisms of action of these drugs 
are generally poorly understood thus leading to a decrease in opportunities for future 
drug development.
On the other hand, African trypanosomes are among the most intriguing families of 
eukaryotic micro-organisms currently known to biologists. Many unique features are 
linked to their development and metabolism. These include: RNA editing, frans-splicing 
of mRNA, the kinetoplast DMA, antigenic variation, trypanothione metabolism and the 
glycosome. Many of these features could be potential targets for further 
chemotherapeutic investigations, as long as two essential requirements are met: firstly, 
the pathway/function is essential for the survival of trypanosome and secondly, that it is
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unique enough that a counterpart does not exist or is sufficiently different in the 
mammalian host to allow for selective inhibition (Wang, 1995).
A useful strategy for understanding the mechanism of drug resistance is the genetic 
basis of resistance. Manipulation of gene structure and expression by gene knock-out 
or gene disruption followed by observations of changes in phenotype would potentially 
lead to a better understanding of the mechanisms of drug resistance.
1.9 TRYPANOSOMATID GENETICS
The genetics of the trypanosoma! group of protozoa have been the subject of 
considerable research over the past 15-20 years (Smith and Parsons, 1996). A sexual 
cycle in T. brucei was discovered over 17 years ago (Jenni et al., 1986). It has been 
demonstrated that genetic exchange occurs between trypanosomes when they infect 
the tsetse fly and, by marker analysis, that the process is non-obligatory to completion 
of the life cycle but has all the characteristics of a Mendelian system (Tait and Tumer, 
1990; Sternberg and Tait, 1990; Turner et a!., 1990; Gibson and Stevens, 1999).
A study was carried out on 17 stocks of trypanosomes isolated in Uganda. Isoenzyme 
analysis of these stocks indicated that the population was consistent with being diploid 
and in Hardy-Weinberg equilibrium. This finding provided strong evidence that these 
trypanosome strains were undergoing random mating (Tait, 1980). These studies 
preceded direct evidence of genetic exchange between trypanosome populations and 
assumed meiosis. Sternberg has also suggested that gene exchange may involve
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meiosis and syngamy and therefore, can be explained in terms of classical Mendelian 
genetics (Sternberg etal., 1989).
The extent to which genetic exchange occurs in natural populations, however is still a 
matter of debate. There are three proposed types of population structure for T. brucei 
based on the extent of sexual recombination: (1) clonal, where there is little genetic 
exchange, (2) epidemic, where there is some genetic exchange but it is masked by 
clonal expansion in some strains and (3) panmictic, where random mating occurs. The 
clonality theory was proposed based on isoenzyme data and evidence for strong 
linkage disequilibrium (Tibayrenc et al., 1990). This is in contrast to the original proposal 
that the population structure of T. brucei was panmictic (Tait, 1980). These two theories 
are to a large extent resolved by considering an epidemic population. In this model one 
or two successful multilocus genotypes expand and mask the underlying occurrence of 
frequent genetic exchange (Maynard Smith et al., 1993). A recent study using isolates 
from four different regions in Africa and mini and microsatellite markers has suggested 
that T. brucei populations have an epidemic genetic structure, but very well 
characterised human infective populations have a clonal structure (MacLeod et al., 
2001). Given this, it would seem that the population structure in T. brucei is neither 
clonal nor panmictic but epidemic. However, this proposal must be treated with caution 
because of the low numbers of isolates screened (MacLeod et al., 2001).
In laboratory studies, the main limitation on the analysis of the mechanism of gene 
exchange in trypanosomes has been, to date, the limited number of hybrid clones
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analysed. Results have indicated that the majority of hybrid clones possess the same 
DNA contents as their parents, supporting a conventional Mendelian system of genetic 
exchange. This is not the case, however, with all products of mating. One study showed 
that approximately 66% of hybrid progeny had 1.5 times DNA content of the parental 
trypanosomes. The interpretation of the results after analysis of these clones was that 
the DNA content reflected triploidy and that the clones arose as a result of fusion 
between haploid and diploid parental nuclei, which is an aberrant event in a genetic 
exchange mechanism involving meiosis (Gibson et al., 1992). In a separate study, 
analysis of 30 recombinant clones were tested for their DNA content and only two of the 
clones were found to have raised DNA content, 1.5 times that of the parents. Marker 
analysis was carried out on these two clones and one was found to be triploid due to the 
fact that for seven of the independent loci the clone was trisomie. The second clone had 
inherited a single allele from each parent for four loci and was therefore, considered 
diploid (Hope etal., 1999).
All laboratory investigations have been carried out using classical marker analysis of 
mixtures of two genetically distinct stocks in order to analyse the genotype of the 
progeny resulting from the co-transmission of these stocks through tsetse flies. The loci 
can be considered in two categories; firstly, where the parents are homozygous for 
different alleles then the products of mating will be either (1) heterozygous or (2) 
homozygous and identical to one or other parent. Secondly, where one or both parents 
are heterozygous for alleles at several loci, thus the products of mating will be, (1) 
identical to one or other parent or (2) show segregation of alleles at each locus with
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heterozygous and homozygous progeny (Sternberg and Tait, 1990). The observation of 
products from crosses that remain identical to one or other parent indicates that genetic 
exchange is non-obligatory. The finding of progeny that have become heterozygous at 
loci where the parents were homozygous indicates that hybrid formation has occurred. 
The segregation of alleles at heterozygous loci indicates that mating is Mendelian.
1.10 MINI AND MICROSATELLITE MARKERS
Three minisatellite loci were used to analyse genetically distinct stocks and hybrids; 
MS42 localised on Chromosome I, CRAM localised on Chromosome X and 292 
localised on Chromosome III. Allelic variation at each of these loci has been detected 
involving alleles of different size shown to represent differences in the number of repeat 
units (MacLeod et a/., 1999).
Analysis of the inheritance of this allelic variation in crosses between stocks of STIB 
(Swiss Tropical Institute, Basel) 386, STIB 247 and TREU (Trypanosome Research 
Edinburgh University) 927 has indicated that the alleles are inherited in a Mendelian 
manner with each FI progeny clone inheriting a single allele from each parent 
(MacLeod et al., 1999). Two microsatellite markers, PLC and JS2 (MacLeod et al., 
2000), which localised on chromosomes II and V respectively also showed allelic 
variation and segregation at these loci. The implication from this finding is that 
inheritance of each individual alleles can be traced in the progeny clones between 
crosses by exploiting the different sized alleles for all three minisatellites, MS42, CRAM 
and 292 and the two microsatellite markers PLC and JS2.
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There have been 90 candidate polymorphic microsatellites identified for chromosome I 
as a result of sequencing the T. brucei stock Tb927 by the Sanger institute. With these 
microsatellites a genetic map of chromosome I has been constructed. Crossover 
frequencies for chromosome I range from -8  to >90 kb/cM, which gives an average 
physical size for the recombination unit of 22 kb/cM. This is similar to that found for P. 
falciparum (Hall et al., 2003). A genetic map has also been constructed for chromosome 
II, where the physical size for the recombination unit was 12.1 kb/cM (El-Sayed et a!., 
2003). These maps are essential for determining the inheritance of each allele in the 
progeny clones and eventually the localisation of a trait of interest to a defined region on 
a chromosome.
1.11 GENETIC ANALYSIS OF PHENOTYPE
Genetic analysis of phenotypic traits is a tool that can be used to define the function of 
genes identified by sequencing projects of various parasitic protozoa. Genetic 
techniques can be divided into two classes, forward and reverse, which is dependent on 
whether analysis is started at the level of phenotype or gene, respectively. There are 
two approaches that can be used for fonward genetic analysis of phenotype, firstly 
classical genetic analysis where the genetic basis of existing variation in phenotype can 
be determined and secondly the generation of mutants and subsequent genetic analysis 
to identify the genes.
The classical genetic approach has been used in this study to determine the genetic 
basis of drug resistance. This approach uses naturally occurring variation (drug
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resistance/sensrtivity) between trypanosome stocks followed by crosses to determine 
the genetic basis of variation using segregational analyses in the F1 progeny. The three 
trypanosome stocks were initially isolated from the field and cloned lines of these stocks 
were shown to differ in their sensitivity to killing by Cymelarsan where STIB 386 and 
TREU 927 were resistant in comparison to STIB 247 in vivo (Table 1.2) (Scott et a!., 
1996; Tait et al., 2002). Using the results obtained from the segregation analyses a 
genetic model of inheritance of phenotype can be proposed and tested by either a 
backcross or by the generation of F2 progeny.
Details of Parental stocks
stock
Number
STIB 247 
STIB 386 
TREU 927
Place of 
isolation
Tanzania 
ivory Coast 
Kenya
Host Species
Hartebeest T. b. brucei
Man T. b. gambiense
Tsetse fly T. b. brucei
Cymelarsan
Resistance
S
R
R
Year of Isolation
1971
1978
1969
Table 1.2: Details of each parental trypanosome stock used in this investigation as described in 
Tumer et al., (1990). The Cymelarsan resistance data was based on an In vivo assay (Scott 
etal., 1996). S, sensitive; R, resistant.
Genetic mapping can be used to define loci that contribute to heritable phenotypes in 
organisms that undergo sexual recombination. This approach uses genetic maps 
comprising of polymorphic markers that can be scored easily at numerous loci to 
demarcate a unique pattern of heritable alleles, known as haplotypes, for each 
individual progeny clone. The co-segregation of specific marker alleles and a phenotype 
can then allow a chromosomal region to be linked to the trait of interest. In contrast to 
biochemical approaches examining protein pathways to gene discovery, genetic
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mapping uses the association between genotype and phenotype to determine markers 
linked to a particular trait. As a result, this requires no prior knowledge of the 
biochemical processes that give rise to the trait although it can be used to test a 
hypothesis about the role of a specific gene in conferring a phenotype (Ferdig and Su, 
2000).
In order to identify the genes involved in determining the trait of interest, linkage 
analysis is required using molecular markers in established genetic maps and 
consequently the region of the genome where the gene lies can be identified. As the 
genome sequence of T. brucei is nearing completion (http//:www.tigr.org: 
http//:sanger.ac.uk) with chromosomes I and II annotated (Hall et ai., 2003; El-Sayed et 
ai., 2003, respectively) and a nearly complete genetic map has been made (MacLeod 
and Tweedie, unpublished results) then with polymorphic markers at defined locations 
on the physical map, it is possible to map a locus determining a particular phenotype to 
a particular physical region on the genome. Based on the flanking linked markers, it is 
then possible to define the candidate open reading frames that define the locus. If the 
region between the flanking markers is relatively large, >100 kb then fine mapping 
within this defined region can be undertaken in order to narrow the region further and so 
reduce the number of candidate genes involved in determining the trait of interest. At 
this point a reverse genetic approach can be undertaken, which involves knocking out 
each candidate gene or allele in turn and determining if there is a change in phenotype 
in the parental stock.
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There have been a number of genetic mapping studies conducted to identify the 
determinants causing particular traits in parasitic protozoa. Perhaps the most widely 
studied and extensive of these is chloroquine resistance in P. falciparum, where it is 
thought that resistance is determined by mutations in the pfcrt gene. A cross between a 
chloroquine resistant clone (Dd2) and a chloroquine sensitive clone (HB3) was 
undertaken and linkage mapping localised the chloroquine resistance determinant to a 
36 kb segment of P. falciparum chromosome 7. Further analysis ruled out the role of the 
pfmdr 1 gene as a determinant of chloroquine drug resistance (Su et al., 1997). Instead, 
evidence was obtained that mutations in a highly interrupted and previously undetected 
gene, pfcrt, in the 36 kb segment was involved in conferring chloroquine resistance 
(Fidock et al., 2000). Translation of the Dd2 pfcrt coding region produced a 424 amino 
acid, 48.6 kDa protein and database searches revealed that PfCRT belonged to a family 
of putative transporters or channels with ten transmembrane domains (Tm).
Sequence comparisons of the pfcrt gene from strains Dd2, HB3 and two progeny clones 
revealed eight codon differences between the chloroquine resistant and sensitive clones 
which localized in or near the Tm domains (Fidock et aL, 2000). To determine whether 
these mutations in pfcrt were sufficient to confer chloroquine resistance, allelic 
exchange was undertaken to replace the pfcrt allele of a chloroquine sensitive line with 
the pfcrt allele from a chloroquine resistant line. Phenotypic analysis showed that the 
transfected mutant pfcrt allele conferred a chloroquine resistant phenotype to the 
chloroquine sensitive P. falciparum. All the transfected cell lines grew in 8 0 -  100 nM
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chloroquine which is the level previously proposed as a threshold diagnostic of in vivo 
resistant lines (Sidhu et al., 2002).
Genetic analysis has also been carried out in Toxoplasma gondii (Su et ai, 2002 B) and 
Eimeria tenella (Shirley and Harvey, 2000). Studies on the inheritance of virulence in T. 
gondii have been conducted using 26 recombinant progeny derived from genetic 
crosses between a virulent and non-virulent strain using 112 polymorphic markers. 
Linkage analysis and fine mapping have identified that the gene controlling virulence 
lies between two markers on chromosome VII (Su et ai, 2002). Similarly, the gene 
controlling resistance to arprinocid in E. tenella has been inked to a region on 
chromosome I (Shirley and Harvey, 2000). These results are discussed further in 
Chapter 5.
Genetic dissection of potentially complex traits, such as development, virulence, 
transmission and drug resistance, is now being undertaken. In the years since it was 
recognized that genetic inheritance could be traced with naturally occurring DNA 
sequence variation, the identification of genes responsible for simple Mendelian traits 
has become a straightforward but labour intensive task. Over 500 such genes have 
been mapped to specific chromosomal regions in the human and over 60 of these have 
been cloned based on their position in the genome (Lander and Kruglyak, 1995).
In terms of genetic mapping of a particular phenotype, two central questions need to be 
addressed in order to establish the feasibility of the study: 1) sufficient numbers of
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progeny to enable accurate map construction and 2) the demonstration of crossing 
over, in conjunction with the determination of the physical size of the recombination unit. 
The number of progeny affects the ability to determine statistical significance of a 
segregating phenotype in relation to the number of loci or alleles determining the trait of 
interest and also, the level of resolution of a genetic map. At the beginning of this study 
there were 37 hybrid progeny available, which were previously generated from genetic 
crosses between the three parental stocks in all pair-wise combinations (Fig 1.6) 
(Turner et ai, 1990; Tait and MacLeod, unpublished results). The size of the 
recombination unit determines the number of markers required for a map in order to 
determine statistically significant linkage within a specified and workable physical 
distance for the trait of interest (Tait et ai, 2002).
TREU 927
FI (7)F1 (18)
STIB 386STIB 247
FI (12)
Fig 1.6: The three stocks used for the generation of a panel of Pi progeny. Crosses were performed 
in all pair-wise combinations of the three stocks. Numbers in brackets indicate the number of 
unique F1 progeny available for analysis for each cross.
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1.12 OVERALL AIMS
The aim of this project was to undertake the genetic analysis of arsenical drug 
resistance in order to gain a better understanding of the mechanisms of resistance in 
T.brucei. Analyses was conducted to identify the genes involved in arsenical resistance 
using a classical genetic approach.
The project addresses the following questions:
1. Is the genetic mechanism of resistance inherited in a dominant or recessive 
manner?
2. What numbers of genetic loci and alleles are involved?
3. Where in the genome are the genetic loci determining drug resistance?
4. Are the resistance genes identified In the laboratory of any relevance in the field?
Before any of these questions were addressed, the number of F1 hybrid progeny 
derived from each cross needed to be increased as the number of progeny affects the 
statistical significance of segregating phenotypes and the resolution of the genetic 
maps. The procedure for generating F1 hybrid progeny is the subject of the following 
Chapter.
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CHAPTER 2
GENERATION OF UNIQUE HYBRID LINES IN VITRO AND IN VIVO
2.1 INTRODUCTION
Our current understanding of the mechanism of genetic exchange in T. brucei is 
constrained by the numbers of independent hybrid progeny available from any single 
cross and the currently available progeny are summarized in Table 2.1. Low numbers of 
progeny prevent the formal demonstration that inheritance is Mendelian and the 
accuracy and robustness of genetic maps are reduced, which in turn limits our ability to 
undertake linkage analysis of a phenotypic trait of interest.
The first genetic cross demonstrated hybrid cell formation (Jenni et a!., 1986), but 
exhaustive marker analysis indicated that the three clones isolated were all vegetative 
products of a single mating event (Table 2.1) and were all triploid, with DNA contents 
greater than the parental clones. A number of subsequent crosses have confirmed 
hybrid formation and demonstrated allelic segregation and assortment of alleles at 
unlinked loci (Sternberg et a!., 1989 and Turner et al., 1990), which is consistent with 
Mendelian inheritance (Tait et al., 2002). A formal definition of Mendelian inheritance 
requires, however, agreement with theoretically predicted segregation ratios. The 
numbers of hybrids available are not adequate to support statistically robust agreement 
with predicted segregation ratios. Thus an increase in the numbers of independent 
progeny available from a cross would provide the statistical power to permit an analysis 
as to whether genetic exchange in T. brucei is indeed Mendelian.
39
Chapter 2 Generation of unique hybrid lines in vitro and in vivo
Numbers of progeny
Cross Total Hybrids Products of independent 
mating events
Reference
247x386 10 3 1 Jenni etal., 1986
247 X 386 4 1 1 Sternberg etal., 1988
247x386 >80 8 8 Sternberg etal., 1989
247x386 11 5 4 Turner etal., 1990
247 X 386 24 19 12 MacLeod and Tait (Unpublished)
247 X 927 36 24 18 Turner etal., 1990
386x927 18 9 3 Turner ef a/., 1990
386x927 62 26 4 MacLeod and Tait (Unpublished)
247x777 4 Schwelzer et a!., 1994
058x196 10 5 3 Gibson, 1989
196x310 25 12 2 Gibson and Garside, 1991
058HXKP2N 91 29 2 Gibson and Bailey, 1994
Self fertilisation
247x386 27 5 1 Tail etal., 1996
TH2N X 058H 5 Gibson etal., 1997
Backcross
058H X P20 13 Gibson etal., 1995
Table 2.1 A summary of T. brucei genetic crosses. As can be seen from columns 3 and 4 each hybrid 
clone is not necessarily a product of a unique mating event. For example in the cross 
conducted by Jenni (1986) three hybrid progeny were detected but as all three had exactly the 
same genotype for a series of markers these hybrid were the vegetative derivatives of a single 
mating event.
A further limitation is more directly related to the subject of this thesis, which is that the 
small numbers of hybrids limits the resolution of a genetic map and potential linkage
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analysis of a phenotype to a locus within that map. This limitation arises because 
mapping is determined by the number of recombination events detected between linked 
loci, which is in turn a product of the average recombination ratio and the number of 
progeny screened.
The procedure for making a genetic cross between cloned stocks is shown in Fig 2.1 
where flies harbouring mixed infections are identified by marker analysis of progeny 
populations. From previous studies it is known that flies with mixed infections are also 
likely to contain the products of crossing (Jenni et al., 1986; Sternberg et al., 1988; 
Gibson, 1989; Tait et al., 1989). Individual trypanosome clones obtained from a tsetse 
fly carrying a mixed infection, are then isolated and expanded in mice so that they can 
be subjected to marker analysis and phenotype screening. The available data show that 
the products of mating are the equivalent of the FI progeny of a Mendelian genetic 
system.
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Stock A Stock B\  /
mixed and presented 
to tsetse flies
fly feeds/infects mice
4 ^  4 ^
/  "  \
single fcrfoodstream 
Trypanosomes isolated
l l i i  Uii 
^  ^  ^
Blocxistream clones
single metacyclics isolated
i i i
Metacyclic clones
Fig 2.1 : The procedure for generating a genetic cross in T. brucei. Two genetically distinct T. brucei 
stocks are mixed and fed to tsetse flies. Flies harbouring mature infections are fed on mice, 
which then develop infections, the parasites in which can be screened for the presence of 
hybrid cells. Single trypanosomes are isolated optically either from metacyclic populations or 
from infected blood and each inoculated into another mouse.
Two methods have been used to isolate cloned products of crosses. Firstly, clones 
derived directly from the salivary glands of the tsetse fly (metacyclic clones). The 
resulting clones have been genotyped using a range of polymorphic markers in order to
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define hybrid progeny and then determine which were new and unique genotypes. A 
relatively low number of F1 progeny were identified (27%) but 80% of these were 
genotypically unique (Tait et al., 2002). Secondly, a fly carrying a mixed-infection was 
allowed to bite a mouse. Single trypanosomes were then isolated from the resultant 
infected bloodstream population and single trypanosomes from this population 
inoculated into separate mice followed by genotyping of each clone. Using this method 
80% of the clones were F1 progeny but only 60% were unique. As the proportion of 
progeny was higher in the bloodstream clones, despite the fact that there were a lower 
number of unique genotypes, this approach generated a larger number of independent 
progeny and ultimately a larger set of unique clones required for linkage analysis (Tait 
et al., 2002). Thirty-seven unique hybrid clones were previously available derived from 
crosses between the three parental lines (Table 2.2) (MacLeod, 1999). However these 
numbers needed to be increased to provide the statistical significance required for 
determining linkage to a trait of interest.
43
Chapter 2 Generation o f  unique hybrid lines in vitro and in vivo
Table 2.2: Genotypically unique F I hybrid progeny previously generated from genetic crosses.
Genotypically unique trypanosome F1 hybrids derived from genetic crosses
Markers
Identification Lysate
No.
GUP
No.
CRAM 292 MS42 JS2 PLC
Parental 247 
Parental 386 
Parental 927
1 -1  
1 -2  
3 - 4
5 - 6  
1 -2  
3 - 4
5 - 5  
1 -2  
3 - 4
5 - 6  
1 -2  
3 - 4
5 - 5  
1 -2  
3 - 4
Cross 247 x 927
F124/28 bsci 05 71 4635 1 -4 3 - 5 4 - 5 4 - 6 4 - 5
F124/28 bscI B3 73 4923 1 -4 3 -5 4 - 5 4 - 6 3 - 5
F974/70 mcl 4 77 3086 1 -4 3 -5 4 - 5 3 - 5 4 - 5
F532/63 bsci 2 80 4630 1 -4 3 -5 3 - 5 3 - 6 4 - 5
F532/63 bsci 3 78 4925 1 -4 4 - 5 4 - 5 4 - 5 4 - 5
F532/63 bsci 7 79b 4631 1 -4 4 - 5 4 - 5 3 - 6 4 - 5
F532/63 bsci 5 81 4634 1 "3 3 - 5 4 - 5 3 - 6 4 - 5
F632/72 mcl 5 88 4392 1 -4 4 - 5 4 - 5 3 - 5 3 - 5
F532/72 mcl 1 84 4391 1 -4 4 - 5 3 - 5 3 - 5 3 - 5
F532/72 mcl 2 85 4636 1 -4 4 - 5 3 - 5 4 - 5 4 - 5
F532/72 mcl 3 86 4427 1 -4 4 - 5 4 - 5 4 - 5 3 - 5
F532/72 mcl 6 89 4393 1 -3 3 - 5 3 - 5 4 - 5 4 - 5
F532/72 mcl 7 90 4628 1 -4 4 - 5 4 - 5 4 - 6 3 - 5
F532/72 mcl 8 91 3538 1 -4 3 -5 4 - 5 4 - 5 3 - 5
F532/63 cl 16 171 1 -4 3 - 5 4 - 5 3 - 5 3 - 5
F632/72 mcl 9 92 4366 1 -4 4 - 5 4 - 5 3 - 6 3 - 5
F532/63 cl A11 170 1 -3 4 - 5 3 - 5 3 - 6 4 - 5
F532/63 bsci A14/1 346 1 -3 3 - 5 4 - 5 3 - 6 3 - 5
Cross 247 x 386
F9/45 mcl 2 30 3300 1 -2 1 -5 2 - 5 1 -5 1 -5
F9/45 mcl 10 34 5060 1 -1 2 - 5 1 -5 1 -6 2 - 5
F9/45 mcl 11 35 3287 1 -2 1 -5 1 -5 1 -5 2 - 5
B80 cl 2 162 1 -2 2 - 5 2 - 5 2 - 6 2 - 5
F492/50 bsci 1 174 174 1 -1 2 - 5 1 -5 2 - 6 2 - 5
F492/50 bsci 5/1 b 332 5316 1 -2 1 -5 1 -5 2 - 6 2 - 5
F492/50 bsci 8 181 5317 1 -1 2 -5 1 -5 1 -6 2 - 5
F492/50 bsci 9 182 4688 1 -2 1 -5 2 - 5 2 - 5 2 - 5
F492/50 bsci 12 185 1 -1 2 - 5 2 - 5 2 - 5 1 -5
F492/50 bsci 18 191 4949 1 -2 1 -5 1 -5 2 - 6 2 - 5
F492/50 bsci 21 194 4950 1 -1 1 -5 1 -5 2 - 6 2 - 5
F492/50 bsci 23 196 4954 1 -2 1 -5 1 -5 2 - 5 2 - 5
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Table 2.2 cont
Genotypically unique trypanosome F1 hybrids derived from genetic crosses
Identification Lysate
No.
GUP
No.
CRAM 292
Markers
MS42 JS2 PLC
Parental 247 
Parental 386 
Parental 927
1 -1  
1 -2  
3 - 4
6 - 5  
1 -2  
3 - 4
5 - 5
1 - 2
3 - 4
5 - 6  
1 -2
3 - 4
5 - 5  
1 -2  
3 - 4
Cross 386 x 927
F296/39 22/1 264 1 -4 1 -3 1 -3 1 -4 2 - 3
F296/39 24/1 269 1 -4 2 - 3 1 -3 2 - 3 1 -3
F296/39 bsci 7 207 1 -4 2 - 3 1 -3 2 - 3 1 -3
F296/39 bsci 9 209 1 -4 2 - 3 1 -3 2 - 3 1 -3
F296/44 bsci 1 2 3199 2 - 3 2 - 3 1 -3 1 -3 2 - 3
F296/44 bsci 3 6 3201 1 -3 1 -3 1 -3 1 -4 2 - 3
F296/44 bsci 4 5 3204 1 -4 1 -4 1 -4 1 -3 1 -3
Table 2.2: All genotypically unique FI hybrid progeny previously generated from genetic crosses 
(MacLeod, 1999). The cross from which each clone is derived and their individual 
Identification numbers are listed in column 1, and these are used throughout the study. The 
nomenclature follows that of Sternberg et at., 1989. For example F296/39 bsci 7, was the 
seventh clone isolated from fly 296, on day 39 post infection. Columns 2 and 3 give additional 
identification numbers i.e. stabilates and lysate numbers, where available. Columns 4-7 give 
the results of the mini and microsatellite marker analysis. Alleies are numbered 1-5 for the 
minisatellites, CRAM, 292, MS42 and PLC, and 1-6 for the micro satellite JS2. GUP, Glasgow 
University Parasitology. Bloodstream clones from the same tsetse fly, sampled on the same 
day and conferring the same genotypic pattern were considered to have arisen from one 
sexual recombination event and so were represented by one clone in the above tables.
Since uncloned bloodstream trypanosomes from crosses were already available as 
frozen stabilates, I used the second approach to generate new clones from pre-existing 
crosses, thereby increasing the number of hybrid clones to map the drug resistance 
trait. This chapter describes the methods used to produce new unique hybrid progeny 
from such crosses and define their genotype. The nomenclature for clone identification 
used throughout this chapter follows that of Sternberg et al (1989), for example F532/72 
bsci 1, is the first bloodstream clone derived from fly 532, on day 72 post infection.
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Marker analysis of hybrid clones has previously relied on isoenzyme, RFLP and 
karyotype analysis (Sternberg et al., 1989; Turner et al., 1990; Gibson, 1989; Gibson 
and Bailey, 1994). This study, however, used the highly informative polymorphic mini 
and microsatellite markers CRAM, MS42, 292, PLC and JS2 (Lee et al., 1990; Lee et 
al., 1994; Barrett et al., 1997; MacLeod et al., 1999; Sasse, 1998; MacLeod, 1999; 
MacLeod et al., 2000) to analyse the clones derived from each genetic cross. Each of 
these mini and microsatellite markers are located on different chromosomes and so are 
unlinked and PCR based methods have been developed for detecting variation at these 
loci using crude lysates of procyclic or bloodstream clones as templates (MacLeod et 
al., 2000). They are genetically easily interpreted markers, each being able to 
distinguish between two to four alleles in the parental clones. These markers would, 
therefore, allow the theoretical identification of 64 possible genotypes for the FI 
progeny clones of each of the crosses STIB 247 x TREU 927 and STIB 247 x STIB 386.
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2.2 MATERIALS AND METHODS
A number of solutions, buffers and media were used throughout this study, the 
components of each of these are listed in Appendix A1.
2.2.1 PREPARATION OF DNA FROM TRYPANOSOMES
2.2.1.1 Crude Lysates
Crude lysates were prepared from 200 pi of procyclic cultures in log phase of growth at 
a density of ~ 1 x 10® trypanosomes / ml. The cells were centrifuged at 1,100 g for 7 min 
at 4°C, the supernatant discarded and the pellet re-suspended in 200 pi of Phosphate 
buffered saline (PBS) and centrifuged again at 2,500 g for 5 min. This washing process 
was repeated 3 times. The final pellet was then re-suspended in 50 pi lysis buffer and 
0.64 mg/ml of proteinase K and incubated overnight at 56°C. The proteinase K was heat 
inactivated the following day at 95°C for 5 min. The lysates were then diluted 1/50 in 
deionised water and stored at -20°C. One pi of lysate was then used as template in 
subsequent PCR reactions.
2.2.1.2 DNA extraction from trypanosomes
For DNA preparations the following method was used. Lysates were prepared from 200 
pi of procyclic cultures in log phase of growth at a density of ~ 1 x 10® trypanosomes/ ml 
The cells were centrifuged at 1,100 g for 15 min at 5°C. The pellet was re-suspended in 
450 pi of DNA extraction buffer with 50 pi of 10% SDS and 25 pi (10 mg/ml) proteinase 
K added. The DNA pellet was then incubated with gentle agitation at 37°C for 2hr. 500 
pi of liquid phenol was added and vortexed until the solution became milky in
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appearance. The mixture was separated by microcentrifugation for 5 min at 13,000 g. 
The top aqueous layer was then transferred to a sterile tube and an equal volume (500 
pi) of 50:50 phenol/chloroform was added, vortexed thoroughly and centrifuged as 
before. The upper layer was transferred to a fresh tube and 40 p! of 3 M sodium acetate 
plus 1 ml of 100% ice-cold ethanol was added and mixed by gentle inversion, left at - 
20°C for 30 min and then centrifuged for 15 min at 13,000 g to pellet the DNA. The 
ethanol was removed, the pellet washed with 70% ethanol, left to dry in a flow cabinet, 
re-suspended in sterile double distilled water and then stored at -20®C.
2.2.2 Trypanosome stocks and mice
Three cloned trypanosome lines were used as parents in this study. These were STIB 
(Swiss Tropical Institute, Basel) 247, STIB 386 and TREU (Trypanosome Research 
Edinburgh University) 927. The line STIB 247 was originally isolated from a hartebeest, 
STIB 386 was isolated from a man and TREU 927 was isolated from a tsetse fly (Turner 
etal., 1990).
A number of previously uncloned bloodstream populations derived from genetic crosses 
between the three parental lines above were also used for this investigation. Using the 
nomenclature described previously these uncloned stocks were, FI 24/28, F532/72 and 
F974/78 (STIB 247 x TREU 927), F9/41, F I9/31, F28/46, F57/40 and F29/46 (STIB 247 
X STIB 386). Routine growth and in vivo cloning of trypanosomes were carried out in 
adult female ICR mice. Immunosuppression of mice was conducted 24 hr prior to in vivo
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cloning of trypanosomes using cyclophosphamide at a dose of 150 mg/kg by 
intraperitoneal (i.p.) inoculation (Scott etal., 1997)
2.2.3 Optical cloning
Bloodstream form clones were produced by direct observation of single trypanosomes, 
under an inverted microscope, from the blood of an infected mouse. Blood was 
collected from the mouse by cardiac puncture into 150 pi of Carter’s Balanced Salt 
Solution (CBSS) and heparin. A drop was added to a 1:1 solution of guinea pig serum 
(GPS) (Sigma) and phosphate buffered saline with 1% glucose (PBSG). Drops were 
applied to the centre of each well in the plate, using the tip of a paper clip, making sure 
the drop did not touch the side. Dilutions of the blood in GPS+PBSG were carried out 
until a single trypanosome was observed from a drop of the mix observed in a well of a 
humidified Terasaki plate.
After detection of a single trypanosome, 10 pi of fresh GPS+PBSG was added to the 
well and then taken up into a syringe containing 150 pi of CBSS and heparin. The single 
trypanosome was then immediately inoculated into a mouse immunosuppressed with 
cyclophosphamide 24 hr previously. The mice were monitored daily for the presence of 
trypanosomes for up to 14 days. The parasites were then harvested at high 
parasitaemia (greater than 3.2 x 10  ^ml of blood) for PCR analysis. 200 pi of infected 
blood was used to make stabilates on the same day as harvesting from the mouse and 
cryopreserved (See below). The remainder of the blood was differentially spun at 1,100 
g for 7 mins to separate the trypanosomes from the blood. The serum was decanted 
and the buffy coat was removed and used to make DNA preparations for PCR analysis.
49
Chapter 2 Generation o f  unique hybrid lines in vitro and in vivo
2.2.4 In vitro growth of procyclic form trypanosomes
Blood was taken by cardiac puncture from infected ICR mice. Ten drops of infected 
blood was added to a culture flask containing 4.6 ml SDM-79 with 10% foetal calf serum 
and 3mM cis-Aconitate (to transform to procyclics forms) under sterile conditions (Brun 
and Schonenberger, 1981; Hunt et a/., 1994) and placed at 27°C for two-three days. 
The culture medium, containing procyclic forms was decanted, leaving the blood at the 
bottom of the flask, and re-suspended in 5 ml SDM-79 with 10% foetal calf serum and 
left to grow to a trypanosome density of 1 x 10® / ml at 27°C.
2.2.5 Procyclic cioning
Procyclic trypanosomes were cultivated in SDM-79 with 10% foetal calf serum (Gibco) 
and 2% gentamycin (Sigma) (Brun and Schonenberger, 1979) (See Appendix Table 
A1.A). A 10 pi aliquot was taken from the culture flask and the trypanosomes were 
counted using an Improved Neubauer haemocytometer. Procyclic clones were then 
obtained by diluting the culture to a concentration of 10 trypanosomes/ml in 
Cunninghams medium supplemented with 30% foetal calf serum and 2% 
streptomycin/penicillin. Cunninghams medium contains supplementary components to 
SDM-79 and has been shown to promote the growth of single trypanosomes, see 
Appendix Table A1.B (Cunningham, 1977). 100 pi aliquots of the diluted trypanosomes 
were added to the wells of a 96 well plate so as to obtain an average density of one 
trypanosome per well. The plate was then incubated at 27°C in an atmosphere of 5% 
CO2 for 14-28 days. The wells were screened for growing trypanosomes by microscopy 
and positive wells expanded by transferring the trypanosomes to culture flasks
50
Chapter 2 Generation o f  unique hybrid lines in vitro and in vivo
containing SDM -  79 and 10% foetal calf serum. After 2 - 3  days of growth DNA was 
prepared and the trypanosome genotype determined.
2.2.6 Stabilate preparation of bloodstream forms
Blood was withdrawn from an infected mouse and an equal volume of 7.5 % DMSO in 
CBSS (final concentration) was added to the blood. This was then injected into a 30 cm 
length of 2 mm Portex tubing (Portex Ltd) and the tubing cut into 1 cm lengths. These 
were then placed horizontally into a cryotube, placed in a polystyrene box filled with 
cotton wool and left at -70°C for 4-6 hr. The stabilates were then transferred to a liquid 
nitrogen container until required.
2.2.7 Stabilate preparation of procyclic forms
Cells at a density of not less than 10® / ml were taken from a culture flask and 900 pi of 
cell suspension was placed in a cryotube and 100 pi glycerol was added and the 
contents mixed by gentle inversion. The tubes were then placed at -70°C in a 
polystyrene box (described above), left overnight, and then transferred to liquid nitrogen 
until required.
2.2.8 General Polymerase chain reaction (PCR) procedure
All clones generated from both bloodstream and procyclic forms were genotyped using 
the polymorphic markers CRAM, MS 45, 292, PLC and JS2 (MacLeod et al., 1999; 
Barrett et al., 1997; Sasse et al., 1998; MacLeod, 1999). The primer sequences for 
these polymorphic markers are listed in Table 2.3. Due to the sensitivity of PCR, every 
precaution was taken to ensure that all reagents and materials were kept free of
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contaminating DNA. Therefore, all pipette tips and tubes were taken directly from the 
manufacture’s packaging in order to minimize exposure to laboratory contaminants. All 
PCR preparation was carried out in a laminar flow hood to avoid aerosol contamination.
All PCR reactions were prepared in 10 pi reaction volumes, unless otherwise stated, in 
45mM Tris-HCI pH 8.8, 11 mM (NH4)2S04, 4.5 mM MgCb, 6.7mM 2-mercaptoethanol, 
4.4mM EDTA, 113 pg/ml BSA, ImM each of the four deoxyribonucleotide triphosphates, 
1 pM of each oligonucleotide primer and one unit of Amplitaq Polymerase (Perkin 
Elmer, Cetus USA) using as the DNA template 1 pi of diluted crude lysate. Reaction 
mixtures were overlaid with mineral oil to prevent evaporation and amplifications were 
carried out in a Robocycier gradient 96 (Stratagene). The cycling conditions for each 
primer are listed in Table 2.3. PCR products were separated by electrophoresis in a 1 % 
Seakem agarose gel in 0.5 x TBE buffer (See Appendix A1) or a 4 % NuSieve gel for 
products under 800 bp and stained with ethidium bromide (0.5 pg/ml) and visualized by 
UV illumination.
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2.2.9 Quality control analysis for the determination of unique genotypes
Any possible new unique F1 progeny found were re-genotyped and scored by A.
MacLeod and A. Tweedie independently. Both sets of scored genotypes were then 
given to A. Tait for comparison to make sure they were new unique hybrids before any 
further analysis was carried out. A triple checking system is critical for linkage analysis, 
making sure all hybrids are unique and scored correctly.
The difference between independent progeny clones and unique progeny clones should 
be made clear. An independent progeny clone is defined as either having an unique 
genotype from all other progeny clones derived from the same fly when genotyped with 
the five polymorphic markers described above or, if not of unique genotype, then 
isolated from a different mating event i.e. a different fly.
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2.3 RESULTS
Genetic characterisation of clones as being hybrid was based on the inheritance of two 
PCR amplified bands that corresponded to one band from each parent for all the 
markers used. With the five polymorphic markers used for genotyping the progeny there 
were 64 possible progeny genotypes, which could be generated from each of the 
crosses STIB 247 x TREU 927 and STIB 247 x STIB 386. This is because STIB 247 
was homozygous for each of four of the markers CRAM, MS42, 292 and PLC whereas 
STIB 386 and TREU 927 were both heterozygous for each marker. All three parents 
were heterozygous for the microsatellite JS2 (Fig 2.2 A -  E). This prediction is based on 
the assumption of a Mendelian system of inheritance, i.e. the progeny are the products 
of mating between the two parental stocks, and that each inherits one allele from each 
parent.
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2.3.1 Generation of unique FI hybrid progeny in vitro
One stabilate containing the uncloned population F532/72 was thawed, inoculated into 
an ICR mouse and infected blood was collected and the trypanosomes transformed into 
procyclic stage trypanosomes (See Materials and Methods, section 2.2.4). Single 
procyclic trypanosomes were isolated from this culture and grown as clones. Initially 
cloning was carried out using SDM-79 medium, but no growing trypanosomes were 
obtained. Cunningham’s Medium contains supplementary components that have 
previously been shown to promote the growth of single trypanosomes (Cunningham, 
1977) and so this medium was tested in the cloning procedure and proved to be 
successful. Over 5,000 wells were screened for the presence of growing trypanosomes. 
After screening these wells for 4-5 weeks, a relatively low proportion of the wells were 
positive for growing trypanosomes, with 450 wells in total (9 %). It was found that 137 of 
the 450 wells (30 %) contained ‘clones’ that had inherited all alleles from both parents 
for one or more of the markers (See Appendix Table A2.A) and were thus likely to 
contain mixtures of more than one genotype (discussed later in this chapter). A further 
five clones had parental genotypes, that is they only inherited the two alleles of TREU 
927, this is discussed later in the chapter. The remaining 308 clones were identified as 
FI progeny, however the majority of these were identical to each other in terms of 
genotype using the markers described. For example, 52 FI progeny generated from the 
same batch of cloning gave identical genotypes for the markers used therefore only 1 
genotype was obtained (Fig 2.3), this occurred for two other batches of clones. One 
possible explanation for this finding was that selection of a particular genotype occurred 
either in the mouse or procyclic population prior to cloning. In total only 14 of the 308
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(4.5 %) F1 progeny were different genotypes and only 4 of these were new unique 
genotypes (28%) (Table 2.4). Therefore of the original 450 clones only 0.8 % were new 
genotypically unique F1 hybrid progeny. All hybrid progeny generated are listed in Table 
A2.A of the appendix.
Together, the low efficiency rates and the time required for the growth of cloned 
procyclics (approximately 4 weeks) led me to abandon this method as being too in­
efficient to generate the numbers of progeny required for this study in the time available. 
Also, although procyclic clones were useful for genetic mapping and phenotype studies 
in which the phenotype was expressed in procyclics, they could not be used in the 
future to study phenotypes expressed only in bloodstream forms, for example anaemia, 
without cyclical transmission of each new clone through tsetse flies. For these reasons, 
an alternative approach of optical cloning of bloodstream forms was undertaken.
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M 247 927 1 2 3 4 5 6 7 8 9 10 11
Allele 3 
Allele 4 
Alleles
Fig 2.3: PCR amplification of mlnlsatelllte marker 292 for 11 procyclic clones. Lanes 1 - 1 1  show 
the same pattern of allele inheritance for all the clones isolated from F532/72, derived from STIB 
247 X TREU 927 cross. Hybrids with identical genotype pattems are likely to be vegetative 
derivatives of a single mating event. M, 10Obp DNA ladder.
2.3.2 Isolation of unique FI hybrid progeny in vivo
Clones were made from three different uncloned hybrid trypanosome stocks (F124/28, 
F532/72 and F974/78) from the STIB 247 x TREU 927 cross. The stabilates from the 
three stocks were thawed, grown in mice and then single trypanosomes isolated 
optically and regrown in mice as outlined in Materials and Methods. In total, 145 mice 
were inoculated with single trypanosomes. Of the 145 injected mice, 61 developed 
trypanosome infections (42 %). After screening of these 61 clones it was found that 31 
were FI progeny (51 %). From the 31 FI hybrid progeny 15 were new unique FI 
progeny (49 %) (Table 2.4). There was some variation between the numbers of FI 
progeny generated from each of the three uncloned stabilates populations, with clones 
from F I24/28 producing the highest number of unique hybrids (Table 2.4 and Appendix 
Table A2.B).
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Five of the clones derived from mixed infected tsetse flies (one from F124/28 and four 
from F974/78) demonstrated the same allelic pattern as one of the parents for all of the 
markers analysed Fig 2.4, also Appendix Table A2.B. This is predicted as it has been 
shown that sexual recombination is not obligatory (Turner et al., 1990).
The remaining 25 clones (bloodstream forms) were mixtures/trisomic/ triploid. Analysis 
of these clones using the mini- and microsatellite markers indicated that these clones 
had inherited three alleles for one or more markers; both alleles from one parent (TREU 
927) and one alle from the other (STIB 247) (Appendix Table A2.B). Therefore, they 
appeard to be trisomie for one or two of the loci examined and appear to have the 
normal number of alleles for the other mini- and microsatellite markers. Inorder to 
determine if these clones are mixtures or trisomie they would require re-cloning. If the 
three band pattern disappeared on re-cloning then this would suggest that the clone 
was a mixture of two hybrid clones which differed at one/two loci. If, however, the clones 
continue to give a three band pattern after re-cloning this would indicate that these 
clones carried an extra allele at the locus/loci and it could be concluded that these 
clones were trisomie. Only one batch of clones (procyclic forms) appeared to be triploid, 
the results indicate that clones F532/72 pci 1-118 are probably trisomie for each of the 
chromosomes tested (each marker is located on a different chromosome), however 
analysis of their DNA content would need to be determined in order to prove if they are 
triploid (Appendix Table A2.A). Unfortunately it was beyond the scope of this study to 
investigate whether the clones were mixtures/trisomic or triploid.
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The same procedure was carried out for the generation of F1 progeny from the STIB 
247 X STIB 386 cross, using five uncloned populations; F9/41, FI 9/31, F28/46, F29/46 
and F57/40. In total 140 mice were inoculated with single trypanosomes from the five 
uncloned stocks and 44 developed trypanosome infections (31%). After screening with 
five mini and microsatellite markers it was found that three of the clones were parental 
(had the same genotypic pattern as the 386 parent for all markers) and 2 were 
mixtures/trisomic/triploid. The remaining 39 clones were FI hybrid clones of which 22 
were new unique genotypes (56 %) (Table 2.4 and Appendix Table A2.C). Similar 
numbers of unique hybrids were derived from each of the populations used. However 
for stabilate F57/40, only 3 clones were produced and when genotyped it was found that 
they were identical to the STIB 386 parent.
M 1 2 3 4 5 6 7 247 927
Allele 3 
Allele 4 
Allele 5
Fig 2.4: Identification of parental clones derived from a genetic cross of STIB 247 x TREU 927.
Lanes 1 -  7 are bloodstream clones derived from the optical cloning of F974/74.Genotype 
analysis with the minisatellite 292 revealed that clones 1, 2, 4 and 5 had alleles of the parental 
line TREU 927 and so were considered parental clones. M 10Obp DNA ladder.
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Some hybrids inherited more than two alleles from the parental lines when analysed 
with one of the mini or microsatellite markers. However, for the other markers the same 
clones appeared to have inherited two alleles only. Fig 2.5 illustrates tri-allelic 
inheritance for the minisatellite marker 292. There are three plausible explanations for 
this result. Firstly, that the sample was a mix of two hybrid clones that differed only at 
the 292 locus. Secondly, the clone could be trisomie for the chromosome carrying the 
292 marker (chromosome 111). Finally, a gene duplication event could have generated 
an extra copy of the locus (MacLeod, A., personal communication). In order to prove if 
the clones displaying a three band pattern were trisomie they would all have needed to 
be recloned and their genotype determined. If the three band pattern was still observed 
then the clones would be considered trisomie. If the clones, however, no longer gave a 
three band pattern after recloning then the original stock must have been a mixture of 
two hybrid clones. Unfortunately it was beyond the scope of this study to redone all the 
possible trisomie clones. Only one mix/trisomic clone was recloned to determine if it was 
trisomie and also to potentially generate more unique F1 progeny from a mixture. The 
results of the recloning of F532/72 bsci 15 are discussed below.
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M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 247 927 M
Allele 3 
Allele 4 
Allele 5
Fig 2.5: Identification of mixtures/trisomic clones. Lanes 1 - 2 3  were bloodstream clones isolated 
after optical cloning of F I24/28 derived from STIB 247 x TREU 927 cross. Lanes 4, 7, 8, 10, 21 
and 23 have inherited two alleles from parent TREU 927 giving a 3 banded pattern when 
genotyped with the minisatellite 292. Further analysis would be required to determine if these 
clones are trisomie or just mixtures (See text). M, lOObp and 260bp DNA ladders. All PCR 
conditions are listed in Materials and Methods and Table 2.2
It is obvious from these data that there is a startling difference between the numbers of 
new unique F1 hybrid progeny generated from bloodstream compared to procyclic 
cloning approaches. Analysis of all the clones using the four minisatellites and one 
microsatellite are presented in Tables A2.A-C of the appendix and a summary of the 
results is presented in Table 2.5. From the procyclic cloning only 1.3 % of the 308 FI 
hybrid clones were new unique FI progeny whereas with the optical cloning of 
bloodstream forms 43 % and 56 % of the FI clones were new for the STIB 247 x TREU 
927 and STIB 247 x STIB 386 crosses, respectively. The only limitations with 
generating even larger numbers of bloodstream form clones were the numbers of 
animals required and the time and labour involved.
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In order to try and boost the number of hybrids for the F532/72 population a mix/trisomic 
clone previously isolated from the first round of cloning, F532/72 bsci 15, was recloned. 
This isolate had a mix of parental alleles for marker JS2, that is, it had inherited more 
than one allele from one of the parents. After recloning of F532/72 bsci 15, the three 
band pattern for JS2 disappeared, confirming that the original stock must have been a 
mixture of two hybrid clones. Analysis revealed one further new unique hybrid, F532/72 
bsci 15 5b, from the seven sub-clones that were isolated (Appendix Table A2.B).
There may be several explanations for the variation observed in the numbers of unique 
hybrid progeny isolated from the different crosses. For example, only 3 new genotypes 
were detected from F532/72 bloodstream clones in comparison to 10 for F I24/28 from 
the STIB 247 x TREU 927 crosses. However for the STIB 247 x STIB 386 cross there 
were approximately equal numbers of unique hybrid progeny generated from each of 
the uncloned stabilates. There are several proposed explanations for the lack of genetic 
diversity amongst the hybrids generated from F532/72. 1) It is possible that selection for 
particular genotypes occurs in the salivary glands of the tsetse, with certain genotypes 
not being viable. 2) The expansion of the population in a mouse selected for a particular 
genotype. 3) It has been shown that the parental stocks have different rates of growth in 
mice (Turner et al., 1995). The most likely scenario is, however, that as bloodstream 
clones had previously been isolated from fly F532/72, the predominant genotypes had 
already been identified.
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In summary, the results of these experiments were that the number of progeny available 
for genetic analysis for the cross STIB 247 x TREU 927 increased from 18 to 38. The 
equivalent increase for the cross STIB 247 x STIB 386 was from 12 to 34. The number 
of hybrid progeny aids in the determination of Mendelian inheritance of the trait of 
interest i.e. if it segregates in a 1:1 ratio. Therefore, if the number of hybrid progeny is 
high then proving or disproving Mendelian inheritance is much easier and gives 
confidence in the result determined.
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Table 2A: All genotypically unique F I hybrid progeny generated from genetic crosses._____
Genotypically unique trypanosome F1 hybrids derived from genetic crosses
Markers
Identification Lysate
No.
GUP
No.
CRAM 292 MS42 JS2 PLC
Parental 247 
Parental 386 
Parental 927
1 -1  
1 -2  
3 - 4
5 - 5  
1 -2  
3 - 4
5 - 5  
1 -2  
3 - 4
5 - 6  
1 -2  
3 - 4
5 - 5  
1 -2  
3 - 4
Cross 247 x 927
F124/28 bsci 05 71 4635 1 -4 3 - 5 4 - 5 4 - 6 4 - 5
F I24/28 bsci B3 73 4923 1 -4 3 -5 4 - 5 4 - 6 3 - 5
F974/70 mcl 4 77 3086 1 -4 3 - 5 4 - 5 3 - 5 4 - 5
F532/63 bsci 2 80 4630 1 -4 3 - 5 3 - 5 3 - 6 4 - 5
F532/63 bsci 3 78 4925 1 -4 4 - 5 4 - 5 4 - 5 4 - 5
F532/63 bsci 7 79b 4631 1 -4 4 - 5 4 - 5 3 - 6 4 - 5
F532/63 bsci 5 81 4634 1 -3 3 - 5 4 - 5 3 - 6 4 - 5
F532/72 mcl 5 88 4392 1 -4 4 - 5 4 - 5 3 - 5 3 - 5
F532/72 mcl 1 84 4391 1 -4 4 - 5 3 - 5 3 - 5 3 - 5
F532/72 mcl 2 85 4636 1 -4 4 - 5 3 - 5 4 - 5 4 - 5
F532/72 mcl 3 86 4427 1 -4 4 - 5 4 - 5 4 - 5 3 - 5
F532/72 mcl 6 89 4393 1 -3 3 -5 3 - 5 4 - 5 4 - 5
F532/72 mcl 7 90 4628 1 -4 4 - 5 4 - 5 4 - 6 3 - 5
F532/72 mcl 8 91 3538 1 -4 3 - 5 4 - 5 4 - 5 3 - 5
F532/63 cl 16 171 1 -4 3 - 5 4 - 5 3 - 5 3 - 5
F532/72 mcl 9 92 4366 1 -4 4 - 5 4 - 5 3 - 6 3 - 5
F532/63 cl A ll 170 1 -3 4 - 5 3 - 5 3 - 6 4 - 5
F532/63 bsci A14/1 346 1 -3 3 -5 4 - 5 3 - 6 3 - 5
F532/72 pci 1 334 1 -3 4 - 5 4 - 5 3 - 5 4 - 5
F532/72 pci 5 359 1 -3 4 - 5 3 - 5 4 - 5 3 - 5
F532/72 pci 7 362 1 -4 3 - 5 3 - 5 4 - 6 3 - 5
F532/72 pci 8 374 1 -3 4 - 5 3 - 5 4 - 6 F
F532/72 bsci 1 356 1 -4 3 - 5 3 - 5 3 - 5 3 - 5
F532/72 bsci 2 357 1 -4 3 - 5 3 - 5 4 - 5 4 - 5
F532/72 bsci 15/5B 434 1 -3 3 - 5 3 - 5 4 - 6 3 - 5
F124/28 bsci 1 361 1 -3 4 - 5 3 - 5 4 - 6 3 - 5
F124/28bscl3 368 1 -3 3 - 5 4 - 5 4 - 5 4 - 5
F124/28bscl5 369 1 -4 3 - 5 4 - 5 3 - 5 4 - 5
F124/28 bsci 9 363 1 -4 3 - 5 3 - 5 3 - 6 3 - 5
F124/28 bsci 12 364 1 -4 3 - 5 3 - 5 4 - 6 3 - 5
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Table 2A  cont.
Genotypically unique trypanosome F1 hybrids derived from genetic crosses
Markers
Identification Lysate
No.
GUP
No.
CRAM 292 MS42 JS2 PLC
Parental STIB 247 1 -1 5 - 5 5 - 5 5 - 6 5 - 5
Parental STIB 386 1 -2 1 -2 1 -2 1 -2 1 -2
Parental TREU 927 3 - 4 3 - 4 3 - 4 3 - 4 3 - 4
Cross 247 x 927
F124/28 bscMS 365 1 -3 3 - 5 3 -5 4 - 6 3 - 5
F124/28 bsci 14 375 1 -4 3 - 5 4 - 5 3 - 5 3 - 5
F124/28 bsci 15 366 1 -3 4 - 5 4 - 5 4 - 5 4 - 5
F I24/28 bsci 20 367 1 -3 3 - 5 3 - 5 4 - 5 F
F124/28 bsci 22 373 1 -4 4 - 5 4 - 5 4 - 5 4 - 5 ,  ^
F974/78 bsci 3 370 1 -4 4 - 5 3 - 5 4 - 5 4 - 5 " 4
F974/78 bsci 6 371 1 -3 4 - 5 4 - 5 4 - 6 3 - 5  S
F974/78 bsci 7 372 1 -4 3 - 5 3 -5 4 - 5 4 - 5
Cross 247 x 386
F9/45 mcl 2 30 3300 1 -2 1 -5 2 - 5 1 -5 1 -5
F9/45 mcl 10 34 5060 1 -1 2 - 5 1 -5 1 -6 2 - 5
F9/45 mcl 11 35 3287 1 -2 1 -5 1 -5 1 -5 2 - 5
B80 cl 2 162 1 -2 2 - 5 2 - 5 2 - 6 2 - 5
F492/50 bsci 1 174 174 1 -1 2 - 5 1 -5 2 - 6 2 - 5
F492/50 bsci 5/1 b 332 5316 1 -2 1 -5 1 -5 2 - 6 2 - 5
F492/50 bsci 8 181 5317 1 -1 2 - 5 1 -5 1 -6 2 - 5
F492/50 bsci 9 182 4688 1 -2 1 -5 2 - 5 2 - 5 2 - 5
F492/50 bsci 12 185 1 -1 2 - 5 2 - 5 2 - 5 1 -5
F492/50 bsci 18 191 4949 1 -2 1 -5 1 -5 2 - 6 2 - 5
F492/50 bsci 21 194 4950 1 -1 1 -5 1 -5 2 - 6 2 - 5
F492/50 bsci 23 196 4954 1 -2 1 -5 1 -5 2 - 5 2 - 5
F9M1 bsci 1 415 1 -1 2 - 5 2 - 5 1 -6 1 -5
F9/41 bsci 2 416 1 -1 1 -5 1 -5 1 -6 1 -5
F9/41 bsci 5 383 1 -2 2 - 5 2 - 5 1 -5 2 - 5
F9/41 bsci 7 384 1 -2 2 - 5 2 - 5 1 -5 1 -5
F9/41 bsci 8 420 1 -1 2 - 5 1 -5 1 -5 1 -5
F9/41 bsci 9 385 1 -1 1 -5 1 -5 2 - 6 2 - 5
67
Chapter 2 Generation of unique hybrid lines in vitro  and in vivo
Table 2A  cont.
Genotypically unique trypanosome F1 hybrids derived from genetic crosses
Markers
Identification Lysate
No.
GUP
No.
CRAM 292 MS42 JS2 PLC
Parental STIB 247 1 -1 5 - 5 5 - 5 5 - 6 5 - 5
Parental STIB 386 1 -2 1 -2 1 -2 1 -2 1 -2
Parental TREU 927 3 - 4 3 - 4 3 - 4 3 - 4 3 - 4
Cross 247 x 386
F9/41 bsci 11 422 1 -2 1 -5 1 -5 1 -5 2 - 5
FI 9/31 bsci 1 389 1 -2 2 - 5 1 -5 1 -6 1 -5
FI 9/31 bsci 5 425 1 -1 1 -5 1 -5 1 -6 2 - 5
F I9/31 bsci 8 428 1 -2 1 -5 1 -5 2 - 5 2 - 5
FI 9/31 bsci 10 430 1 -2 1 -5 1 -5 2 - 6 2 - 5
FI 9/31 bsci 11 391 1 -1 1 -5 1 -5 1 -5 2 - 5
F28/46 bsci 1 407 1 -1 1 -5 1 -5 2 - 5 1 -5
F28/46 bsci 4 409.1 1 -2 1 -5 1 -5 2 - 6 2 - 5
F28/46 bsci 6 394.1 1 -2 1 -5 1 -5 2 - 5 2 - 5
F28/46 bsci 7 410.1 1 -1 2 - 5 1 -5 2 - 5 1 -5
F28/46 bsci 8 411 1 -2 2 - 5 2 - 5 2 - 6 2 - 5
F28/46 bsci 11 405 1 -2 2 - 5 2 - 5 2 - 5 2 - 5
F29/46 bsci 1 414 1 -1 2 - 5 1 -5 1 -5 1 -5
F29/46 bsci 2 406 1 -1 1 -5 1 -5 2 - 6 2 - 5
F29/46 bsci 3 386.1 1 -1 1 -5 1 -5 2 - 6 2 - 5
F29/46 bsci 4 387.1 1 -1 1 -5 1 -5 2 - 6 1 -5
Cross 386 x 927
F296/39 22/1 264 1 -4 1 -3 1 -3 1 -4 2 - 3
F296/39 24/1 269 1 -4 2 - 3 1 -3 2 - 3 1 -3
F296/39 bsci 7 207 1 -4 2 - 3 1 -3 2 - 3 1 -3
F296/39 bsci 9 209 1 -4 2 - 3 1 -3 2 - 3 1 -3
F296/44 bsci 1 2 3199 2 - 3 2 - 3 1 -3 1 -3 2 - 3
F296/44 bsci 3 6 3201 1 -3 1 -3 1 -3 1 -4 2 - 3
F296/44 bsci 4 5 3204 1 -4 1 -4 1 -4 1 -3 1 -3
Table 2.4: All genotypically unique F1 hybrid progeny generated from genetic crosses. The cross 
from which each clone Is derived and individual identification numbers given to each hybrid 
clone are listed in column 1 and these are used throughout the study. The nomenclature 
follows that of Sternberg et al., 1989. For example F28/46 bsci 6, was the sixth clone isolated 
from fly 28, on day 46 post infection. Columns 2 and 3 give additional identification numbers 
i.e. stabilates and lysate numbers, where available. Columns 4-7 give the results of the mini 
and microsatellite marker analysis. Alleles are numbered 1-5 for the minisatellites, CRAM, 
292, MS42 and PLC, and 1-6 for the microsatellite JS2. Shaded rows indicate the new unique 
FI hybrid progeny generated in this study. GUP, Glasgow University Parasitology. 
Bloodstream clones from the same tsetse fly, sampled on the same day and conferring the 
same genotypic pattem were considered to have arisen from one sexual recombination event 
and so were represented by one clone in the above tables. The complete sets of results of all 
clones are listed in Tables A2.A-C of the Appendix.
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Stabilate BSCL
or
PCL
P I P2 Total 
No. of 
Clones
Hybrid
progeny
Mix/
Trisomic/Triploid
Parentals No.
Unique
progeny
F532/72 PCL 247 927 450 313 137 0 4
F532/72 BSCL 247 927 18 10 8 0 2
F124/28 BSCL 247 927 34 16 17 1 10
F974/78 BSCL 247 927 9 5 0 4 3
F532/72 15/5B BSCL 247 927 7 7 0 0 1
F9/41 BSCL 247 386 11 10 1 0 7
FI 9/31 BSCL 247 386 14 13 1 0 5
F28/26 BSCL 247 386 11 11 0 0 6
F29/46 BSCL 247 386 5 5 0 0 4
F57/40 BSCL 247 386 3 0 0 3 0
Table 2.5: Summary table of all clones generated for STIB 247 x TREU 927 and STiB 247 x STIB 
386 crosses. Listed In column 1 is the identification of the tsetse fly from which the clones 
were derived, using the nomenclature previously described by Sternberg et al., 1989. 
Column 2 states whether the clones were procyclic forms (PCL) or bloodstream forms 
(BSCL). Columns 3 and 4 are the parental lines used for the genetic cross. Columns 5-8  
list the overall total of clones obtained from cloning of single trypanosomes from each 
tsetse fly, the number of hybrid progeny, number of mixes/trlsomics/triploids and parentals. 
Finally, column 9 lists the overall number of new unique FI hybrid progeny generated from 
each tsetse fly. P I and 2, parent 1 and 2.
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2.3.3 Inheritance of mini and microsatellite marker for all hybrids generated from 
crosses.
The alleles at each locus appear to be inherited in a Mendelian manner as most allele 
combinations were observed in the F1 hybrid progeny (Table 2.4). The pattern of allele 
inheritance also shows that alleles at unlinked loci assort independently (see for 
example Fig 2.6). Thus the progeny are genetically different and as a result must be the 
products of independent mating events.
For the STIB 247 x TREU 927 cross, 16 unique genotypes were detected out of 38 
hybrids (excluding mixes and parentals) from optical cloning of bloodstream forms and 
of the 308 procyclic clones (excluding mixes) only four had unique genotypes. With the 
STIB 247 X STIB 386 cross 22 unique genotypes were detected out of 39 hybrids 
(excluding mixes and parentals) (Table 2.5). As shown in Table 2.4 some genotypes of 
the unique progeny clones are identical but because they have been isolated from 
different flies (independent crosses) they were considered as independent progeny as 
they were products of separate mating events. The probability of obtaining an identical 
progeny clone from two independent crosses will be very low in the absence of 
selection. Thus although the progeny clones are identical for the five markers screened 
here, they should be different when further markers are analysed.
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A CRAM
M 1 2 3 4 5 6 7 8 9 10 11 247 386 M
BMS42
 <------  Allele 1
 < Allele 2
M 1 2 3 4 5 6 7 8 9 10 11 247 386 M
Allele 1 
Allele 2 
Allele 5
Fig 2.6 Inheritance of minisatellite markers for hybrid clones. STIB 247 x STIB 386 cross hybrid 
progeny clones (lanes 1 - 1 1 )  generated from the population F9/41 screened for (A) CRAM and 
(B) MS42. Each panel shows allelic segregation and a comparison of the panels shows 
independent assortment. M is a 100 bp DNA marker.
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2.3.4 Test for Mendelian inheritance of each marker for STIB 247 x TREU 927 and 
STIB 247 X STIB 386 crosses
The generation of a larger number of unique progeny clones and their genotyping with 
five markers each located on different chromosomes allows the testing of whether T. 
brucei has a Mendelian genetic system. In order to determine if the ratio of the hybrid 
genotypes segregate in a manner that conforms to those predicted by Mendelian 
segregation a statistical analysis was undertaken (Table 2.6). The data used to 
determine Mendelian segregation were obtained by combining the results from the 
clones previously generated (MacLeod, 1999) and the newly generated clones from this 
study. Comparisons were made between the observed frequency of genotypes and the 
expected number of genotypes assuming 1:1 segregation of alleles inherited from either 
STIB 386 or TREU 927. This analysis demonstrated that the majority of markers do not 
deviate from the allele segregation ratio predicted by Mendelian inheritance i.e. 1:1 
ratio. Two markers, MS42 and PLC however, show a statistical deviation from a 1:1 
segregation, for the STIB 247 x STiB 386 cross. There are a number of reasons that 
could explain why these markers did not agree with Mendelian segregation; 1) 
Segregation distortion where there was selection of one particular genotype over 
another, 2) There was a relatively small sample size, therefore, if the number of hybrid 
progeny was increased this distortion could disappear.
72
Chapter 2 Generation o f  unique hybrid lines in vitro and in vivo
Cross Marker Segregating
Alleles
Observed
(Expected)
t
Accept/ reject 
df Ho significance 
of 0.05
CRAM 3 15(19) Accept
STIB247 X TREU927 4 23(19) 1.68 1 0.2 > P>0.1
MS 42 3 19(19) Accept
4 19(19) 0 1 P < 0.99
292 3 21 (19) Accept
4 17(19) 0.42 1 0.7 > P > 0.5
JS2 3 14(19) Accept
4 24(19) 2.6 1 0.2 > P>0.1
PLC 3 19(19) Accept
4 19(19) 0 1 P <0.98
CRAM 1 17(17) Accept
STIB247 X STIB386 2 17(17) 0 1 P < 0.99
MS 42 1 25 (17) Reject
2 9(17) 7.52 1 P <0-01
292 1 20(17) Accept
2 14(17) 1.06 1 0.5 > P > 0.3
JS2 1 14(17) Accept
2 20 (17) 1.06 1 0.5 > P > 0.3
PLC 1 11 (17) Reject
2 23 (17) 4.2 1 0.05 > P > 0.02
Table 2.6: Statistical test of segregation ratios for each of the five markers in the crosses STiB 
247 X TREU 927 and STiB 247 x STIB 386. The numbers of each allele type inherited into 
the F1 progeny is indicated in column 3 (observed). The expected numbers are shown In 
brackets and assume a 1:1 segregation in all cases. The final column shows whether or not 
the null hypothesis is accepted or rejected at a significance level of 0.05.
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2.4 DISCUSSION
The generation of new unique F1 hybrid progeny from previously uncloned populations 
from STIB 247 x TREU 927 and STIB 247 x STIB 386 crosses increased the number 
available for further analysis from 18 to 38 and 12 to 34 respectively.
There was a marked variation in the number of unique genotypes generated by cloning 
procyclic forms or bloodstream forms. Only four new progeny clones were generated 
from procyclic forms whilst all other new FI hybrids were derived from bloodstream form 
cloning. The initial problem with procyclic cloning was the culture medium used. Whilst 
SDM-79 was effective for the long term maintenance of procyclic forms it was not 
suitable for the growth of a single trypanosome, giving cloning efficiency rates of 5- 
10%. It was found that when the same procedure was carried out using Cunningham’s 
medium, with 30% foetal calf serum, the efficiency rate increased to approximately 30%. 
Even with this increase in efficiency, however, the number of unique genotypes 
generated was low in comparison to the number produced by the optical cloning of 
bloodstream forms.
One possible explanation as to why the procyclic cloning was not efficient in generating 
many different genotypes could be that the trypanosome population had gone through a 
potential bottleneck that might reduce the diversity in the uncloned population. The 
reason for this is that within the mammalian host it is known that trypanosomes of 
different genotypes grow at varying rates, which could lead to selection (Turner et ai, 
1995).
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Optical cloning of bloodstream forms was not, however, without its drawbacks. It 
required the use of a large number of animals and was a very time consuming, labour 
intensive task and yielded a high number of mixed infections due to the difficulty in 
trying to isolate a single trypanosome and introducing it successfully to an 
immunosuppressed mouse within a minimal time period. However, the data suggest 
that, in principle, generating large numbers of unique progeny clones would be possible.
The data show that the alleles at five loci segregate into the F1 progeny in ratios that 
conform to those predicted by Mendelian segregation i.e. 1:1 ratio, for most of the 
markers tested, as would be predicted in a standard diploid genetic system involving 
meiosis. The independent assortment of alleles at different loci has also been 
demonstrated (Fig 2.6). Taken together, the data establish that the sexual process in T. 
brucei follows a Mendelian system. The formal proof that the genetic system is 
Mendelian allows the analysis of the segregation of phenotypes that differ between the 
parental lines and from this the analysis of the genetic basis for such phenotypes.
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CHAPTER 3
AN INVESTIGATION OF THE POTENTIAL DEVELOPMENT OF BLOODSTREAM 
FORMS FROM PROCYCLIC FORMS WITHOUT CYCLICAL TRANSMISSION
THROUGH TSETSE FLIES
3.1 INTRODUCTION
Procyclic trypanosomes have been widely used in trypanosome research, largely 
because of the ease with which they can be grown to substantial numbers in in vitro 
culture (Brun and Jenni, 1985). In the particular context of genetic studies, they are 
useful for genetic mapping and analysis of the inheritance of traits such as arsenical 
drug resistance where the trait is expressed in procyclic cells. They cannot be used, 
however, to investigate the inheritance of traits that are expressed only in the 
bloodstream stage of the life-cycle such as human serum resistance, virulence and 
anaemia.
Transformation of trypanosomes from bloodstream to procyclic forms is a tractable and 
well characterised developmental process in the life-cycle (Matthews and Gull, 1994), 
in comparison with developmental processes in the rest of the life-cycle, which are only 
poorly understood (Van den Abbeele et al., 1998) and it has proven extremely difficult to 
replicate development in the fly in in vitro culture (Hirumi et al., 1992).
There would be considerable advantages in being able to move trypanosomes from 
procyclic forms, which are easy to grow and genetically manipulate, to bloodstream 
forms that cause disease if it avoided the requirement for full cyclical development
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through tsetse flies. There is slight evidence in the literature that an approach to avoid 
full development through the life-cycle and transform procyclics to bloodstream forms 
directly should be possible, but this evidence is barely more than anecdotal reports 
(Cross, 1975; Kaminsky ef a/., 1987; Hirumi, 1992).
In this Chapter 1 describe a systematic series of experiments to follow up on these 
reports by manipulating procyclic forms in a number of simple ways and testing whether 
they become infective for mice.
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3.2 MATERIALS AND METHODS
3.2.1 Inoculation of mice with procyciic forms
Procyclic forms of STIB 247 and TREU 927 were cultivated in SDM-79 with 10% foetal 
calf serum, as described in Materials and Methods, section 2.2.4, grown to a density of 
2 X 10® /ml. The cells were then re-suspended in, Cunninghams medium with 30% 
foetal calf serum or SDM-79 with 10 % foetal calf serum. Five immunosuppressed mice 
for each group (Materials and Methods, section 2.2.2) were inoculated via i.p inoculation 
with 1x10® trypanosomes/ml from log phase cultures. Mice were monitored for 14 days 
for evidence of parasitaemia. The same procedure was also carried out with procyclic 
cells that had reached stationary phase of growth. Two procyclic clones (PCL) derived 
from procyclic cloning, F532/72 PCL 8 and F532/72 PCL 12, were also grown to log and 
stationary phases in both media listed above and mice were inoculated with 1x10® 
trypanosomes/ml and parasitaemia monitored.
3.2.2 Tsetse fly infection
In parallel, the two procyclic clones, STIB 247 and TREU 927 were separately cultivated 
in both Cunninghams and SDM-79 media to a density of 2 x 10® /ml. Ten tsetse flies 
(Glossina morsitans) for each of the four lines and for both types of media were placed 
in individual holding tubes. The 8 groups of tsetse flies were membrane-fed with 5 ml 
horse blood containing 1x10® trypanosomes/ml of each culture of trypanosomes. A 
sample from the horse blood inoculated with procyclic forms was taken to check that the 
cells had not lysed and after 45min the cells were still found to be viable. Two days later 
the flies were fed again with infected blood. The fifth day after infection the flies were
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given a maintenance feed with horse blood. Eight to ten days after the first infective 
feed the flies were dissected and the presence of a midgut infection determined. The 
flies were maintained at 28°C in 75% humidity.
3.2.3 Tsetse fly dissection and mouse inoculation
The tsetse flies were placed on ice for 30 min. Their wings and legs were then removed 
and their body immobilized with a pin through the thorax. The tsetse flies were 
dissected by making a dorsal mid -  line incision through the abdomen. The gut was 
removed, placed on a slide with a drop of PBS and examined microscopically for the 
presence of trypanosomes. The entire contents of any positive gut infections were taken 
up into a syringe containing 1 ml PBS and injected into immunosuppressed mice. One 
mouse was used for each infected fly gut. The mice were monitored for parasitaemia for 
14 days.
3.2.4 Full Cyclical Development In the Tsetse fly
Tsetse flies were infected in the same way as described above. After maintenance for 
28 days each tsetse was probed for the presence of a metacyclic infection. This was 
achieved by placing each tubed fly on a microscope slide on top of a heating plate. The 
flies are attracted to the heat and they salivate onto the slide. Microscopic examination 
of the slide determines the presence of metacyclic trypanosomes. If any infection was 
detected then the flies were allowed to feed directly on an immunosuppressed mouse 
and the development of a bloodstream infection was monitored over 14 days.
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3.3 RESULTS
STIB 247, TREU 927 and two procyclic clones were grown to log phase in SDM-79, 
inoculated into five mice but yielded no bloodstream infections in mice. Similarly, the 20 
mice inoculated with the lines grown to log phase in Cunninghams medium gave no 
bloodstream infections after 21 days of monitoring. The same result was observed with 
the cells that had been grown in both culture media until stationary phase -  no 
bloodstream infections developed after 21 days of monitoring for parasitaemia.
Of the 80 tsetse flies infected with STIB 247, TREU 927 and two procyclic clones, 36 
survived past one week. Of these 36 flies 23 contained the forms grown in 
Cunninghams medium. In total 21 flies had developed midgut infections 16 of which 
were those grown initially in Cunninghams medium (Table 3.1). The percentage of flies 
in which midgut infections established was in the range of 33-88% (Table 3.1). The 
values were consistently higher when the procyclic trypanosomes were grown in 
Cunninghams medium rather than SDM-79. Immunosuppressed mice were inoculated 
with the gut contents of the tsetse flies suspended in PBS and their parasitaemias 
monitored for 14 days. After 14 days, however no bloodstream infections were 
observed.
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Procyclic Culture No. of 
surviving 
flies
No. of flies with 
mid-gut 
infections
DAY 8 -DAY 10
% of fly gut 
Infections
No. of mice 
developing 
parasitaemia
STIB 247 (SDM-79) 5 2/5 40 0
STIB 247 (CUNN) 8 7/8 88 0
TREU 927 (SDM-79) 2 1/2 50 0
TREU 927 (CUNN) 5 3/5 60 0
F532/72 PCL 8 (SDM-79) 3 1/3 33 0
F532/72 PCL 8 (CUNN) 6 4/6 66 0
F532/72 PCL12(SDM-79) 3 1/3 33 0
F532/72 PCL 12(CUNN) 4 2/4 50 0
Table 3.1; Tsetse flies infected with procyciic trypanosome cultures. Column 1 shows the procyclic 
trypanosome lines used to infect tsetse flies and the culture medium they were cultivated in. 
Column 2 indicates the number of flies, out of ten, which survived infection. Dissection of the 
surviving tsetse flies showed that 21 of the flies had trypanosome mid-gut infections on either 
day 8 or 10 post Infection as indicated in column 3. The percentage of fly gut infections for 
each group is given in column 4. Finally, column 6 shows the number of mice developing 
bloodstream infection after inoculation with the contents of the Infected mW-gut Cunn -  
Cunninghams medium.
As the percentage of tsetse flies developing fly gut infection was substantially higher 
using Cunninghams medium it was decided to repeat the experiment. Due to the fact 
that the procyclic forms in the previous experiment had initially been transformed from 
bloodstream forms to procyclic forms in SDM-79 and then transferred to Cunninghams 
it was thought that SDM-79 could have had an adverse effect on the transmissibility to 
the tsetse flies. Therefore, bloodstream forms of STIB 247 and TREU 927 were grown 
up in mice, harvested at the peak of parasitaemia and transferred to Cunninghams 
medium with 30% foetal calf serum (without cis-Aconitate) and grown to a density of 2 x 
10® /ml (see Materials and Methods, section 2.2.4). These procyclic forms were then
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used to infect 20 tsetse flies, 10 for each line, and after 10 days the flies were dissected 
and the presence of midgut infection determined. It was found that 15 of the 20 flies had 
midgut infections (Table 3.2). The content of each midgut was transferred to an 
immunosuppressed mouse, but after 14 days of monitoring no bloodstream infections 
were observed.
Procyclic Culture No. of surviving No. of flies with 
flies mid-gut
infections
DAY 10
% of fly gut 
infections
No. of mice 
developing 
parasitaemia
STIB 247 
TREU 927
8/9
7/9
89
78
Table 3.2: Tsetse flies infected with procyclic trypanosome cultures grown in Cunninghams 
medium. Column 1 shows the procyclic trypanosome lines used to infect tsetse flies and the 
culture medium friey were cultivated in. Column 2 Indicates the number of flies, out of ten, 
which survived infection. Dissectbn of the surviving tsetse flies showed that 15 of the flies 
had trypanosome mid-gut infections on either day 10 post infection as indicated in column 3. 
The percentage of fly gut infections for each group Is given in column 4. Finally, column 5 
shows the number of mice developing bloodstream infection after inoculation with the 
contents of the infected mid-gut.
The two FI procyclic clones, F532/72 PCL 8 and F532/72 PCL 12 were also taken 
through full cyclical development in the tsetse fly as positive controls. Of the ten flies 
infected for each clone two of the flies infected with F532/72 PCL 8 had metacyclics 
present in the salivary glands and three of the flies infected with F532/72 PCL 12. 
After these five flies were allowed to feed on immunosuppressed mice bloodstream 
infections were observed in one of the mice inoculated with F532/72 PCL 8 metacyclics 
and two of the mice that had been inoculated with F532/72 PCL 12 metacyclics. This 
indicated that full cyclical development in the tsetse fly is required to obtain bloodstream 
forms from procyclic forms. These two clones are represented in Table 2.4 as F532/72
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BCL 1 and BCL 2, respectively as they were transformed from procyclic clones to 
bloodstream clones, but only after full development in the tsetse fly. Sarah McLelland 
did the majority of the positive control analysis.
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3.4 DISCUSSION
Unfortunately this was not a very fruitful investigation in that no bloodstream forms were 
derived from procyclic forms without cyclical transmission through tsetse flies. There are 
several explanations why transformation from procyclic forms to bloodstream forms 
without firstly developing to metacyclics during cyclical transmission through tsetse flies 
may occur.
The life cycle stages in the vector are well documented, from the procyclic midgut 
infection to the development of metacyclic trypanosomes (Vickerman, 1985) and have 
been described in Chapter 1. Little is known, however, about the intermediate phase 
that involves the migration of T. brucei from the midgut through the proventriculus to the 
salivary glands. It is possible that this migratory phase is of vital biological significance 
for the completion of the developmental cycle in the tsetse fly (Van den Abbeele et al., 
1998). In order to complete the life-cycle the trypanosome must get through two 
successive barriers, colonization of the midgut and establishment in the salivary gland 
both of which are independent of each other (Van den Abbeele et a!., 1998). The post 
mesocyclic migratory stage in the parasite life-cycle is an essential bridge for the 
established midgut infection and metacyclic development in the salivary glands (Van 
den Abbeele et a!., 1998). Midgut infections, which do not continue development, 
therefore remain procyclic immature infections for the life of the tsetse fly and are non- 
infective (Welburn and Maudlin, 1997).
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During the developmental cycle the trypanosome is expressing different genes. For 
example, trypanosomes switch off variable antigen gene expression when bloodstream 
T. brucei transform to procyclic forms because of the change in environment. 
Trypanosomes at different developmental stages, however, may occupy the same 
environment, e.g. epimastigote and metacyclic forms in the salivary glands. As a result, 
it is likely that a predetermined series of events leads to the production of the mature 
metacyclic infective form (Vickerman, 1985). If is not known if the trypanosome cycle is 
unidirectional i.e. if stages A B—> C , can also transform B ->A or C B. Similarly, 
can any stage be omitted completely and full cyclical development still occur (A C)? 
One study found that when procyclic trypanosomes were grown in vitro in the presence 
Anopheies gambiae cells, some developed into metacyclic forms infective for mice, and 
the animals developed non-relasping and fatal infections. Control cultures, however, 
that had been grown in the absence of A. gambiae cells also produced forms that lead 
to infections in mice but these were weak parasitaemias that did not kill the mice during 
the 30-day period of observation (Kaminsky et ai., 1987).
The above data suggest that either reversion or omission of a life-cycle stage may be 
possible, but contrast with our understanding as to how trypanosomes protect 
themselves from immune killing in the mammalian host. Bloodstream trypanosomes 
express variant surface glycoprotein but on entering the fly VSG synthesis is repressed 
until the salivary gland trypomastigotes reactivate VSG genes and the trypanosomes 
reacquire their surface coat. It has been shown that the loss of the surface coat is 2 -  3 
times faster in the posterior than the anterior midgut, the former being the more
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important site for initiation of fly infection (Vickerman et al., 1988). It is this surface coat 
that enables the trypanosome to evade the hosts’ immune responses. It follows, 
therefore, that as the procyclic forms had no surface coat the immune response 
mounted by the immunosuppressed mouse was sufficient to kill the trypanosomes 
before a bloodstream infection developed.
In view of these considerations, anecdotal evidence of the development of bloodstream 
forms from procyclic forms without complete cyclical transmission through tsetse flies is 
surprising, but published. This systematic investigation, however, failed to support these 
published findings.
One interesting finding, however, has been observed from the results obtained. Of the 
36 flies that survived infection, 23 had been infected with procyclic forms grown in 
Cunningham’s medium. Also 16 of the 21 flies with midgut infections were cultivated in 
Cunningham’s medium (Table 3.1). These results follow those found previously where 
Cunningham’s medium was more efficient at producing procyclic clones than SDM-79 
(Chapter 2). Therefore, in the future, any procyclic trypanosome lines that are to 
undergo cyclical transmission in the tsetse fly should be cultivated in Cunningham’s 
medium rather that SDM-79 in order to increase the efficiency rates of producing 
midgut infections.
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CHAPTER 4
THE INHERITANCE OF ARSENICAL DRUG RESISTANCE IN GENETIC CROSSES
4.1 INTRODUCTION
Classical genetic analysis can be used to determine the genetic basis of variation of 
phenotype. This approach exploits a naturally occurring variation in cymelarsan 
sensitivity between the parasite stocks. STIB 247 is sensitive to killing by the arsenical 
drug Cymelarsan relative to STIB 386 and TREU 927 (Table 1.1). Genetic crosses 
between these stocks then permitted a determination of the genetic basis (number of 
loci, dominance etc) of drug resistance.
This chapter describes the characterisation of the drug resistant phenotype in the three 
parental stocks and the inheritance into hybrid progeny generated from crosses (Fig 
2.1). Currently only the FI progeny of crosses are available as no F2 or backcross 
progeny have been generated in sufficient numbers for analysis. Two methods to 
assess the activity of two classes of trypanocides, the arsenicals and the diamidines 
have been used; the growth inhibition assay (Kaminsky and Zweygarth, 1989) and the 
AlamarBlue assay (Raz et al, 1997).
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4.2 MATERIALS AND METHODS
4.2.1 Drugs
Cymelarsan (MelCy) was a kind gift from Rhone Merieux, France; Melarsoprol (MelB, 
Arsobal), Trimelarsan (MelW) and Melarsen oxide (MelOx) were kind gifts from Dr. 
Frank Jennings, Glasgow University. Pentamidine, Diminazene aceturate (Berenil) and 
Phenylarsine oxide (PhenOx) were supplied by Sigma. MelCy, MelW, Berenil, 
Pentamidine and PhenOx were dissolved in phosphate buffered saline (PBS). MelB and 
MelOx were in an aqueous solution of propylene glycol, at a concentration of 3.6%, and 
were re-suspended in peanut oil (Sigma) (propylene glycol is miscible in water) 
immediately prior to use. For the in vitro assays, the drugs were dissolved in SDM-79 
complete medium. For the in vivo assays MelCy was dissolved in double distilled de­
ionised water (dddHaO).
4.2.2 In vitro 24-hr Growth Inhibition Assay
Samples taken from trypanosome procyclic stage cultures were in log phase of growth. 
Cymelarsan was dissolved in complete SDM-79 medium and filter-sterilised through a 
0.22 pm filter immediately before use. Trypanosome procyclic cultures were 
resuspended at a density of 2 x 10® /ml in SDM-79 with 10% foetal calf serum. 50 pi of 
the culture was added to each well of a 96 well microtitre plate containing 50 pi of the 
drug solutions giving a starting density of 10® trypanosomes/ml (Scott et a/., 1996). 
Control cultures were included using the same conditions but with PBS in place of drug. 
The cultures were incubated at 27°C for 24 hr. All experiments were carried out in 
duplicate. After incubation, an aliquot of 10 pi was removed from each well and 
transferred to an Improved Neubauer haemocytometer and the number of cells counted
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for each concentration of drug used. The increased number of trypanosomes, which 
occurred in drug-treated and control cultures, was calculated from each well (number of 
trypanosomes after 24 hr growth-number of trypanosomes at Ohr) and the relative 
growth of trypanosome populations was determined by comparison with the number of 
trypanosomes (100%) occurring in the control cultures. The effective concentration that 
inhibited the growth of trypanosome populations by 50% (EC50) was determined (values 
>100% and <0% were rejected) (Kaminsky and Zweygarth, 1989).
4.2.3 In vivo drug susceptibility assay
Female inbred ICR mice, weighing 20-25 g, were used for the in vivo drug tests based 
on a method previously described (Turner et ai., 1988). Mice were inoculated 
intraperitoneally (ip) each with 1x10® trypanosomes, and treatment was administered 
24 hr after inoculation. Drugs were administered ip at the appropriate concentration, at a 
volume/weight (v/w) ratio of 0.25 ml/25 g of mouse weight. The range of concentrations 
of MelCy used was 0.1, 0.2, 0.5, 1, 2,5, and 7.5 mg/kg. The tail blood of the mice was 
examined three times a week for the presence of trypanosomes for a total of 14 days 
using the wet film technique. The lowest dose of MelCy that prevented parasitaemia 
occurring was used to define the sensitivity of each trypanosome line.
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4.2.4 In vitro growth of trypanosomes for assessment of drug susceptibility for 
procyciic forms
For the growth of sufficient trypanosomes for the drug sensitivity assay, trypanosomes 
were taken, by cardiac puncture, from infected ICR mice. Ten drops of infected blood 
was added to 4.5 ml SDM-79 and 0.5 mis of 3mM cis-Aconitate (to transform to 
procyclics forms) (Hunt et a!., 1994) and placed at 27°C for two-three days. The culture 
medium, containing procyclic forms was decanted off, leaving the blood at the bottom of 
the flask, and re-suspended in 5 ml SDM-79, incubated at 27°C and grown to a 
trypanosome density of 1 x 10®.
4.2.5 In vitro growth of trypanosomes for assessment of drug susceptibility for 
bloodstream forms
The medium used for the propagation of bloodstream forms was HMI-9 (Chapter 2) 
supplemented with 20% foetal calf serum. The same method for the isolation of 
trypanosomes was used as that for procyclic forms with the exception that no cis- 
Aconitate was added to the culture medium and the trypanosomes were incubated at 
37°C in 5% C02/95% air. After 24 hr incubation at 37°C the bloodstream trypanosomes 
were resuspended at a density of 2 x 10® in HMI-9 ready for analysis of drug sensitivity 
with the AlamarBlue assay.
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4.2.6 AlamarBlue assay
Procyclic or bloodstream stage trypanosomes were suspended at a density of 2 x 10®. 
Drugs were dissolved in SDM-79 and HMI-9, respectively. 100 pi of the cultures were 
added to each well of a 96 well microtitre plate containing 100 pi of the drug solutions 
giving a starting density of 10® trypanosomes/ml. Control cultures were included using 
the same conditions but with PBS in place of drug. Finally 20 pi of AlamarBlue dye was 
added and the plates incubated at 27°C for procyclic forms and 37°C for bloodstream 
forms for 24hrs. Reduction of AlamarBlue to a fluorescent product only occurs if there 
are viable cells present. Thus the level of fluorescence, measured at OD590, is 
proportional to the number of viable cells (Raz et al., 1997). Four arsenical drugs were 
tested: MelCy, MelW, MelB and melarsen oxide at final drug concentrations of, 0.001, 
0.01, 0.1, 1, 10, 100 and 1000 pM as well as phenylarsenoxide at a concentration range 
of 0.001, 0.01, 0.1 and 1 pM. The sensitivity of the three stocks STIB 247, STIB 386 and 
TREU 927, to each concentration was assessed. The assay was also carried out using 
the diamidines; berenil and pentamidine in the same concentration range as MelCy. 
Each experiment included a control sample containing trypanosomes in the relevant 
culture media. For testing Pentamidine, cells were incubated in the presence of drug for 
24hr, then the dye was added and the cells incubated for a further 24 hr. Fluorescence 
was measured after 48hr. All assays were repeated at least twice.
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4.3 RESULTS
Detailed laboratory based studies on drug resistance have been largely restricted to 
experiments using mice. The maintenance of trypanosomes in vitro is a major step 
forward in facilitating detailed studies of mechanisms of drug resistance in parasites 
(Kaminsky et ai., 1989). The development of semi-defined medium has been invaluable 
for this study due to the large number of progeny requiring analysis for their responses 
to seven different trypanocidal drugs. However given the number of progeny requiring 
analysis, a rapid, reliable and reproducible screening assay was required. A comparison 
between two in vitro screening assays was carried out to determine which was more 
suited for this study, the growth inhibition assay or the AlamarBlue assay.
The principal of the growth inhibition assay was based on that previously described 
(Kaminsky and Zweygarth 1989). Below a certain drug concentration there was no 
measurable effect on growth (100% growth). Conversely, above a certain concentration 
of drug no measurable growth could be observed (0% growth). These cut-off points 
allowed for the calculation of the effective concentration that inhibited 50% growth 
(ECso). Procyclic forms of the parental lines STIB 247, STIB 386 and TREU 927 were 
assessed, in duplicate, for their levels of resistance to MelCy. The growth inhibition of 
the three parental lines after 24 hr incubation in the presence of increasing 
concentration of MelCy is illustrated in Fig 4.1, where the percentage growth is 
measured for each line relative to control cultures in the absence of drug.
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Growth of STIB 247 was inhibited after incubation with MelCy at a concentration of 0.1 
(jM and above. No growth was detectable at a concentration of 1 pM. In contrast, STIB 
386 and TREU 927 showed only a minor reduction in rate of growth at a concentration 
of 1 |jM MelCy, however the rate of growth diminished at concentrations of 5 pM and 
above. These data implied that lines STIB 386 and TREU 927 expressed a resistance 
phenotype in comparison to line STIB 247. Hence, lines STIB 386 and TREU 927 were 
MelCy resistant and STIB 247 was sensitive. The ECso values were 0.7 pM, 7.5 pM and 
8 pM for the lines STIB 247, STIB 386 and TREU 927, for procyclic forms respectively 
(Fig 4.1 A). For the bloodstream forms the ECso were 0.3 pM, 5 pM and 6 pM for the 
lines STIB 247, STIB 386 and TREU 927, respectively (Fig 4.1 B)
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Fig 4.1 A and B: Growth inhibition assay for the three parental lines. (A)The percentage growth 
inhibition in procyclic cultures with increasing doses of MelCy indicated that lines STIB 
386 # )  and TREU 927 # )  expressed a resistance phenotype in comparison to line 
STIB 247 (&). (B) The percentage growth inhibition in bloodstream cultures with MelCy 
giving almost identical results as those determined for the procyclic forms. The x-axis 
represents the percentage growth after 24hr incubation in the presence of MelCy, the 
y-axis represents increasing concentrations of MelCy.
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Whilst the growth inhibition assay is quite reliable for determining drug susceptibility of 
the trypanosome lines, it is very time consuming and difficult to accurately assess the 
end-point of the assay. None the less, it was possible to distinguish between sensitive 
and resistant phenotypes in both procyclic and bloodstream forms (Fig 4.1 A and B). As 
over 70 progeny and seven different drugs were to be analysed so as to determine the 
inheritance of phenotype, it was necessary to use a more rapid assay that was both 
reliable and reproducible.
The results observed from the growth inhibition assay gave a good guide as to the 
sensitivity patterns of the three parental lines in the presence of MelCy. These would 
serve as an indicator as to whether the AlamarBlue assay could be used as an 
alternative to the growth inhibition assay. The AlamarBlue assay used here was based 
on a previous study (Raz et a/., 1997) where the determination of cell viability and 
proliferation in the presence of drugs was measured fluorometrically.
Using the AlamarBlue assay for screening procyclic and bloodstream forms in vitro, the 
phenotypes of the three parental lines were determined. The procyclic forms were 
inoculated into 96 well flat bottomed microtitre plates at a density of 2 x 10® /ml and 
incubated in the presence of increasing concentrations of MelCy (0.001 -  1000 pM) for 
24 hr with 10% AlamarBlue dye. The conversion of the AlamarBlue dye to its 
fluorescent product was relatively unaffected in the range of MelCy concentrations used 
with the procyclic forms of lines STIB 386 and TREU 927. Thereby suggesting that 
there was no significant effect on cell viability or proliferation of these lines. However, for
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line STIB 247 the measure of fluorescence was significantly reduced suggesting cell 
viability was severely affected at MelCy concentrations of 0.1 pM and above (Fig 4.2 A). 
Bloodstream forms were also tested in vitro using AlamarBlue and the pattern of 
susceptibility to MelCy for the three lines were the same as those determined for the 
procyclic forms; cell viability was relatively unaffected for STIB 386 and TREU 927 in 
comparison to STIB 247(Fig 4.2 B). However, with the bloodstream forms it was 
observed that the fluorometric reading for the three lines were slightly lower than those 
observed for the procyclic forms. This may have been due to the fact that these 
bloodstream forms have not been adapted to culture and so a reduction in viability 
would be expected. Given these data, it was clear that the AlamarBlue assay could be 
used as an alternative to the growth inhibition assay as it gave the same drug 
susceptibility profile for the three parental lines i.e. STIB 247 was sensitive while STIB 
386 and TREU 927 were resistant to MelCy.
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Fig 4.2 A and B: Dose response of the three parental lines used for crosses determined using the 
AlamarBlue screening assay and fluorescence spectrometry. (A) Indicates that 
STIB 386 (■ ) and TREU 927 # )  are resistant to MelCy in comparison to STIB 247 ^ ). 
(B) The response of bloodstream forms in the presence of Cymelarsan, where STIB 
386 and TREU 927 gave a resistant phenotype in comparison to STIB 247. The x-axis 
represents the measure of fluorescence at O D 590, and the y-axis represents the 
increasing concentrations of Cymelarsan.
To prove that the results obtained from the in vitro screening assays reflected those 
obtained, in vivo, assessment of drug resistance pattems for the three parental lines 
was carried out in mice. Groups of five immunosuppressed ICR mice were infected (i.p) 
with trypanosomes and drug treated after 24hr with MelCy ranging in concentration 
from 0 . 1 - 5  mg/kg. Following drug treatment the parasitaemia for each group of mice 
was monitored from tail blood for patent infection for a period of 14 days. If no 
trypanosomes were observed after this time period drug treatment was considered to 
have been effective. Drug failure was judged to have occurred if trypanosomes were 
observed by direct microscopy of tail blood. The results obtained were expressed as the
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minimum curative dose (MIC) of MelCy required to clear the infection from all five mice 
in each group. The results showed that the MIC was 0.5 mg/kg for STIB 247, 5 mg/kg 
for STIB 386 and 5 mg/kg for TREU 927. These data indicated that STIB 386 and TREU 
927 were 10 fold more resistant than STIB 247 to MelCy in vivo (Table 4.1). These 
results were consistent with those found for the in vitro screening assays of these three 
lines. On this basis, the AlamarBlue assay was used for screening of the FI hybrid 
progeny to determine the inheritance of the drug resistance phenotype of the parental 
lines.
Stock MelCy concentration No. of Mice with patent 
infection
STIB 247 0 . 1  mg/kg 5/5
0 . 2  mg/kg 3/5
0.5 mg/kg 0/5
STIB 386 0.5 mg/kg 3/5
1 mg/kg 3/5
2  mg/kg 1/5
5 mg/kg 0/5
TREU 927 1 mg/kg 5/5
2  mg/kg 5/5
5 mg/kg 0/5
Table 4.1: Screening the drug resistance phenotype of ttie three parental lines, in vivo, with 
increasing doses of Cymelarsan. The table indicates the resuits for the mouse screens 
(five for each concentration of MelCy) used to determine the resistance phenotype of the 
three parental lines. The minimum inhibitory concentration (MIC) of MelCy required to clear 
infection of STIB 247 was 0.5 mg/kg. The MIC of MelCy required to clear STIB 386 and 
TREU 927 infection was 5 mg/kg. These results confirm the findings obtained from the in vitro 
assays i.e. STIB 386 and TREU 927 display resistance phenotypes in comparison to STIB 
247. A complete set of results are in Appendix Table A3 .A
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The in vitro drug response of 38 F1 hybrid progeny derived from a genetic cross 
between STIB 247 x TREU 927 to MelCy was determined using the AlamarBlue assay. 
The assay was carried out in an identical manner to that used for the testing of the three 
parental lines. These data showed that the progeny clearly segregated into either the 
resistant or sensitive phenotype (Fig 4.3). Twenty-two of the progeny followed the 
pattern of resistance observed for TREU 927 while 16 followed the same phenotypic 
pattern as the sensitive STIB 247. There were no intermediate or non-parental 
phenotypes observed, which suggested that one gene determined resistance (Fig 4.3). 
The analysis was also carried out for bloodstream forms of STIB 247, TREU 927 and 10 
of the 38 FI hybrid progeny from the cross STIB 247 x TREU 927 using the in vitro 
AlamarBlue assay. The results for each line agreed with those observed for the 
procyclic forms, which suggested that the mechanism determining drug resistance was 
the same for both bloodstream and procyclic forms (Fig 4.4).
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Fig 4.3: Dose response to MelCy of the hybrid progeny clones of the cross STIB 247 x TREU 927 
determined by the AlamarBlue assay and fluorescence spectrometry. The results show that 
the progeny segregated into two phenotypes, either sensitive (A ) or resistant (• ), in the same 
manor as either parent. There were no intermediate or non-parental phenotypes detected, 
which suggested that one gene govemed resistance. The x-axis represents the measure of 
fluorescence at O D 590, and the y-axis represents the increasing concentrations of Cymelarsan.
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Fig 4.4: Effect of MelCy on 10 F1 hybrid progeny bloodstream forms of the STIB 247 x TREU 927 
cross, In vitro, using the AlamarBlue screening assay. These results followed those found 
for the procyclic forms in that they segregated into two phenotypes and each F1 progeny clone 
had the same phenotype in both assays. STIB 247 (♦), TREU 927 f" ), resistant F1 progeny ( •  ) 
and sensitive F1 progeny (4 ). The x-axis represents the measure of fluorescence at O D 590, and 
the y-axis represents the increasing concentrations of Cymelarsan.
In order to conclusively prove that the results obtained from the AlamarBlue assay for 
the F1 hybrid progeny reflected resistance/sensitivity, a selection of F1 hybrids were 
tested in vivo. The method used was exactly the same as that used to test the parental 
lines. Six F1 hybrids, three sensitive and three resistant according to the AlamarBlue 
results, were tested for their response to a range of MelCy concentrations (0.1, 0.2, 0.5, 
1, 2 and 5 mg/kg) (Table 4.2). The three hybrids that were sensitive in vitro also gave a 
sensitive phenotype in vivo with infection being cleared from the five mice in this group 
with 0.5 mg/kg MelCy, the same as that for the parental line STIB 247. The three in vitro 
resistant progeny were also resistant in vivo with the infection being cleared from the 
group of mice at a MelCy concentration of 5 mg/kg (Table 4.2), the same as that found 
for the parental line TREU 927 (Table 4.1). Thus the results obtained were very clear- 
cut, with the hybrid progeny behaving like one or other parent, either being completely
99
Chapter 4; The Inheritance o f  Arsenical Drug Resistance in Genetic Crosses
sensitive or resistant to increasing doses of MelCy in all tests used. See Appendix A3.B 
for the complete set of in vivo results of the hybrid progeny.
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F1 Hybrid MelCy concentration No. of Mice with patent 
infection
F532/72 MCL 5 (S) 0.1 mg/kg 4/5
0.2 mg/kg 3/5
0.5 mg/kg 1/5
1 mg/kg 0/5
FI 24/28 BCL 20 (S) 0.1 mg/kg 3/5
0.2 mg/kg 3/5
0.5 mg/kg 0/5
1 mg/kg 0/5
F532/72 BCL 1 (S) 0.1 mg/kg 5/5
0.2 mg/kg 3/5
0.5 mg/kg 1/5
1 mg/kg 0/5
F532/63 BCL 2 (R) 0.5 mg/kg 5/5
1 mg/kg 4/5
2 mg/kg 3/5
5 mg/kg 0/5
F532/63 CLA11 (R) 0.5 mg/kg 3/5
1 mg/kg 4/5
2 mg/kg 2/5
5 mg/kg 0/5
F974/78 BCL 3 (R) 0.5 mg/kg 5/5
1 mg/kg 4/5
2 mg/kg 2/5
5 mg/kg 0/5
Table 4.2: Screening the drug resistance phenotype of six F1 hybrids of the STIB 247 x TREU 927 
cross, in vivo, with increasing doses of Cymelarsan. The table Indicates the results for the 
mouse screens (five for each concentration of MelCy) used to determine the resistance 
phenotype of the six F1 hybrids. The minimum inhibitory concentration (MIC) of MelCy 
required to clear infection of F532/72 MCL 2, F124/28 BCL 20 and F532/72 BCL 1 was 0.5 
mg/kg. The MIC of MelCy required to clear F532/63 BCL 2, F532/63 CL A11 and F974/78 BCL 
3 Infection was found to be 5 mg/kg. These results confirm the findings obtained from the in 
vitro assays i.e. F532/72 MCL 5 and F124/28 BCL 20 dispiayed sensitive phenotypes and 
F532/63 BCL 2 and F532/63 CL A11 had resistant phenotypes. S -  sensitive in vitro\ R -  
resistant in vitro. A complete set of results are in Appendix Table A3.B
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The 34 F1 hybrid progeny of the STIB 247 x STIB 386 cross were screened as procycllc 
forms for their resistance to MelCy using the AlamarBiue assay in vitro and it was found 
that 19 of the progeny were sensitive and 15 were resistant. The 19 sensitive progeny 
expressed MelCy sensitivity with levels equivalent to those found for the parental line 
STIB 247. The 15 resistant progeny expressed the same phenotypic pattern as the 
resistant parental line STIB 386 (Fig 4.5). Once again there were no intermediate or non 
-parental phenotypes detected. Ten of the FI hybrid progeny were also tested in vitro 
using bloodstream forms. The phenotypes obtained for these hybrids were the same as 
those found for the equivalent procyclic forms of the same hybrids (Fig 4.6).
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Fig 4.5: Dose response to MelCy of the hybrid progeny clones of the cross STIB 247 x STIB 386 
determined by the AlamarBiue assay and fluorescence spectrometry. The results show that 
the progeny segregated into two phenotypes, either sensitive or resistant, in the same manor as 
either parent. There were no intermediate or non-pa rental phenotypes detected, which 
suggested that one gene governed resistance. STIB 247 ( ♦  ), STIB 386 (■  ), resistant F1 
progeny (■ ) and sensitive F1 progeny (A ). The x-axis represents the measure of fluorescence 
at O D 590, and the y-axis represents the increasing concentrations of Cymelarsan.
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Fig 4.6. Effect of MelCy on 10 F1 hybrid progeny bioodstream forms of the STiB 247 x STIB 386 
cross, In vitro, using the AlamarBiue screening assay. These results followed those found 
for the procyclic forms in that they segregated into two phenotypes and therefore backed up the 
results found using the AlamarBiue assay. STIB 247 (♦), TREU 927 pi), resistant F1 progeny 
(■ ) and sensitive F1 progeny (à ). The x-axis represents the measure of fluorescence at O D 590, 
and the y-axis represents the increasing concentrations of Cymelarsan.
As with the hybrids from the STIB 247 x TREU 927 cross, six hybrid progeny (three 
sensitive and three resistant), were tested in vivo for their response to a range of 
concentrations of MelCy (0.1, 0.2, 0.5, 1, 2 and 5 mg/kg). The results obtained agreed 
with those found from the in vitro assays. The three sensitive hybrids also expressed a 
sensitive phenotype in vivo with infection being cleared from the group of five mice at a 
concentration of 0.5 mg/kg MelCy, the same as that found for the parental line STIB 
247. The three in vitro resistant hybrids also expressed a resistant phenotype in vivo 
with infection being cleared at a concentration of 5 mg/kg MelCy the same as that 
previously found for the parental line STIB 386 (Table 4.3).
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F I Hybrid MelCy concentration No. of Mice with patent 
infection
F9/45 MCL 11 (S) 0.2 mg/kg 2/5
0.5 mg/kg 1/5
1 mg/kg 0/5
F492/50 BCL 23 (S) 0.2 mg/kg 3/5
0,5 mg/kg 0/5
1 mg/kg 0/5
FI 9/31 BCL 11 (8) 0.2 mg/kg 3/5
0.5 mg/kg 1/5
1 mg/kg 0/5
F492/50 BCL 8 (R) 0.5 mg/kg 5/5
1 mg/kg 4/5
2 mg/kg 4/5
5 mg/kg 1/5
F492/50 BCL 21 (R) 0.5 mg/kg 5/5
1 mg/kg 4/5
2 mg/kg 1/5
5 mg/kg 0/5
F9/41 BCL 7 (R) 0.5 mg/kg 5/5
1 mg/kg 3/5
2 mg/kg 2/5
5 mg/kg 0/5
Table 4.3: Screening the drug resistance phenotype of six F I hybrids of the STIB 247x TREU927 
cross, in vivo, with increasing doses of Cymelarsan. The table indicates the results for the 
mouse screens (five for each concentration of MelCy) used to determine the resistance 
phenotype of the six F1 hybrids. The minimum inhibitory concentration (MIC) of MelCy 
required to clear infection of F9/45 MCL 11, F492/92 BCL 23 and F I9/31 BCL 11 was 0.5 
mg/kg. The MIC of MelCy required to clear F492/50 BCL 8 , F492/50 BCL 21 and F9/41 BCL 7 
infection was found to be 5 mg/kg. These results confirm the findings obtained from the in vitro 
assays l.e. F9/45 MCL 11 and F492/50 BCL 23 displayed sensitive phenotypes and F492/50 
BCL 8 and F492/50 BCL 21 had resistant phenotypes. S -  sensitive in vitro; R -  resistant in 
vitro. A complete set of results are in Appendix Table A3.C
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As cross resistance both between different arsenlcals, Berenil and Pentamidine has 
been widely reported in the literature, experiments were undertaken to determine if 
there was any cross-resistance between MelCy and other trypanocides namely, 
melarsoprol (MelB), trimelarsan (MelW), melarsen oxide (MelOx), pentamidine, 
diminazene aceturate (Berenil) and phenylarsenoxide (PhenOx). Analysis was initially 
carried out on the parental lines STIB 247 and TREU 927. As can be observed from Fig
4.7 A -  E there was a rapid decrease in cell viability for line STIB 247 at concentrations 
of 1 pM and above for MelB, MelW, MelOx, Pentamidine and Berenil. With PhenOx, 
however, cell viability decreased at concentrations of 0.001 pM and above for STIB 247, 
suggesting that PhenOx is much more potent that the melaminophenyi arsenicals (Fig
4.7 F). In comparison the results obtained for the MelCy resistant line TREU 927 
indicated that MelW, Pentamidine and Berenil had no marked effect on cell viability at 
concentrations up to 100 pM, the same as those observed for MelCy, while an effect 
with PhenOx was only observed at 1 pM (Fig 4.7 B, D, E and F). With MelB and MelOx, 
however, cell viability began to decrease at concentrations of 1 pM but never reached 
the same levels of reduced viability as those observed for STIB 247 (Fig 4.7 A and C). 
The drug screening assay of the hybrid progeny of the STIB 247 x TREU 927 cross 
revealed that the resistant phenotype correlated with either parent with the same 
progeny being resistant to MelB, MelW, MelOx, Berenil and PhenOx as MelCy. Similarly 
those that were sensitive to MelCy were also sensitive to MelB, MelW, MelOx, Berenil 
and PhenOx (Fig 4.7 A -  C, E and F). As with MelCy there were no intermediate or 
non-pa rental phenotypes detected. The results for Pentamidine showed that all the 
hybrid progeny had a sensitive phenotype following the same pattern as that found for
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STIB 247 (Fig 4.7 D). This result shows that sensitivity is dominant to resistance in the 
progeny, implying that a different locus determines the resistance phenotype for this 
diamidine.
Fig 4.7 A -  F: Determination of cross-resistance between MelCy and six other trypanocidal drugs 
for the F1 hybrid progeny clones of the STIB 247 (4  ) x TREU 927 (■  ) cross; 
melarsoprol (A), trimelarsan (B), melarsen oxide (0), pentamidine (D), berenil (E) and 
phenyl arsenoxide (F), using the AlamarBiue screening assay.
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Fig 4.7 A-F: These graphs indicated that there was cross-resistance to all but one of the drugs tested, as 
the progeny segregated in a 1:1 ratio the same as that found for MelCy. The exception to 
this finding was pentamidine where all the progeny were sensitive (D). STIB 247 ( ♦  ), 
TREU 927 ( ■ ) ,  resistant FI progeny ( • )  and sensitive FI progeny ( A ) .  The x-axis 
represents the measure of fluorescence at OD590, and the y-axis represents the increasing 
concentrations of each drug.
An identical analysis was carried out for STIB 386 and the hybrid progeny derived from 
the STIB 247 x STIB 386 cross. Firstly, for STIB 386, incubation with MelW, 
Pentamidine and Berenil showed no marked effect on cell viability at concentrations of 
100 pM and above (Fig 4.8 B, D and E). For MelB and MelOx cell viability began to 
decrease at concentrations of 1 pM and above but as with TREU 927 never reached the 
same levels of sensitivity as STIB 247 (Fig 4.8 A and C). With PhenOx, STIB 386 cell 
viability began to decrease at concentrations of 0.001 pM and above but this stock was 
still 100 fold more resistant than STIB 247 (Fig 4.8 F). Therefore, STIB 386 was more 
sensitive to PhenOx than TREU 927 (Figs 4.7 and 4.8 F). Analysis of the progeny from 
this cross, indicated that those progeny which were resistant to MelCy were also 
resistant to the six other drugs tested. Similarly those that were sensitive to MelCy were 
also sensitive to the other six drugs. The one difference between the progeny of the two
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crosses was that the inheritance of Pentamidine resistance was different in the STIB 
247 X TREU 927 cross compared to the STIB 247 x STIB 386 cross. In the latter cross 
C O -  segregation of Pentamidine resistance with the resistance to the other six drugs 
was observed.
Fig 4.8 A - F :  Determination of cross-resistance between MelCy and six other trypanocidal drugs 
for the F1 hybrid progeny clones of the STIB 247 (■  ) x STIB 386 ( ■ )  cross;
melarsoprol (A), trimelarsan (B), melarsen oxide (0), pentamidine (D), berenil (E) and 
phenyl arsenoxide (F), using the AlamarBiue screening assay.
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Fig 4.8 A-F; These graphs indicated that there was cross-resistance to all the drugs tested as the 
progeny segregated in a 1:1 ratio the same as that found for MelCy. The interesting result 
found was that for this cross the progeny segregated in a 1:1 ratio for pentamidine (D), 
which was not the case for the STIB 247 X TREU 927 cross. Therefore, suggesting that 
resistance to pentamidine was governed by more than one gene. STIB 386 #  ), STIB 247 
(■ ) , Resistant FI progeny (■  ) and Sensitive FI progeny (A).  The x-axis represents the 
measure of fluorescence at O D 590, and the y-axis represents the increasing concentrations 
of each drug.
With these sets of data, a genetic model of inheritance for MelCy resistance could be 
proposed. The pattern of the segregation of phenotype in the progeny allows models for 
the number of loci and alleles involved in conferring the trait of interest to be defined. As 
the progeny segregate into only the two parental phenotypic classes, a single locus 
model can be put foreward as any multilocus model is likely to generate progeny with 
levels of resistance intermediate between those of the parental lines.
The simplest model for the inheritance of the drug resistance phenotype in the FI 
progeny that fits the experimental data would be where the resistance phenotype is 
determined by two alleles at a single locus with the resistant parent being heterozygous
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for a dominant resistant allele and the sensitive parent being homozygous for a 
sensitive allele, as illustrated in Fig 4.9.
Based on this model, half the F1 progeny would inherit the dominant resistance allele 
and half would inherit the recessive sensitive allele leading to a prediction of a 1:1 
segregation of resistant:sensitive phenotypes in the progeny. The observed segregation 
for the cross between STIB 247 x TREU 927 is 16 sensitive progeny and 22 resistant 
progeny and this does not differ significantly from a 1:1 ratio as determined by Thus, 
the data obtained support a single locus model in which the resistant TREU 927 
parental line is heterozygous for a dominant allele determining resistance to the four 
arsenical compounds and Berenil but not Pentamidine (Fig 4.7 and Fig 4.9). Analysis of 
the progeny of the cross between STIB 247 and STIB 386 found that there were 19 
sensitive progeny and 15 resistant progeny. Therefore, the same conclusions can be 
drawn from this cross i.e. a single locus model in which the resistant STIB 386 parental 
line is heterozygous for a dominant allele determining resistance to the four arsenicals, 
Berenil and Pentamidine (Fig 4.8 and Fig 4.9).
Parent - Phenotype S(247) x R(927)
Genotype ss x Rs
FI phenotype S x R
Genotype ss ss x sR sR
Predicted ratio 1 1
Observed ratio 16 22
Figure 4.9 : A predicted Genetic Model for Cymelarsan Resistance. A genetic model for Cymelarsan 
resistance for 247 x 927 was determined. One parent must be heterozygous otherwise the 
data set wouid be either all sensitive or all resistant. The progeny are inherited In 1:1 ratio 
(chP = 0.52, df =1, p>0.06).
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The availability of progeny from a cross between the two resistant lines (STIB 386 and 
TREU 927) allows the genetic models for the inheritance in the two crosses between 
each of these resistant lines and the sensitive line to be tested without the need for a 
backcross or F2 progeny. As only seven independent progeny were available from the 
STIB 386 X TREU 927 cross, it is difficult to analyse the segregation statistically. 
However, two sensitive progeny were obtained from the cross between the two resistant 
parents, providing strong evidence, based on a single locus model, that the two parental 
lines are heterozygous with a sensitive recessive allele (Fig 4.10). If the models are 
correct, a cross between two resistant lines that are heterozygous for a dominant 
resistant allele should yield progeny that segregate 1:3 between sensitive and resistant 
phenotypes (Fig 4.11). These data, therefore, validate the genetic model proposed for 
both parental resistant lines.
600 •
500 .
S 300.
r  200 .
100 .
Concentration (pM)
Fig 4.10: Dose response to MelCy of the seven hybrid progeny ciones from the cross STIB 386 x 
TREU 927 determined by the AiamarBiue assay. The results Indicate that two of the progeny 
(A),  followed the sensitive phenotype found for the STB 247 parental line (♦ ) ,  whilst five 
progeny (#) followed the phenotype found for the two resistant parental lines STIB 386 # )  and 
TREU 927 (■ ). These data confirm the proposed genetic model for both parental resistant 
phenotypes. The x-axis represents the measure of fluorescence at O D 5 9 0 ,  and the y-axis 
represents the increasing concentrations of Cymelarsan.
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Parental - Phenotype R(386) x R(927)
Genotype sR sR
F1 phenotype S R
Predicted Genotype ratio ss x sR sR RR
Predicted phenotype ratio 1 3
Observed phenotype ratio 2 5
Fig 4.11; Genetic cross of the two resistant ilnes to vaiidate the predicted genetic model of 
inheritance of drug resistance phenotype. If the genetic model was correct, where 
resistance was heterozygous and dominant then a cross between the two resistant lines would 
be expected to produce some sensitive progeny. As can be seen two of the progeny derived 
from the cross between STIB 386 x TREU 927 were sensitive to MelCy, thereby validating the 
genetic model of inheritance (Fig 4.9).
This model, however, did not fit with the data obtained for the pentamidine phenotype of 
the progeny for the STIB 247 x TREU 927 cross where all the progeny were sensitive 
(Fig 4.3 D). These data suggested that another locus was involved in conferring 
pentamidine resistance situated on another region of the genome, however it was not 
possible to identify this locus due to its lack of segregation. There are two single locus 
models of inheritance that would fit this data that are detailed in Fig 4.12. However, 
these models could only be tested by generating F2 or backcross progeny. It is also 
formally possible that the same locus as that determining MelCy resistance in TREU 
927 determines Pentamidine resistance but that the dominance relationships in the 
allele in TREU 927 is different from that in STIB 386.
STIB 247 X TREU 927
SS X rr
SS X rS
Figure 4.12 : Models for Pentamidine. The only genetic models for Pentamidine which can be used for 
S being dominant. These Indicate that for S to be dominant it must be homozygous.
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4.4 DISCUSSION
Initially the in vitro growth inhibition assay was used to determine the phenotype of the 
three parental lines, STIB 247, STIB 386 and TREU 927, for both procyclic and 
bloodstream forms. It was found that STIB 386 and TREU 927 were resistant to MelCy 
in comparison to line STIB 247 in both life cycle stages (Fig 4.1). Whilst this screening 
assay was reliable and reproducible, it was very time consuming and with the numbers 
of hybrid progeny requiring testing with MelCy and five other drugs, a more rapid 
screening assay was required.
The AlamarBiue assay had previously been used to determine drug sensitivity of 
trypanosomes (Raz et ai., 1997) and found to be very effective, it was, therefore, 
decided to test this assay to see if the results obtained for the three parental lines were 
consistent with those determined from the growth inhibition assay. The AlamarBiue 
assay is essentially a measure of cell viability based on the reduction of the dye to a 
fluorescent form by viable cells with the measurement of this product fluorometrically. 
Therefore, if the cell viability was compromised by the presence of increasing doses of 
drug then the dye would not be reduced to its fluorescent form. As can be seen from the 
results, the same phenotypes were observed using the AlamarBiue assay as those 
found from the growth inhibition assay i.e. STIB 386 and TREU 927 were resistant to 
MelCy in comparison to STIB 247 for both procyclic and bloodstream forms (Fig 4.2). 
The AlamarBiue screening assay was, therefore, found to be reliable, reproducible and 
much less time consuming than the growth inhibition assay.
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The differences between the three parental lines allowed the inheritance of the drug 
resistant phenotype to be determined by the analysis of the hybrid progeny generated 
from genetic crosses between the three lines could be determined. Analysis of the 38 
F1 hybrid progeny generated from the STIB 247 x TREU 927 cross (Chapter 2), showed 
that 22 of the progeny followed the same resistance pattern as that found for the 
parental line TREU 927 while the remaining 16 progeny were sensitive and of the same 
phenotype as STIB 247 (Fig 4.3). There were no intermediate or non-parental 
phenotypes detected, suggesting that a single locus conferred drug resistance. The 
same pattern of inheritance was found for bloodstream forms in vitro, using the 
AlamarBiue assay.
The results obtained from the in vitro screening of phenotype were backed up in vivo. 
The parental lines and three sensitive and three resistant progeny were tested for their 
response to increasing doses on MelCy, in vivo. As can be seen from Table 4,2 the 
minimum curative dose of MelCy required to clear infection with STIB 247 and the three 
sensitive progeny was 0.5 mg/kg, whilst a concentration of 5 mg/kg was required to 
clear infection for TREU 927 and the three resistant progeny. These results therefore 
suggested that the same mechanism is involved in conferring the drug resistance 
phenotype in both procyclic and bloodstream forms using either in vivo or in vitro 
assays.
Using the same screening assays the parental line STIB 386 and the 34 FI hybrid 
progeny derived from the genetic cross, STIB 247 x STIB 386 were also analysed. It
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was shown that 19 of the progeny gave a sensitive phenotype, following the same 
levels as that found for the parental line STIB 247, while the remaining 15 progeny had 
a similar resistance to the parental line STIB 386 (Fig 4.5). Once again there were no 
intermediate or non-parental phenotypes detected. Six hybrid progeny (three sensitive 
and three resistant) and the parent STIB 386 were also tested in vivo for their response 
to increasing doses of MelCy. The results were consistent with those found using the in 
vitro screening assay i.e. STIB 386 and the three resistant progeny were resistant by 
comparison to STIB 247 and the three sensitive progeny (Table 4.3 and Appendix Table 
A3.C).
The results obtained from the screening of the hybrid progeny derived from the two 
genetic crosses revealed several interesting findings. Firstly, the segregation of 
resistant or sensitive phenotypes in the progeny indicated that a single locus was 
involved in conferring the drug resistance trait. Secondly, the drug resistance trait was 
inherited as 15 and 22 of the progeny followed the same phenotypic pattern of 
resistance as the parental lines STIB 386 and TREU 927, respectively. Finally, previous 
studies have indicated that the P2 transporter is involved in conferring drug resistance 
(Carter et al., 1999; de Koning et al., 2000) but P2 activity is not detected in procyclic 
forms (de Koning, 2001). However, the results obtained in this study clearly indicated 
that procyclics as well as bloodstream forms express a resistant phenotype, thus 
suggesting that there are other mechanisms by which the drug resistance phenotype 
arises in trypanosomes.
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These data showed that the level of resistance to MelCy was consistently lower in STIB 
247 than STIB 386 and TREU 927. There are a number of possible explanations for the 
differences in phenotype between the lines. STIB 386 was isolated from a human in 
West Africa and is a Type 2 T. b. gambiense (Gibson, 1986; Hide, 1990) and TREU 927 
was isolated from a tsetse fly and found to be of intermediate resistance to human 
serum (VanHamme et aL, 2003; Turner et al., In Press), Due to the fact that these are 
both human infective forms of Trypanosoma brucei, it could be assumed that they had 
been exposed to melarsoprol (structurally related to MelCy) treatment. TREU 927 could 
also have been exposed to Berenil if it had previously infected cattle or to arsenicals if it 
had infected a human. As STIB 247 was isolated from a hartebeest and game are not 
treated, it would not have been likely to have been previously exposed to drug selection 
therefore the lower level of resistance expressed by STIB 247 would be expected.
The next stage of this analysis was to determine if there was any cross-resistance 
between the arsenicals and the diamidines, Berenil and Pentamidine. It should be noted 
that these comparisons were carried out In vitro only. As can be observed from the 
results (Fig 4.7 A-F) there was cross-resistance and co-segregation of phenotype for 
MelCy, MelB, MelW, MelOx, PhenOx and Berenil for the STIB 247 x TREU 927 cross. 
One noticeable difference in the resistance profiles of these drugs was that the 
concentration of PhenOx required to bring about a loss in cell viability was much lower 
(1pM) for the resistant lines. PhenOx is a lipid-soluble arsenical, which lacks a 
melaminyl-group and therefore can cross the trypanosome membrane barrier by 
diffusion causing a loss in cell viability at much lower concentrations than the other
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diffusion causing a loss in cell viability at much lower concentrations than the other 
melaminophenyi arsenicals and diamidines (Fairlamb et al., 1992). The trypanosome 
membrane acts as a permeability barrier and selective drug uptake mechanisms exist. 
However, this does not suggest that only one route exists for the uptake of the 
melaminophenyi arsenicals. If this were the case then it would be expected that all the 
drugs would have had the same levels of resistance, but MelCy was more potent than 
MelOx, this could be because they have better action on the intracellular target, varying 
diffusion rates into the cell and different affinities for the transporter given they have 
different structures (Fig 1.2) and EC50 values. The suggestion that different 
routes/mechanisms are involved in conferring the resistance phenotype follows the 
proposal that the P2 transporter is not the only route by which resistance comes about.
Another very interesting finding arising from the analysis of cross-resistance for the 
STIB 247 X TREU 927 cross was that all 38 hybrid progeny were sensitive to 
Pentamidine but the parental line TREU 927 remained resistant (Fig 4.6 D). Studies 
carried out on the T. brucei RU15 clone, which does not express P2 activity, showed 
that this line was resistant to melaminophenyi arsenicals but not to Pentamidine 
(Fairlamb et ai., 1992). It was also found that field and laboratory strains that were 
resistant to melaminophenyi arsenicals were usually cross-resistant to Berenil but not 
to Pentamidine (Bacchi and Yarlett, 1993). These data led to the hypothesis that 
Pentamidine must be taken up by a route other than the P2 transporter (de Koning, 
2001), which would further support the findings of this study. This hypothesis, however, 
could not explain why the TREU 927 parental line expressed resistance to Pentamidine
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whilst the hybrid progeny were all sensitive. An explanation for this result could be that a 
different gene may be involved in conferring Pentamidine resistance in TREU 927. 
Alternatively an explanation could be that the sensitive alleles in STIB 247 are dominant 
over the resistant alleles in TREU 927 in relation to Pentamidine resistance/sensitivity.
Analysis of the 34 hybrid progeny derived from the STIB 247 x STIB 386 cross for 
cross-resistance patterns indicated that the phenotype segregated in the same manner 
for all the drugs tested including pentamidine i.e. 19 sensitive and 15 resistant. The only 
difference was that STIB 386 and the resistant progeny were more sensitive to PhenOx 
than TREU 927 and the resistant progeny of the STIB 247 x TREU 927 cross (Figs 4.7 
F and 4.8 F). For the most part, however cross-resistance does exist between the 
melaminophenyi arsenicals and diamidines.
Finally, with the inheritance of phenotype data a model for the genetic basis for 
resistance could be proposed. As can be seen from the data, the progeny segregated in 
a 1:1 ratio (sensitive:resistant) as would be expected in a diploid Mendelian system. 
Using the data, a simple single locus genetic model was constructed (Fig 4.9), in which 
STIB 386 and TREU 927 are heterozygous for a dominant resistance allele. In order to 
prove this model was correct and in the absence of a backcross, progeny from a cross 
between the two resistant lines, STIB 386 and TREU 927 were analysed (Rs x Rs). 
Seven progeny were available from this cross and it would be expected at least some of j
these progeny would have a sensitive phenotype if the proposed model was correct. ;
After screening of these progeny it was found that two had a sensitive phenotype and
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five had a resistant phenotype (Fig 4.10), which is consistent with the model and 
establishes that both resistant stocks must have a sensitive allele. (This provides direct 
evidence that each parental line had a sensitive allele at the locus). Two models have 
been proposed for the data obtained for the results with Pentamidine for the STIB 247 x 
TREU 927 cross (Fig 4.12), but as previously stated either F2 or backcross progeny 
would need to be generated in order to determine which model is correct.
In conclusion, with these data the next step for the determination of the genetic basis of 
drug resistance was to map this locus initially to a chromosome and then a region within 
the chromosome of the T. brucei genome by linkage analysis followed by positional 
cloning. This analysis is the subject of the following chapters.
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CHAPTER 5
POSITIONAL CLONING OF A LOCUS FOR RESISTANCE TO CYMELARSAN
5.1 INTRODUCTION
Positional cloning of the drug resistant trait involves identifying loci at which alleles co- 
segregate with the drug resistance trait in the progeny of crosses. Logically, this 
involves three steps: scanning the genome, chromosome by chromosome, using 
polymorphic genetic markers to construct a genetic map; analysis of the linkage 
between the drug resistance phenotype and each marker interval on the genome and 
finally identification of the loci which shows linkage. Linkage can be expressed in a 
number of ways, but the traditional statistic is the log odds of difference (LOD) score. It 
is generally accepted that a LOD score of more than three is considered as significant 
linkage (Lander and Kruglyak, 1995).
The availability of partial genetic maps for each of the chromosomes, using mini and 
microsatellite markers (Hall et al., 2003; El-Sayed et al., 2003; MacLeod and Tweedie, 
unpublished results) and significant numbers of recombinant progeny (Chapter 2) allow 
linkage analysis to be undertaken. All the progeny had been previously phenotyped for 
resistance to Cymelarsan and shown to segregate in a 1:1 ratio. The model for the 
inheritance of resistance predicted that the resistance allele was dominant at a single 
heterozygous locus in each of the strains STIB 386 and TREU 927 (Chapter 4). 
Therefore, the linkage between the phenotype of the progeny and the molecular 
markers on the genetic maps could be analysed, which would allow the identification of
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the region of the genome that determines the arsenical resistance phenotype in T. 
brucei. The statistical significance of such linkage can be determined from the LOD 
score and the region of the genome containing the gene located from the position of the 
linked markers. The availability of the genome sequence meant that the physical 
location of linked markers could be defined on chromosomes and from this the open 
reading frames (ORFs) that lay between the flanking markers could be identified.
Mapping trait loci by genetic analysis is dependent upon the segregation relationships 
between polymorphic markers and the phenotype under investigation in the progeny of 
laboratory generated crosses of phenotypically distinct parental lines. Factors that 
determine the ease with which trait conferring loci can be defined include the number of 
loci involved and the availability of sufficient numbers of progeny to make any result 
statistically significant. For example, if a trait is heritable and a single locus determines 
the majority of phenotypic variation, then polymorphic markers, linked to a genomic 
segment carrying that gene, will co-segregate with the phenotype. This will pinpoint a 
crossover defined interval that carries the gene determining the trait. This situation has 
been identified in mapping chloroquine resistance in Plasmodium falciparum where it 
was shown that a single locus determined the resistance phenotype (Ferdig and Su, 
2000). The determinant involved in chloroquine resistance was initially mapped to an 
interval of 400 kb on chromosome VII using 16 progeny from a cross and 88 restriction 
fragment length polymorphic (RFLP) markers (Wellems et al., 1991). Further 
development of microsatellite markers and isolation of more than 1000 additional 
progeny identified five meiotic crossover events at various points along the 400 kb
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segment. Comparisons of chloroquine responses in five of the progeny with marker 
inheritance patterns Identified a locus controlling drug response that lay between two 
markers. These markers defined a 36 kb segment of chromosome VII and identified 
open reading frames (ORFs) of eight potential resistance genes (Su et al., 1997).
A similar study has been conducted in Toxoplasma gondii (T. gondii) where analysis of 
26 independent recombinant progeny, from two crosses between an acute virulent 
strain (type I) and a chronic virulent strain (type III), were analysed using 112 
polymorphic markers across the 11 chromosomes of T gondii to elucidate the genetic 
basis of acute virulence. Acute virulence, defined by cumulative mortality, was linked to 
loci on chromosome VII by association with marker inheritance. The locus responsible 
for virulence was located between two markers on chromosome VII, which were 14 map 
units apart (equivalent to 1.5 Mb) and accounted for approximately 50% of the variance 
seen in virulence between the progeny. In addition, when considered as a strict 
Mendelian trait (i.e. + scoring), the phenotype of uniform lethality had a LOD score of 
3.9 to one of the markers, which is considered highly significant linkage to the virulence 
trait (Su et al., 2002). Genetic linkage analysis of a simple Mendelian trait has also been 
examined in Elmerla tenella for the inheritance of 443 polymorphic markers in 22 
recombinant cloned progeny to determine the gene/genes responsible for both the rapid 
completion of the life cycle (precocious development) and resistance to aprinocid. In 
avian Elmerla spp, intracellular growth is shortened by serial selection for the first 
parasites to complete the transition from asexual to sexual reproduction (yielding 
precocious lines) leading to lines that enter the sexual cycle significantly faster than
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those of the parents. Preliminary analysis suggests that precocious development is 
linked to chromosome II and drug resistance to chromosome I (Shirley and Harvey, 
2000).
Partial genetic maps for TREU 927 were already available for chromosomes I, II, III, IV, 
IX and X with 12, 5, 16, 19, 17 and 12 informative polymorphic markers on each 
chromosome, respectively (MacLeod and Tweddie, unpublished results). The plan was, 
therefore, to determine if there was any linkage of the Cymelarsan resistance 
phenotype, initially to any of these chromosomes and then to a marker defined interval 
on the chromosome. Fine scale mapping between the markers of interest should narrow 
the marker defined region further thus pinpointing a crossover defined interval carrying 
the gene determining the Cymelarsan resistance trait.
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5.2 MATERIALS AND METHODS
5.2.1 Linkage analysis
Linkage was assessed between phenotype (resistance to Cymelarsan) and genotype 
for all the FI hybrid progeny derived from the genetic crosses STIB 247x STIB 386 and 
STIB 247 X TREU 927. As the drug resistance trait is heritable and a single locus seems 
to control most of the phenotypic variation in the progeny, then the polymorphic markers 
linked to a segment in the genome will co-segregate with the phenotype, thus 
pinpointing a crossover defined interval that carries the gene/genes controlling the 
inheritance of the trait. The significance of linkage analysis was calculated in order to 
obtain a LOD score value. The formula for calculating the LOD score is given below.
5.2.2 LOD score
LOD scores are used to determine if there is significant linkage for the trait of interest to 
a region on the genome. It is accepted that a LOD score is statistically more significant 
than a P value. A P value of 0.05 is accepted as significant whereas a LOD score of 3 is 
considered significant which is equivalent to a P value of 0.001. For this reason LOD 
scores are used to determine linkage as opposed to P values, where only LOD scores 
of 3 and above are considered as indicating significant linkage. This means that the 
likelihood of linkage occurring is 1000 times greater than no linkage to a region on the 
genome (Lander and Kruglyak, 1995).
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There are four steps involved in the calculation of LOD scores : 
1 ) Total number of progeny (TP) Recombination frequency (RF)
Number of recombinant progeny (RP) for each marker
2) 1 -  RF
= A2
3) (A) X (B)
(0.25)^^
4) The log of the value found for C will give the LOD score 
The values of A and B must add up to 0.5, i.e. 0.5 -  A will give value for B. When two 
genes are unlinked the recombination frequency is 0.5. Therefore, the probability of any 
given genotype would be 0.25.
*NRP are the non -  recombinant progeny i.e. TP -  RP.
5.2.3 Generation of genetic markers
To create a finer resolution genetic map of chromosome II, more genetic markers 
needed to be identified. Two approaches were used; firstly, the identification of mini and 
microsatellite markers and secondly, identification of RFLP markers.
5.2.4 Mini and microsatellite markers
Micro- and minisatellites were identified, by analysing the chromosome II sequence 
available from Sanger and TIGR with the Tandem repeat finder programme (Benson, 
1999). The former were defined as sequences containing >10 copies of a repeat motif 
of 2-5 nucleotides with >70% sequence identity and the latter were defined using the
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same criteria but with a repeat motif of >6 nucleotides. In total 73 microsatellites and 
nine minisatellites were identified on chromosome II (MacLeod and Tweddie, 
unpublished results). Primers were designed to unique sequence flanking these 
candidate markers to generate PCR products distributed across the chromosome. Of 
the 82 markers 17 were selected for map construction because they showed size 
variation, and were heterozygous for TREU 927 and/or STIB 386 but homozygous for 
STIB 247 (El-Sayed et a/., 2003) (Fig 5.1). The 17 primer sequences and robocycler 
conditions for each of the markers are listed in Table 5.1. The PCR amplification 
conditions were the same as those given in Materials and Methods, Chapter 2. The 
hybrid progeny used were the 18 previously available and the 20 generated during this 
study all of which are listed in Table 2.3. The haplotypes for each of these polymorphic 
markers were determined according to those most frequently inherited in the panel of 38 
FI progeny from the STIB 247 x TREU 927 cross.
247 386 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Allele 1 
Allele 2/4
Fig 5.1 : PCR amplification of the mlcrosatelllte A34, from the parental Ilnes STIB 247 and STIB 386 
and 17 hybrid progeny. A34 was one of the 17 markers used for fine scale mapping of 
chromosome II because It showed size variation, and was heterozygous for STIB 386 but 
homozygous for STIB 247. Allele scoring and robocycler conditions are listed in Table 5.1.
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5.2.5 PCR -  RFLP Markers
After screening for informative mini and microsatellite markers on chromosome II was 
exhausted, the determination of informative RFLP markers was undertaken. In total 30 
sets of candidate RFLP markers were designed from BAG 1008 on chromosome II that 
lay between the polymorphic markers 2 and 6 (See Below). Primer pairs were designed 
approximately 5 kb apart with an average PCR fragment size of 1 kb.
Restriction fragment length polymorphisms (RFLP) that showed variation between the 
parental lines, STIB 247 and TREU 927 were identified from PCR amplified DNA 
digested with the restriction enzymes Rsa 1 or Alu 1 (New England Bio-Lab) (Table 
5.1). DNA was prepared from the 38 FI progeny by the method given in Chapter 2. 
After PCR amplification of DNA, using the selected sets of primers (Robocyler 
conditions: 95°C for 50 sec, 56°C for 50 sec and 65°C for 2 mins), 2 pi of the product 
was digested with 2 pi of the selected endonuclease, 2 pi of buffer, NEB 1 and NEB 2 
respectively as recommended by the supplier, and 14 pi of sterile water. This 20 pi 
reaction mix was left to digest overnight in a waterbath at 37°C. Then the 20 pi digestion 
reactions were separated by electrophoresis on 2% Seakem agarose (20 cm x 20 cm), 
stained with 0.5 pg/ml ethidium bromide and visualized by UV illumination.
5.2.6 Construction of a genetic map
The genetic map of chromosome II was generated by determining the inheritance of 
TREU 927 alleles into the panel of 38 FI progeny from the STIB 247 x TREU 927 cross. 
To do this, the parental haplotypes were determined on the basis of the two most
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frequently inherited haplotypes and the positions of the crossover events were then 
identified from the more rare recombinant haplotypes. Each of the hybrid progeny was 
genotyped by PCR amplification of each locus and separation of the products by 
agarose gel electrophoresis using the conditions listed in Table 5.1. A. MacLeod and A. 
Tweddie undertook most of the screening of the hybrid progeny with the polymorphic 
markers leading to the construction of the genetic map.
5.2.7 Genetic Map
Centimorgan (cM) distance was calculated from the observed number of crossover 
events between each pair of marker pairs divided by the total number of crossovers and 
multiplying by 100.
5.2.8 Calculations
Chi squared test (x^ ) to determine if the number of crossover events were randomly 
distributed and if there were any recombination Hot or Cold spots between markers.
I  = Sum of
O = observed number of crossovers 
E = expected number of crossovers
The expected number of crossovers were calculated by:
Total number of crossover events divided by the total length of the chromosome 
covered by markers (giving the average number of crossovers per kb) then multiplied by 
the distance (kb) between each pair of markers.
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5.3 RESULTS
5.3.1 Linkage Analysis
At the time of initiating the linkage analysis, genetic maps were available for 
chromosomes I and II and partial maps were available for chromosomes III, IV, IX and X 
(Hall et al., 2003; El-Sayed et al., 2003; MacLeod and Tweedie, unpublished results). 
Linkage was assessed by comparing the inheritance pattern of each marker with 
inheritance of the cymelarsan resistance phenotype for the 38 F1 progeny of the STIB 
247 X TREU 927 cross. Table 5.2 indicates the number of markers initially available for 
each of the chromosomes and the range of their respective LOD scores for linkage to 
the drug resistance phenotype. This indicated that only those markers on chromosome 
II detected linkage to the cymelarsan phenotype, with a highest LOD score of 6.4 for 
marker 5, which is classified as significant linkage (Lander and Krugylak 1995). One 
other marker (6) gave LOD scores >3 further confirming the linkage to a region of 
chromosome II. The remaining markers on this chromosome (A5, 2, 7 and PLC) gave 
lower LOD scores and, given the physical order of these markers (A5 -  2 -  5 - 6 - 7 -  
PLC) suggested that the Cymelarsan locus was located in a central region of the 
chromosome. The markers on the other chromosomes analysed showed no significant 
linkage, giving LOD score values of <3.
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Chromosome Markers n LOD score
I 12 0 -  0.75
II A5 2.5
2 2.5
5 6.4
6 3.1
7 2.5
PLC 0.1
III 16 0 -0 .5
IV 19 0-1.08
IX 17 0-1 .5
X 12 0-0.14
Table 5.2: Linkage analysis of Cymelarsan resistance to markers on genetic maps for six of the 
eleven chromosomes. Statistically significant iinkage was observed for a region on 
chromosome li with a maximum LOD score of 6.4. No significant linkage was observed with 
markers on any other chromosomes. N -  number of polymorphic markers.
The parental haplotypes for each of the 17 polymorphic markers, listed in Table 5.1, 
were determined for TREU 927 using each pair of markers according to those most 
frequently inherited in the panel of 38 FI progeny from the STIB 247 x TREU 927 cross 
(Fig 5.1). A colour was then assigned for each parental haplotype depending on which 
pairs of TREU 927 alleles were inherited in the FI progeny (Fig 5.2) and the association 
between the haplotypes and the phenotype of the progeny defined. The haplotypes 
indicated in yellow in Fig 5.2 were associated with resistance while those indicated in 
blue associated with sensitivity.
By determining the inheritance of phenotype with crossover events in the recombinant 
progeny an association could be pinpointed to a region on chromosome II. It follows, 
therefore, that if there was 100% linkage to a pair of markers on chromosome II then all 
the cymelarsan resistant progeny should be yellow and all the sensitive progeny should
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be blue. As can be seen in Fig 5.3 crossover events in the progeny defined the region 
bounded by markers 2 and 6 as carrying the cymelarsan resistant trait i.e. polymorphic 
markers that are linked to a segment of the genome should co-segregate with 
phenotype, with marker 5 giving a LOD score of 6.4 (Table 5.2). As it could not be 
determined whether the gene conferring the resistance trait was to the left or right of 
marker 5, fine scale mapping of the region bounded by markers 2 and 6 was 
undertaken.
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X 6 A 5
927 Parental chromosomes
2o 5-o 6o 7o PLCo
Haplotypes 
X 8  3
Recombinant chromosomes
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Fig 5.2: Recombination diagram of the haplotypes of TREU 927. Shown are 14 parental haplotypes 
in blue or yellow and 24 recombinant types. The figure also shows the relationship between 
genotype and phenotype (yellow, resistant haplotype: blue, sensitive haplotype). Initial findings 
suggest that the resistance determinant lies between markers 2 and 6. See Fig 5.3 for a more 
comprehensive analysis.
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Fig 5.3: Recombination diagram showing the region of chromosome carrying the resistance 
determinant. Polymorphic marker inheritance patterns and cymelarsan responses (R, 
resistant and S, sensitive) are shown for four of the progeny from the STIB 247 x TREU 927 
cross. The polymorphisms that detected chromosome crossovers are represented are 
represented with a red box (Yellow, resistant haplotype, Blue, sensitive haplotype). 
Crossovers occurred between the region bounded by the markers 2 and 6.
As chromosome II has been sequenced (El-Sayed et al., 2003) the distance between 
markers 2 and 6 was known (Fig 5.4 A) together with the number, order and identity of 
the open reading frames (ORFs) in this region. The region between markers 2 and 6 
was a 263kb segment of chromosome II, containing 50 ORFs.
With the parental haplotypes determined and the positions of crossover events 
identified in the recombinant haplotypes a genetic map of chromosome II was 
constructed (Fig 5.4 B). The genetic map was 100 cM (centimorgan) in length, which 
gave an average of one marker per 16.6 cM. This map so far only covered 738 kb of the
1.2 Mb length of chromosome II, giving an average physical size for the recombination 
unit of 7.38 kb/cM. Thus, suggesting that the identification of additional crossover
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events in the progeny would localise the resistance determinant to a smaller region of
the 263 kb segment. Genetic markers had been defined every 123 kb along the
chromosome, however a comparison between the genetic and physical maps indicated 
that recombination was unevenly distributed along its length (x^  =11, df = 4, 0.05 > P > 
0.02; taking the null hypothesis that there is an equal probability of crossovers in all 
regions of the chromosome). The chi squared (x^ ) value was determined by using the 
formula shown in the methods section and adding the values for each pair of markers 
together. As can be seen from Fig 5.2 there were 15 crossover events between markers 
2 and 6 where linkage to the resistance determinant lies. In accordance with this map, 
however, there should have been approximately one crossover every 30 kb. It was 
determined, however, that there was a recombination ‘hot spot’ between markers 2 and 
5 where crossovers occurred readily, with 11 observed crossovers in comparison to the 
5 expected within a 185 kb region (Table 5.3).
Given the availability of the physical map of chromosome II, markers could be
developed within the 263 kb region between markers 2 and 6. Thus, this fine scale 
mapping should localise the resistance determinant to a smaller region of the 
chromosome and as a result cut down the number of genes from 50, hopefully to a 
more workable number. Therefore fine scale mapping of this 263 kb region was 
undertaken which would also improve the resolution of the genetic map of chromosome
II. It should also be noted that some informative makers were also found outside the 
263 kb region of interest which subsequently led to improve the genetic map.
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Chromosome II Genetic Map for TREU 927
A Okb 100 200 300 400 500 600 700 800 900 1Mb 1.1 1.2
B
f t
AS 2
1 1 1
t t t
5 6 7 
1 1 1
f
P LC  
1 1
46 185 78 49 379 kb
8 44 16 4 28 cM
2 11 4 1 7 No of crossoV
5.8 4.2 4.8 12.25 13.5 kb/cM
Fig 5.4 : Position of polymorphic markers on chromosome ii and a genetic map. (A) The location of 
the polymorphic markers along chromosome II. (B) Genetic map showing ttie physical distances 
between the markers (kb), and the genetic distances (cM) calculated from the recombination 
frequencies (see Materials and Methods). The relationship between hot and cold spots of 
recombination (kb/cM) are also Indicated (Hot, red line. Cold, blue line), see also Table 5.3.
Marker Pairs on 
Chromosome II
Distance between Number of Crossovers
Observed Expected
A5&2 46.3 2 2.7
2 & 5 185 11
5 & 6 78 4 2.3
6 & 7 49 1 1.4
im m Ê
Table 5.3 : Indicating hot and cold spots of recombination. There Is recombination ‘hot spot’ between 
markers 2 and 5 where crossovers occur readily. I.e. exceed the number expected, (2.6 
kb/cM) (red). In contrast, there is a recombination ‘cold spot’ between markers 7 and PLC 
where there were fewer crossovers than expected over the 379 kb region (blue). = 11, df = 
4, 0.05 > P > 0.02, Indicating crossovers do not occur randomly. The methods for these 
calculations are shown In Materials and Methods.
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Ten mini- and microsatellite informative polymorphic markers were identified (Table 5.1) 
which were heterozygous for the TREU 927 parental line used in the cross (Fig 5.1). 
Thirty sets of primers were designed and used to amplify genomic DNA from STIB 247 
and TREU 927. Each amplicon was then digested with either Alu 1 or Rsa 1 to screen 
for polymorphisms between the two parental lines. Only four were found to be 
informative because they showed variation between the two parental lines (Table 5.1). 
As with the mini and microsatellite markers, the parental haplotypes of the four RFLP 
markers were determined as the most frequently inherited haplotypes (presence of 
band (+), absence of band (-)) for the panel of 38 FI progeny of the STIB 247 x TREU 
927 cross (Fig 5.5).
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 247 927
+/-
Fig 5.5: The RFLP inheritance pattern of the 2 parental iines (247 & 927) and 17 hybrid progeny 
digested with restriction enzymes, located on chromosome ii. The RFLP marker M/N was 
scored after digestion with the restriction endonuclease Alul, indicating a polymorphism in the 
restriction fragment (arrowed) that is present in TREU 927 but absent in STIB 247. This 
polymorphism segregated into the FI progeny as shown by the presence of the band in 9 of the 
17 progeny. Robocyder conditions are listed in Table 5.1, the PCR product was digested 
ovemight at 37°C and separated by electrophoresis on 2% Seakem agarose stained with 
ethidium bromide and visualized by UV illumination. M, 100 bp DNA ladder.
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Eleven of the 14 informative markers identified were then used to define a genetic map 
within the 263 kb region where the resistance determinant was thought to be located 
(Fig 5.6). Inheritance patterns of these markers in the 38 FI recombinant progeny 
identified 27 crossover events across the chromosome (Fig 5.7). The boundaries set by 
these crossovers, therefore, defined the locus determining the Cymelarsan phenotype.
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Using the same approach as that previously described for assessing linkage (Fig 5.3), 
analysis revealed that alleles of the ST2 and A9 markers were highly significantly linked 
to the cymelarsan resistance phenotype, giving a LOD score of 7.5. To either side of 
these markers, linkage ratios were reduced due to chromosome crossover events 
among the progeny and Fig 5.8 shows a plot of the LOD scores for all the markers 
across the length of chromosome II. From this data a region of the chromosome, 
between markers A34 and A36, gives LOD scores that are >3. However, it should be 
noted that the distance between these markers is 41 kb and so few crossover events 
would be predicted within this region. This is discussed in more detail later in the 
chapter (See also Fig 5.11).
The positions of crossovers in three of the most informative progeny clones are 
indicated in Fig 5.9. The phenotype of these three hybrid clones was identical to that of 
either the resistant parental line TREU 927 or the sensitive parental line STIB 247. The 
haplotypes of these clones define crossovers between markers ST2 and A9 and the 
phenotypes of these clones can only be explained if the locus determining Cymelarsan 
resistance lies between these markers. The availability of the entire TREU 927 
sequence of chromosome II from TIGR identified this region as spanning 25 kb and 
contained six ORFs with the linkage and haplotypes analysis indicating one of these 
genes as determining resistance to cymelarsan (Fig 5.10).
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5.3.2 Genetic map of TREU 927 for chromosome II
As a result of generating a further 14 informative polymorphic markers on chromosome 
II in addition to the nine already described (El-Sayed et al., 2003; MacLeod and 
Tweddie, personal communication) and increasing the number of independent progeny 
clones from 18 to 38, it was possible to construct a more detailed genetic map of TREU 
927. By calculating the recombination fraction (cM) between each pair of markers along 
the chromosome and adding these together the T. bruce/genetic map of chromosome II 
was 97 cM in length, which gave an average density of approximately one marker per
4.2 cM. The map covers 738 kb of chromosome II, which gives an average physical size 
for a recombination unit of 7.6 kb/cM (Fig 5.11). Thus on average, a crossover event 
occurs every 27 kb along the chromosome II but comparison of the genetic map and the 
physical map indicated that the genetic distance varied in relation to the physical 
distance between markers. In order to determine if recombination events were evenly 
distributed along the chromosome, firstly the observed and expected number of 
crossover was determined for each interval between the markers based on the average 
for the whole chromosome (Materials and Methods, section 5.2.8) (Table 5.4). As some 
of the physical intervals between markers were small and therefore the predicted 
number of crossovers less than expected, the intervals were combined to yield 12 
contiguous pairs of markers between each of which the predicted number of crossovers 
was greater than one. Based on the predicted versus observed numbers of crossovers 
(Table 5.5) in each of the intervals and testing the deviation between these using it 
can be seen that two marker intervals show significant differences between observed 
and expected values. There was one recombination ‘hot spot’ between markers 2 and
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A9 where crossovers occurred readily, with 9 observed crossovers in comparison to the 
2.6 expected value within a 77 kb region (2.3 kb/cM) and one 'cold spot’ between 
markers A22 and A30 where crossovers were absent over a 269 kb region (>269 
kb/cM) but 9.7 crossovers are predicted (Table 5.5) and (Fig 5.11).
Markers on Distance Number of Crossovers
Chromosome II between
Markers (kb) Observed Expected
A5 &2 46 2 1.6
2&A8 24 3 0.8
A8 & ST2 27 3 0.9
ST2&A9 26 3 0.9
A9&A10 66 1 2.3
A10&A34 41 3 1.5
A34&5 1 0 0.03
5&UA/ 0.3 1 0.01
UA/&A12 7 0 0.2
A12&Q/R 1.5 0 0.05
Q/R & M/N 7.5 0 0.27
M/N & l/J 9.5 0 0.3
I/J&A36 14 0 0.5
A36&6 38 3 1.4
6& 7 49 1 1.7
7&A22 121 7 4.3
A22&X 39 0 1.4
X & 8 44 0 1.6
8&A26 129 0 4.6
A26 & 27 37 0 1.4
27 & PLC 9 0 0.3
PLC & 30 11 0 0.4
Table 5.4: Markers, their position, the distance (kb) and the number of crossovers, observed and 
expected, between each of the markers, for the 247 x 927 cross, on chromosome II.
These were then used to determine If there were any recombination ‘hot spots’ or ‘cold spots’ 
on the chromosome. Those with the lowest expected values were merged to raise the 
expected values to 1 or more (Table 5.5). The observed number of crossovers was obtained 
from Fig 5.7. See Materials and Methods for calculation of expected number of crossovers for 
each marker pair.
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Marker Pairs on Distance Number of Crossovers
Chromosome II between
Markers (kb) Observed Expected TA5&2 46 2 1.6 0.1
2& A 9 77 9 2.6 15.7
A9&A10 66 1 2.3 0.73
A10&A34 41 3 1.5 1.5
A34 & A36 40.8 1 1.36 0.95
A36&6 38 3 1.4 1.8
6& 7 49 1 1.7 0.29
7&A22 121 7 4.3 1.7
A22&X 39 0 1.4 1.4
X & 8 44 0 1.6 1.6
8 & A26 129 0 4.6 4.6
A26 & 30 57 0 2.1 2.1
Z2A7
Table 5.5: Isolation of ‘hot and cold spots’ on Chromosome II. After the merging of several groups of 
adjacent markers it was observed that there was one recombination hot spot’ between 
markers 2 and A9, where there were 9 observed crossover events compared with the 
expected value of 2.6 over a 77 kb region (2.3 kb/cM)(red) and one cold spot’ between 
markers A22 and 30 where there were no observed crossovers. The expected value was ~
10 over a 269 kb region (>269 kb/cM) (blue). =  32.47, df = 10 (cumulative data set) and 
P< 0.01, indicating crossovers do not occur randomly.
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5.3.3 Analysis of the STIB 247 x STIB 386 cross
The next step of the analysis was to determine if cymelarsan resistance mapped to the 
same region in STIB 386. To date, genetic maps of STIB 386 are only available for 
chromosomes I and II and mapping of the remaining chromosomes is in progress 
(MacLeod and Tweedie, personal communication). Due to the fact that the STIB 386 
genome has not been sequenced, markers for this line were developed based on the 
TREU 927 sequence (El-Sayed et a/., 2003). The same 82 markers described 
previously for screening TREU 927 (MacLeod and Tweedie, unpublished results), were 
screened using STIB 386 and STIB 247 to determine if they were informative (Materials 
and Methods). I screened 28 of these markers and the remaining 54 were screened by 
A. MacLeod and A. Tweedie and eight were selected for map construction because they 
showed size variation, and were heterozygous for STIB 386 but homozygous for STIB 
247 for chromosome II (Fig 5.1; Table 5.1), similarly there were seven informative 
markers available for chromosome I (MacLeod and Tweedie, unpublished results).
Linkage was assessed by comparing the inheritance pattern of each marker with 
inheritance of the cymelarsan resistance phenotype for the 34 F1 progeny of the STIB 
247 X STIB 386 cross. Table 5.6 presents the number of markers analysed for each of 
the chromosomes and the range of their respective LOD scores for linkage to the drug 
resistance phenotype. This indicated that only markers on chromosome II showed 
linkage to the cymelarsan phenotype, with a LOD score of 4.1 for markers 4, A34, 5 and 
7, which is classified as significant linkage (Fig 5.12).
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As there are, to date, only eight markers available for mapping the resistance 
determinant for this cross, it is difficult to say that the resistance determinant maps to 
the exact region as that identified for the STIB 247 x TREU 927 cross, but these results 
suggest that the locus is at the same end of the chromosome (Fig 5.12).
Chromosome Markers LOD score
1 10 0.2 -  0.41
II A8 1.7
4 4.1
A34 4.1
5 4.1
7 4.1
T 2.7
9 2.7
PLC 1.7
Table 5.6: Linkage analysis of Cymelarsan resistance to markers on genetic maps for 
chromosomes I and II of STIB 386. Statistically significant linkage was observed for a 
region on chromosome II with a maximum LOD score of 4,1. No significant linkage was 
observed with markers on chromosome I.
152
Chapter 5 Positional Cloning o f  a locus for Resistance to Cymelarsan
I8
4.5 
4*
3.5-
3 -
2.5 * 2-
1.5. 1 . 
0.5.
A8 A34 5 7 T
MARKERS
PLC
Fig 5.12: LOD scores for markers situated along chromosome II of STIB 386. Graph indicating the 
region on Chromosome It where linkage to the resistance determinant lies between markers 4 
and 7 with a LOD score of 4.1. To either side of these markers linkage ratios were decreased 
due to crossover events among the progeny.
The haplotypes of each of the markers on chromosome II were determined according to 
those most frequently inherited in the panel of 34 FI progeny from the STIB 247 x STIB 
386 cross. Linkage to cymelarsan resistance was determined by analysing the 
Inheritance of genotype with phenotype in the 34 FI progeny (Fig 5.13). The 
polymorphic markers, therefore, that link to a segment in the genome should co- 
segregate with phenotype (Blue, resistant, Red, sensitive). Thus, a crossover defined 
interval carrying the gene controlling the inheritance of the cymelarsan resistance trait 
can be localized to a region on the chromosome.
Taking together, the STIB 386 haplotypes of the 34 FI progeny clones and their co­
segregation with phenotype, crossover events localised the resistance determinant 
between markers A8 and 4 (Fig 5.13). Taking this into account and together with the
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LOD scores available future work should focus on fine grained mapping between 
markers A8 and 4 in order to confirm the exact position of the resistance determinant on 
chromosome II and thus ascertain if it is in the same region as that mapped in line 
TREU 927.
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Fig 5.13: Recombination diagram of the haplotypes of STIB 386. Shown are 22 parental haplotypes in 
blue or red and 12 recombinant types. The figure also shows the relationship between 
genotype and phenotype (blue, resistant haplotype; red, sensitive haplotype). Initial findings 
suggest that the resistance determinant lies between markers A4 and 4 (Black box).
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5.4 DISCUSSION
The availability of a genetic linkage map for T. brucei makes it possible to perform 
classical genetic studies to identify the loci that determine drug resistance, and relies 
upon the ability to conduct genetic crosses between two parents that differ in their drug 
resistance phenotype. Partial genetic maps were previously constructed using mini- and 
microsatellite markers (MacLeod and Tweedie, unpublished results) and anonymous 
AFLP markers (Masiga et al., 2002; Tait et al., 2002). However, the rapid progression of 
the T. brucei sequencing project has meant that genetic mapping and positional cloning 
is now feasible, based on mini and microsatellite markers at defined positions on each 
of the chromosomes. These chromosome-anchored maps provided a baseline for the 
study described in this chapter.
The ability to perform genetic linkage analysis in T. brucei has allowed the investigation 
of the trait of resistance to the arsenical drug cymelarsan. Analysis of the genotype of 
the unique hybrid progeny was conducted using mini and microsatellite and RFLP 
markers. In parallel, each progeny clone was tested for its drug resistance phenotype 
(Chapter 4). By comparing the segregation of the drug resistance phenotype with that of 
markers that are located at known map positions along the chromosome it was possible 
to identify the locus determining drug resistance. More specific, ' fine grained', analysis 
of the locus was possible by using a combination of further linkage analysis combined 
with physical mapping facilitated by the genome project for 7. brucei.
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The results indicated that a major determinant of drug resistance was associated with a 
locus on chromosome II between two polymorphic markers, ST2 and A9, encompassing 
a 25 kb region containing 6 ORFs, identified by TIGR as ‘conserved hypothetical’ or T. 
Wee/family hypothetical proteins’.
As the physical distance between the 23 markers on chromosome II is known from the 
genome sequence (El-Sayed et al., 2003), the physical size of the centimorgan could be 
calculated for each interval (Fig 5.11). The average value obtained was 7.6 kb/cM for 
the marker intervals analysed, however, this is probably an underestimate as this map 
only covers 738 kb of the 1.2 Mb chromosome. This value is comparable to the value 
obtained for Plasmodium (Su et al., 1999) and thus a lOcM map of the genome would 
allow linkage to be determined within 110 kb of any gene. Genetic maps are currently 
being constructed for the Toxoplasma gondii genome and the average map unit is 
estimated to be approximately 215 kb/cM. A locus has been identified on chromosome 
VII that is thought to be involved in acute virulence, a region that spans 1,5 Mb. The 
ongoing genome sequencing project of T. gondii means that physical mapping of this 
region to eventually isolate the gene involved in acute virulence is restricted (Su et al.,
2002). Similarly, construction of genetic maps for Eimeria tenella are in progress. A 
region on chromosome II is thought to be responsible for precocious development in 
progeny (faster completion of life cycle stages than their parents), however because the 
linkage groups where the markers defining this region have not been assigned a 
position on the chromosome the position of crossovers are not known. Physical
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mapping of this trait to a smaller region is not possible until a larger number of 
chromosome II specific markers are identified (Shirley and Harvey, 2000).
Comparison of the predicted sequences of these six ORFs against the protein database 
InterProScan (http://www.ebi.ac.uk) revealed sequence homology to ORF 1 with a 
phospholipase 0 X -  domain, 34 amino acids with an E -  value of 0.21. For ORF 2 
there was sequence homology to a RING finger domain identifying homology for 34 
amino acids of a 103 amino acid sequence and a hypothetical protein that showed 
sequence homology for 27/67 amino acids. A SMART (http://smart.embl) search of ORF 
4 found that there was a transmembrane domain near the N -  terminus, which may 
function to anchor the protein in the membrane. No other sequence homologies were 
detected for the remaining three ORF protein sequences. Given these data, where there 
were no outstanding features of any of the ORFs that would implicate their involvement 
in conferring drug resistance, further investigation of these 6 ORFs is required and this 
is the subject of the following chapter.
The linkage of the cymelarsan resistance determinant in the STIB 247 x STIB 386 cross 
was less conclusive. Analysis showed that the resistance determinant was located on 
chromosome W giving a LOD score of 4.1 between markers 4 and 7 (Table 5.6), which 
suggested significant linkage of the resistance determinant to this region of 
chromosome II. Recombination events in the 34 FI progeny linked the resistance 
determinant between markers A8 and 4 (Fig 5.13). It, therefore, would be important to 
carry out fine grained mapping within the 288 kb region between markers A8 and 7 to
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further refine the region containing the resistance determinant. It is difficult, without the 
entire sequence of STIB 386 chromosome II, to determine if the markers are located 
physically where predicted, due to the fact that these markers were based on the TREU 
927 sequence available from the TIGR 7. Wee/sequencing project (El-Sayed et al.,
2003). These markers, however, are in the same part of chromosome II where there 
was highly significant linkage for the resistance determinant found for the STIB 247 x 
TREU 927 cross.
Fine scale mapping should be a relatively easy task due to the fact that the distance 
between marker A8 and 4 is 142 kb, in strain TREU 927 and this region contains 22 
annotated genes (El-Sayed et al., 2003). With a combination of a genetic map, a 
genome sequence and phenotypic difference between the parents, localisation to a 
smaller region is relatively straightforward.
It is likely, however, that there are additional loci contributing to the drug resistance 
phenotype. For instance the locus/loci which governs the resistance phenotype 
observed for pentamidine for the STIB 247 x TREU 927 cross for which all the progeny 
were sensitive to pentamidine in comparison to the progeny from the STIB 247 x STIB 
386 cross where the progeny segregated in a 1 : 1 ratio sensitive ; resistant which was 
observed for all other drugs tested for both crosses, suggesting that there is a different 
locus involved in pentamidine resistance (Chapter 2). Although, this is not a trivial 
undertaking, this could be resolved by analysis of further progeny from different 
crosses, linkage analysis and the availability of a backcross. These results, however,
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demonstrate that forward genetics offers a powerful means of analysing the genetic 
basis of drug resistance in T.brucei. Similar approaches, therefore, are likely to be 
useful for determining the molecular genetic basis of other complex traits.
Although trait mapping using laboratory derived progeny is an essential tool for studying 
the inheritance of particular trypanosome phenotypes, there are limitations to this 
approach. It is relatively expensive and laborious to generate laboratory crosses and 
large numbers of progeny are required for analysis of the trait of interest. The RNAi 
approach, however, is even more laborious and suffers from often not observing a 
phenotype and therefore the genetic approach for gene identification responsible for a 
particular trait far outweighs the alternative RNAi approach. The relevance of the loci 
identified in the selection of drug resistance in the field remains to be determined. It is 
possible that different alleles at the locus described here and other loci are involved in 
determining resistance to arsenicals. It should, therefore, be remembered that genetic 
analysis of laboratory generated progeny from crosses acts principally to guide testing 
of field isolates for the genes identified.
The process of trait mapping and, ultimately gene identification will dramatically facilitate 
the ongoing T. Wee/sequencing effort. Due to the fact, each mini-microsatellite marker 
in the linkage map corresponds to a sequence tag site (STS) it is possible then that 
these can be readily identified in the expanding sequencing contigs. As a result, 
mapped loci can be linked to physical sequences, and specific candidate genes residing 
within these sequences can be identified and evaluated for their role in trait
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determination. Moreover, the sequencing project will continue to identify thousands of 
simple sequence repeats from which new markers can be identified and used to 
saturate regions of particular interest in the genome. We should not lose sight of the fact 
that proof of the role of any candidate gene will be a rigorous task.
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CHAPTER 6
DETERMINATION OF A PUTATIVE RESISTANCE GENE USING A PCR BASED 
ALLELE DELETION AND REPLACEMENT SYSTEM
6.1 INTRODUCTION
Biochemical studies have indicated that the arsenical drug resistance phenotype arises 
when a plasma membrane nucleoside transporter involved in drug uptake, P2, is altered 
or lost (Carter and Fairlamb, 1993). The gene encoding the P2 transporter, TbAT1, has 
been identified (Maser et ai, 1999) and is located on T. Wee/chromosome XI. Knock­
out experiments have shown that the absence of this gene confers resistance, but not to 
the levels obtained in drug selected cell lines (Matovu et ai, 2003). The data presented 
in previous chapters, however, has shown that a locus on chromosome II is a 
determinant of the drug resistance phenotype (Chapter 5) and therefore resistance can 
arise by mutations in more than one gene (Chapter 4).
The drug resistance phenotype segregated as a Mendelian trait In each of the two 
genetic crosses, STIB 247 x TREU 927 and STIB 247 x STIB 386 where TREU 927 and 
STIB 386 are both drug resistant, relative to STIB 247. Linkage mapping of the STIB 
247 X TREU 927 cross localized the drug resistance determinant to a 25 kb region on 
Chromosome II and a search of this region identified six ORFs (Chapter 5). To further 
investigate if these six candidate ORFs are determinants of the drug resistance 
phenotype, a PCR based gene/allele deletion strategy was undertaken.
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Up until now this study has focused on and demonstrated that forward genetics is a 
powerful approach in the analysis of the molecular basis of drug resistance in T. brucei. 
It is obvious, however, that coupling this approach with reverse genetic techniques 
would potentially prove or disprove the findings of the forward genetic approach, in the 
identification of the gene/genes involved in conferring drug resistance.
Techniques that enable gene deletion are essential for the analysis of gene function. 
The approach used here is based on the PCR amplification of DNA constructs that 
encode a selectable marker gene (internal region) flanked by DNA sequence identical to 
the homologous target locus (external region). In order to generate selectable knock -  
out cassettes, two oligonucleotides were designed for each ORF. The first 
oligonucleotide has a 20 -  30 bp sequence at the 3' end homologous to the 5 end of 
the selectable marker and at the 5' end has a 40 -  80 bp sequence homologous to the 
target gene. The external regions therefore direct the homologous recombination at the 
target locus and insert the antibiotic selectable marker (Gaud et ai., 1997; Shen et ai., 
2001). The major advantage of this technique is that it allows the rapid manipulation of 
genes without the need for cloning steps, which can be very time consuming. Using this 
strategy, I report the identification of a candidate gene involved in the drug resistance 
mechanism.
1 decided to undertake an allele knock-out approach in order to determine the 
Cymelarsan drug resistance determinant as opposed to an RNAi based approach. The 
rationale for this was that as TREU 927 is heterozygous for the allele that determines 
resistance based on the genetic analysis (Chapter 4), it would be difficult to predict the
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phenotype, if RNAi was used to knock down expression of both alleles. If the resistant 
allele was knocked out the prediction would be that TREU 927 would become sensitive 
to Cymelarsan. This strategy and the predicted outcomes are illustrated 
diagrammatically in Fig 6.1 A. Thus, if an allele at one of the six ORFs does determine 
resistance, then 50% of the knock-outs should lead to a change in Cymelarsan 
sensitivity. In ORFs not determining resistance, no change in phenotype would be 
predicted. Similarly, using an allele knock-in approach, the prediction would be that if 
the resistance allele of TREU 927 replaced the sensitive allele in the homozygous STIB 
247 then there would be a change in phenotype i.e. to resistance (Fig 6.1 B). If, 
however, the sensitive allele of TREU 927 replaced the sensitive allele of STIB 247, 
then there would be no change in phenotype. Therefore, if any of the six ORFs were 
involved in conferring the resistance determinant then there should be a change in 
phenotype due to allele deletion or replacement.
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Predicted 927 genotype for MeiCy'
Selection for 
Neo*
X X
Predicted phenotype
B Predicted 247 genotype for MelCy*^
Selection for 
MeiCy'^
927 RReplacement 927 S 
allele
Predicted phenotype S R
Fig 6.1: PCR based allele deletion and replacement A: Knock-out of the resistant and sensitive allele 
in TREU 927. If the resistant allele (yellow) was knocked-out then the prediction would be that 
there would be a change in phenotype to sensitivity in the transfected cells. If, however, the 
sensitive allele (blue) was knocked-out then the prediction would be, no change in phenotype 
i.e. the transfectants would remain resistant. B: Allele replacement of the sensitive STIB 247 
allele with the resistant TREU 927 allele would lead to the prediction that the transfectants would 
change phenotype to resistant. If the sensitive allele of STIB 247 was replaced with the sensitive 
allele of TREU 927 then the prediction would be there would be no change in phenotype.
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6.2 MATERIALS AND METHODS
6.2.1 Primer design for gene deletion
Primer design was carried out according to Gaud et al., (1997). The 876 bp long 
fragment used for disruption of the ORFs under investigation was generated by PCR 
using 1 ng of a neomycin plasmid construct (A kind gift from Keith Matthews, University 
of Manchester) containing the neomycin resistance gene as a template DNA (Gaud et 
a!., 1997). The oligonucleotides used as primers (Table 6.1) in the PCR contain two 
distinct regions: 24bp in the internal regions were designed to amplify the selectable 
marker gene, and 41 bp at the external regions of the primers were identical to the 
flanking sequences of the gene to be disrupted (Fig 6.2). PCR amplification with these 
primers was carried out as described in Materials and Methods, section 2.2.8 and Table
6.1. The PCR amplified deletion constructs were cleaned up and extracted using 
Qiagen A1 Quick PCR purification kit and the DNA was recovered by ethanol 
precipitation. Ethanol precipitation was carried out as follows; 20pl of 3M sodium 
acetate plus 0.5 mis of 100% ice-cold ethanol was added to the DNA pellet and left at 
-20°C for 3hrs or overnight. The DNA was then uttracentifuged at 13,000 g for 15mins at 
4“C. The supernatant was removed and the pellet was washed with 70% alcohol and 
ultracentrifuged again at 9,000 g for 5 mins. The pellet, 6 - lOpg, was then allowed to 
dry in a flow cabinet and re-suspended in lOpI sterile water and used directly for 
electroporation.
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Primer 5 - 3 sequence
1 0RF1 - F c c t t g t ta a t t t g g t t a t t a a c a tg a g a t g c c c t c t g a t a a t t t a a t g t
tc tc ta a g a t t t t ta tg t tg a c a c c g tc a tg a t tg a a c a a g a tg g a t tg
c
2 ORF1 - R gcaagtaagccagctggagggggggaaacagacattattt tacaatcac
tt taacacatatccatggccgccgtagtgctcagaagaactcgtcaaga
ag
1 ORF2 - F g a tcc ac taaa t tc aca aac tcc acacg tt tc c t tacg tg ta ta ta tg a
ttgaacaagatggattgc
2 ORF2 - R ccctttaaccgccgtaaagggggggaagaaaaataatgtttagagtcag
aagaactcgtcaagaag
1 ORF3 - F cgctcccaacaaaatatcacgattcacgtgctgtcgcattggggcgcgt
at taaacgtgcgctactaccacaatgatgattgaacaagatggattgc
2 0RF3 - R gaggcaagacaaccgtagggaacgttgcttaggaaattttcaacacgct
tt tcggcacgccatgtcatcgtcagaagaactcgtcaagaag
1 ORF4 - F ccaca ta tc ta ta t tca tcg t tac gcagc taca a tcca c ta tga t tg aa
caagatggattgc
2 ORF4 - R agcgcctcaaacagtgtagccgaacccatgcgctcagaaatcagaagaa
ctcgtcaagaag
1 ORF5 - F ggagtccaccctaatgggaccacat taaatc ttacctt tga tga ttgaa
caagatggattgc
2 0RF5 - R aaaaa taacccat tact t t tgaagata tgcatta tgcctc tcagaagaa
ctcgtcaagaag
1 ORF6 - F aacggcagttccctggcagttccgatgattcaccttcccgatgattgaa
caagatggattgc
2 ORF6 - R aaaataaataaataaacacacgtgtatgtgcatgtgtgtgtcagaagaa
ctcgtcaagaag
Table 6.1: Oligonudeotkle sequences for each ORF deletion. These primers flank the sequence of 
each ORF. At the end of each primer are the nucleotides homologous to the neo* gene 
sequence that will direct homologous recombination of the neo"^  gene in place of the ORF 
(indicated in red) (Fig 6.1). The PCR conditions were as follows; 95°C for 50 sec., 56°C for 50 
sec. and 65°C for 50 sec. for 30 cycles. The products were separated on a 1 % Seakem 
agarose gel, stained with ethidium bromide and visualized by UV illumination as described in 
Chapter 2, Materials and Methods.
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Primer 1
5' ORF flanking 
region
5' neo coding 
region
neo
PCR
Product
3' neo" coding 
region
5' ORF flanking region
3' ORF flanking 
region
^ -------
Primer 2
neo
3' ORF flanking region
Fig 6.2: Diagrammatic representation of PCR based gene deletion technique and subsequent 
integration into the ORF locus. The arrows represent the position of oligonucleotides.
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6.2.2 Zimmermann post fusion media (ZM buffer)
This buffer comprises of 132mM NaCI, 8mM KCI, 8mM Na2HP04, 1.5mM KH2PO4, 
0.5mM Mg acetate and 90pM CaCl2, and was filter sterilized, aliquoted into 50ml falcon 
tubes and stored at “20®C. For electroporation of bloodstream forms Q.5g glucose / 50ml 
was added.
6.2.3 Transfection of procyciic form trypanosomes
Procyclic stage cells in mid log phase of growth (TREU 927) were used, at a density of 
approximately 5x10® cells/ml. Flasks were prepared with lOmls of pre-warmed SDM- 
79 supplemented with 30% foetal calf serum. The electroporator was set to 1,500 Volts 
and 25 pF. Approximately 5 x 10  ^ were pelleted at 1,100 x g, for 7 min, for each 
transfection. Each pellet was resuspended in lOmls of room temperature Zimmerman 
post fusion media (ZM buffer) and pelleted again as above, this was repeated twice. 
Each pellet was then resuspended in O.Smls ZM buffer and transferred into the tube 
containing the 6 - lOpg of DNA of the PCR transfection amplicon and mixed gently. This 
was then placed into a 0.2cm sterile electrode gap cuvette and placed in an 
electroporator. Cells were electroporated twice with a 10 sec gap. The electroporated 
cells were then immediately transferred to flasks containing the pre-warmed SDM-79 
medium and incubated at 25°C. Drug selection was applied the following day. Care 
was taken to avoid leaving cells in the ZM buffer for any longer than necessary and cell 
pellets were prepared for a maximum of four transfections at any one time. The reason 
for this is that the ZM buffer causes cell lysis after -  20 min exposure (Richard 
Burchmore, personal communication).
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6.2.4 Drug Selection of transfected procyclic forms
After 24hr recovery period geneticin (G418) (Sigma) was added to 15pg / ml. After 7 
days, the dosage was increased to 100pg / ml. G418 resistant trypanosomes became 
apparent after 2 weeks. These cells were then centrifuged at 1,100 g for 7 mins so that 
the dead cells could be removed. The live cells concentrated at the bottom of the falcon 
tube and the dead cells were removed with the supernatant. The live cells were then 
placed back in SDM--79 with 30 % foetal calf serum prior to cloning.
6.2.5 Transfection of bloodstream form trypanosomes
Two ICR mice were inoculated with STIB 247 (Materials and Methods, section 2.2.2) for 
each transfection in order to obtain sufficient numbers of cells for transfections. The 
blood was differentially centrifuged at 1,100 g for 7 min. The top layer (serum and buffy 
coat) was decanted and centrifuged again (as above) to pellet the cells. The procedure 
given above for electroporation was then carried out, using the same number of cells 
and quantity of DNA construct. After electroporation the cells were transferred to flasks 
containing pre-warmed Cunninghams medium and incubated at 37‘*C for one hour to 
allow cells to recover. Immunosuppressed mice (Materials and Methods, section 2.2.2) 
were then inoculated with the transfected cells. After 24 hr each mouse was treated with 
a single dose of 1 mg/kg, 2mg/kg or 5 mg/kg Cymelarsan and their parasitaemia 
monitored (Materials and Methods, section 4.2.3).
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6.2.6 Diagnostic PCR
DNA was extracted from the geneticin resistant trypanosomes 2-3 weeks after 
electroporation. A diagnostic PCR was performed in order to verify if the integration of 
the neomycin resistance gene had occurred at the correct position and in the correct 
orientation and an illustration of this is shown for one of the ORFs (Fig 6.3 and Table 
6.2). The primers for these PCRs were the fonA/ard primer that flanked each of the 
ORFs to be deleted, but lay outside the sequence of the target gene used for the 
deletion construct (3) and a primer that corresponded to a sequence within the 
neomycin resistance gene (4) (Table 6.2).
6.2.7 Cloning of transfected cells
Procyclic clones were obtained by dilution as described in the Materials and Methods 
section 2.2.5. Before cloning of the transfected cells derived after knock-in, in vivo, the 
bloodstream forms were transformed to procyclic forms (Materials and Methods, section 
2.2.4) and then cloned by dilution. Diagnostic PCR was undertaken for these clones.
6.2.8 Determination of phenotype of transfected celts
The AlamarBlue phenotype assay was conducted to determine the Cymelarsan 
resistance of the transfected cells as previously described in Materials and Methods 
section 4.2.6.
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6.2.9 Sequencing of ORF 4
As ORF 4 was 2.6 kb in length it was too large to sequence with oligonucleotides 
flanking the ends. Therefore, eight sets of oligonucleotides were designed which, 
walked across the entire ORF (Table 6.3). PCR amplification of each set of primers was 
carried out using DNA from STIB 247, STIB 386 and TREU 927. PCR amplification of 
these primers was carried out as described in Materials and Methods, section 2.2.8. 
Conditions for amplification were; 95®C for SOsecs, 56°C for SOsecs and 65°C for 2mins 
for 30 cycles and run using 2% Seakem agarose. The PCR products were cleaned up 
and extracted using Qiagen A1 Quick PCR purification kit and sent for sequencing to the 
Molecular Biology Sequencing Unit, University of Glasgow.
Primer_____________5 - 3 sequence_________________   Product size
3 DP0RF1 - F gttacgacatgaaggtatctcccatcc 126 bp
3 DP0RF2 - F caaagaaggtgggagcgaaatcagaagg 127 bp
3 DPORF3 - F cagtgtacgagacaaacattcccttgcggc 129 bp
3 DP0RF4 - F gtatggttaaacaatgagtgtatg 123 bp
3 DP0RF5 - F gtgacagggagcgagcagcttcaa 123 bp
3 DPORF6 - F gctgcagccgactagtgaccgact 123 bp
4 Diagnostic primer gttgtgcccagtcatagccgaatagcctctccac 
Neo
Table 6.2; Oligonucleotide sequences for diagnostic primers. These were used to verify that the neo^ 
gene had integrated In the con'ect position and orientation (Fig 6.2). Column 3 gives the 
expected size of the band that would be observed if the neo  ^ gene had integrated in the 
correct position and orientation. PCR conditions for each primer set were as follows; 95°C for 
50 sec., 56°C for 50 sec. and 65"C for 2 min. for 30 cycles. The products were separated on a 
4 % NuSieve agarose gel, stained with ethidium bromide and visualized by UV illumination as 
described in Chapter 2, Materials and Methods.
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873bp
neo
123bp
Fig 6.3: Diagrammatic representation of the position of the primers used for diagnostic PCR.
These were used to verify the deletion and to determine integration of the neo  ^gene occurred in 
the correct position and orientation. The arrows represent the position of oligonucleotides used 
to verily the deletion, 3 flanked ORF 4 (in this example) but lay outside the deletion construct. 
Primer 4, which corresponded to a sequence within the neo^ gene, was used in conjunction with 
primer 3 to determine that the integration of the neo  ^gene occurred at the correct position (See 
Table 6.2 for diagnostic primers for each ORF) (Gaud et a/., 1997).
Primer 5 - 3 sequence
WALK0RF4-AF gccttgcgtgaccagcattggtttgc
WALK0RF4-AR cagctgtcgtccacgcaaaaggtg
WALK0RF4 - BF gcaatcgcgcatccctcactttag
WALKORF4 - BR gtccaggcgccgcctcacatatgt
WALK0RF4 - CF gtgcttaaccacggttgcgaaag
WALK0RF4 - CR ggaagatggcggtgaagcaacctc
WALK0RF4 - DF cagcagtttcttacgaagtggttc
WALKORF4 - DR cagcgagatgtggtgcatcgcgc
WALKORF4 - EF ccacgttggtcatcacggaattg
WALK0RF4 - ER cgactacgagcatgctggttacag
WALK0RF4 - FF cgccgcgatacagggcgagcgttg
WALKORF4 - FR cgccactggttcgtatgagaagg
WALK0RF4 - GF gacgagttgtgacctccgcgcccac
WALK0RF4 - GR cctgcatcagtagcggcagctgga
WALKORF4 - HF gttgaacttaggaagctgcgtttc
WALK0RF4 - HR gttctaggatctgcgcgcgcatag
Table 6.3: Oligonucleotide sequences used for primer walking of ORF 4.
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6.3 RESULTS
6.3.1 Allele knock-outs
The primers used to generate the targeting constructs for ORFs 1 - 6  consisted of 
sequence complementary to the neomycin resistance (neo^) gene flanked to the 5' side 
by >40 bp from the 5' untranslated region (UTR) and to the 3' side by >40 bp from the 
3' UTR of each of the six ORFs. The length of the DNA sequence primer required for 
either a high efficiency of transfection or a high rate of integration is dependent on the 
size of the gene which is being disrupted so therefore the primers varied in size from 40 
-  80 bp (Shen et al., 2001), the oligonucleotides used for this study are listed in Table
6.1. The UTR sequences were chosen so that recombination between the neo^ gene 
and the flanking sequences occurred at the initiation and stop codons of the targeted 
gene. As a result the translation of the selectable marker depended solely on the 
regulatory sequences flanking each of the target genes (Fig 6.2).
T. brucei line TREU 927 was cultured as procyclic forms in SDM-79 with 10% foetal calf 
serum and electroporated with lOpg of linear DNA containing the neo^ gene and the 
flanking homologous sequence to each of the six ORFs. The trypanosomes were put 
under drug selection 24hr after electroporation using geneticin (G418) and left for two 
weeks (See Materials and Methods, section 6.2.4). DNA was extracted from the 
geneticin resistant trypanosomes and the diagnostic PCR was performed in order to 
determine whether integration of the neo'^ gene had occurred (Fig 6.3).
A diagnostic PCR was carried out using primers 3 and 4 that corresponded to a 
sequence within the neo^ gene (Table 6.2). A 123 -  129 bp product would be expected
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for each of the ORFs (Table 6.2) if the integration of the neo* gene occurred in the 
correct position and this was observed (Fig 6.4).
M 9272 3 4 5 6 7
100 bp ^  123 —129 bp
Fig 6.4: Diagnostic PCR for transfections of TREU 927 cells with neo* using primers 3 and 4 In
lane 1, a negative control using non-electroporated DNA from the parental line TREU 927. 
Lanes 2 - 7  were the cells electroporated with neo  ^ and selected with G418 and represent 
each of the six ORFs respectively. This showed that the 123 bp predicted fragment was present 
and confirmed that the neo*^  gene had integrated at the correct position. M: 100 bp DMA ladder 
(Invitrogen Life Technologies).
The next step of the analysis was to phenotype the uncloned transfected TREU 927 
cells which had been selected for knock-out of a single allele of each of the six ORFs 
i.e. a change to sensitivity in the presence of increasing concentrations of Cymelarsan. 
The drug sensitivity assay, AlamarBlue, was used to test this hypothesis. The results 
obtained indicated that one ORF (number 4) now had an intermediate resistance 
phenotype (Fig 6.5). It should be stressed that the assay was conducted in the 
population of cells before cloning. Two explanations for an intermediate level of 
resistance can be considered. Firstly, as the transfected cells had only been under 
selection in G 418 for seven days, it was likely they contained both transfected and wild 
type cells. Secondly, as only one allele of ORF 4 will have been deleted, half the
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transfectants would be predicted to be resistant to Cymelarsan. To further characterise 
the transfected population with respect to these factors, clones were established.
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Fig 6.5: AlamarBlue drug sensitivity assay with Cymelarsan after deletion of alleles of each of the 
six ORFs. The analysis Indicated that there was an effect on the resistance phenotype for ORF 
4 (■ )  that demonstrated an intermediate phenotype In comparison to the resistant line TREU 
927 (♦  ) and the sensitive line STIB 247 (■  ). The other five ORFs (A  ) all followed the same 
resistance pattern as TREU 927 suggesting they were not Involved In conferring the resistance 
phenotype. The x-axIs represents the measure of fluorescence at OD5 9 0 , and the y-axis 
represents the increasing concentration of Cymelarsan.
After cloning, the cells transfected for ORF 4 these were tested, by PCR, to determine 
which contained the neo* gene. Six of 16 clones were found to contain the neomycin 
insert (Fig 6.6). These were then assayed to determine if their phenotype had changed 
from resistant to sensitive, using the AlamarBlue screening assay.
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M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
100 bp 123 bp
Fig 6.6: Diagnostic PCR to determine presence of neomycin insert in procyclic ciones derived 
from transfection of GRP 4. Of all the clones tested for the neomycin insert only six were 
found to contain the insert in the correct position and orientation 6,11 ,12 ,14 ,15  and 16 above 
respectively. A 123 bp product would be expected if the integration of the neo'^  gene occurred 
at the correct position, and this was observed.
Phenotypic analysis showed that four of the six neo^ containing transfected clones 
conferred a change to a sensitive phenotype with IC50 values in the range of 1 ~ 5 pM 
(Fig 6.7) which were typically 85 -  90% of those observed with the non-transformed 
STIB 247 sensitive line (Chapter 4). It was also found that one of the clones had a 
intermediate phenotype, the simplest explanation for this is that this was not a clone and 
was a mixture of resistant and sensitive cells, but this was not formally tested.
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Fig 6.7: Phenotype analysis of the six procyclic clones derived after replacement of ORF 4 with 
neo* gene. Four of the clones gave a sensitive phenotype when tested with increasing 
concentration of cymelarsan, one remained resistant and one gave an intermediate phenotype 
(#) .  The four clones represented by (4 ) are clones that after PCR analysis did not contain the 
neo* gene and retained the resistant phenotype as would be expected. Wild type parental lines 
represented by: TREU 927 ( ♦  ), STIB 247 ( ■  ). The x-axis represents the measure of 
fluorescence at OD590, and the y-axis represents the increasing concentration of Cymelarsan.
To confirm and extend the finding that disruption of one allele of ORF 4 in TREU 927 
resulted in a sensitive phenotype and therefore that one allele of TREU 927 ORF 4 
determined the Cymelarsan resistance phenotype, knock-in experiments were 
designed. The plan was to transfect the sensitive line STIB 247 with both alleles of 
TREU 927 ORF 4 and then select for Cymelarsan resistance. If one of the alleles of 
TREU 927 ORF 4 determines resistance and is integrated into STIB 247, the resulting 
transfectants should be resistant to Cymelarsan.
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Firstly, I determined if ORF 4 was present in line STIB 247, using the same 
oligonucleotides used to amplify ORF 4 in TREU 927, WALKORF 4 AF and HR, (Table 
6.3), were used. After PCR amplification a product the same size as that obtained for 
ORF 4 in TREU 927 was observed, thus confirming that ORF 4 was present in STIB 
247 (Fig 6.8).
M 247 927
2635 bp
Fig 6.8: PCR analysis to determine presence of ORF 4 in STIB 247. Oligonucleotides designed to 
amplify ORF 4 in TREU 927 were used to detemiine if ORF 4 was present in line STIB 247. As 
can be seen from the gel, a band of the same size was observed in STIB 247 as in TREU 927, 
used as a positive control.
6.3.2 Allele knock-in
Transfection of ORF 4 in STIB 247 was then conducted, replacing one allele with an 
equivalent allele from TREU 927 using the same primers as those used for the knock­
out but without the neo sequence at the end (Table 6.1). After one round of transfection, 
eight immunosuppressed mice were inoculated with the transfected cells. After 24hr 
four of the mice were treated with 1 mg/kg Cymelarsan and four with 2 mg/kg 
Cymelarsan and their parasitaemia monitored. After four days five of the eight mice 
developed parasitaemia, three treated with 1 mg/kg and two treated with 2 mg/kg
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Cymelarsan. Cells, therefore, capable of surviving at the same drug concentrations as 
the wild type resistant line TREU 927 (>2 mg/kg) over the same time period as reported 
previously (Chapter 4) were produced. The remaining three inoculated mice did not 
produce an infection and therefore may have required another round of transfection.
The transfected bloodstream form lines were transformed to procyclic forms and then 
cloned by limiting dilution. Five clones were established in procyclic culture and were 
then analysed for their drug resistance phenotype (Fig 6.9). Four of the clones showed 
a Cymelarsan resistance profile equivalent to that of the parental stock TREU 927 while 
one gave a sensitive phenotype. These data, therefore, indicated that there was a clear 
discrimination between resistance and sensitivity responses in cell lines that have either 
had ORF 4 deleted, or replaced with ORF 4 from a Cymelarsan resistant line.
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Fig 6.9: Phenotypic analysis of procyclic clones derived after transfection of ORF 4 TREU 927 into 
bloodstream forms of STIB 247. Four of the five cell lines tested ( A  ) showed a resistance 
phenotype similar to that of the resistant wild type TREU 927 line (A ). One of the transfected cell 
lines followed the pattern similar to the wild type sensitive line STIB 247 (■  ) which may have 
been due to insufficiency of selection. The x-axis represents the measure of fluorescence at 
OD5 9 0 , and the y-axIs represents the Increasing concentration of Cymelarsan.
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6.3.3 Cross-Resistance
As a result of the transfection experiments, two sets of clones were available. One set 
had one allele of 0RF4 deleted and were sensitive to Cymelarsan while the second set 
had the resistant allele of 0RF4 from TREU 927 in the STIB 247 sensitive stock and 
were Cymelarsan resistant. By testing the resistance/sensitivity phenotype of these 
clones to the arsenicals, Melarsoprol, Trimelarsan, Melarsen oxide and Phenylarsine 
Oxide and the diamidines, Berenil and Pentamidine, it was possible to determine 
whether ORF4 was also the determinant of resistance to these compounds. Drug 
assays revealed that the six clones that had ORF 4 replaced with the neo^ gene in 
TREU 927 four, that were sensitive to Cymelarsan, were also sensitive to all the other 
drugs tested except Pentamidine (Fig 6.10 A-F). Similarly, the five procyclic clones 
derived after ORF 4 in STIB 247 was replaced with alleles of ORF 4 from TREU 927, 
and were resistant to Cymelarsan also became resistant to all the drugs tested except 
Pentamidine (Fig 6.11).
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Fig 6.10 A - F :  AlamarBiue drug sensitivity assay with the four clones that had ORF 4 replaced 
with the neo"* gene in TREU 927. (A) Melarsoprol, (B) Trimelarsan, (C) Melarsan 
oxide, (D) Phenylarsine oxide, (E) Berenil, and (F) Pentamidine. STIB 247 ( ■  ), 
TREU 927 ).
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Fig 6.10 :A -  F represent Melarsoprol, Trimelarsan, Melarsan oxide, Phenylarsine oxide, Berenil, and 
Pentamidine, respectively. After replacement of ORF 4 with the neo gene in TREU 927, it was 
found that four clones derived after transfections and found to have changed phenotype from 
resistant to sensitive for Cymelarsan were also sensitive to Melarsoprol, Trimelarsan, Melarsan 
oxide, Phenylarsine oxide and Berenil. This suggested that the deletion of ORF 4 changed the 
phenotype of these four clones for these drugs as well as Cymelarsan, therefore the same cross 
resistance pattem observed in Chapter 4 tietween Cymelarsan and these five drugs was 
observed here. However, when these clones were assayed using Pentamidine, there was no 
change in phenotype, they remained resistant (F). Therefore, it is clear that the resistance 
conferred by Pentamidine must be due to another gene, which was thought to be the case after 
the results found in Chapter 4. STIB 247 ( ■  ), TREU 927 ( ♦  ), Sensitive F1 progeny ( #  ), 
Resistant F1 progeny (A  ). The x-axis represents the measure of fluorescence at OD5 9 0 , and the 
y-axis represents the increasing concentration of each drug.
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Fig 6.11 A -  F: AlamarBiue drug sensitivity assay with the four clones that had ORF 4 in STIB 247 
replaced with ORF 4 from TREU 927. Melarsoprol, (B) Trimelarsan, (C) 
Melarsan oxide, (D) Phenylarsine oxide, (E) Berenil, and (F) Pentamidine. STIB 247 
(■ ),T R E U  927 (^ ) .
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Fig 6.11: A -  F represent Melarsoprol, Trimelarsan, Melarsan oxide, Phenylarsine oxide, Berenil, and 
Pentamidine, respectively. After replacement of ORF 4 in STIB 247 with ORF 4 from TREU 927, 
it was found that four clones derived after transfections and found to have changed phenotype 
from sensitive to resistant for Cymelarsan were also resistant to Melarsoprol, Trimelarsan, 
Melarsan oxide, Phenylarsine oxide and Berenil. This suggested that the replacement of ORF 4 
changed the phenotype of these four clones for these drugs as well as Cymelarsan, therefore 
the same cross resistance pattem observed in Chapter 4 between Cymelarsan and these five 
drugs was observed here. However, when these clones were assayed using Pentamidine, there 
was no change in phenotype, they remained sensitive (F). Therefore, it is clear that the 
resistance conferred by Pentamidine must be due to another gene. STIB 247 ( ■  ), TREU 927 
(♦), Sensitive F1 progeny ( •  ), Resistant FI progeny (A ). The x-axis represents the measure of 
fluorescence at O D 590, and the y-axis represents the increasing concentration of each drug.
Taken together, these data demonstrate that allelic differences in the coding sequence 
of ORF 4 determine resistance to Cymelarsan, and cross-resistance to Melarsoprol, 
Melarsen oxide, Trimelarsan, Phenylarsine oxide and Berenil. The results obtained from 
AlamarBiue drug sensitivity assay for Pentamidine after allele deletion and replacement 
of 0RF4, however, did not follow this pattem (Fig 6.10 and 6.11 F). The results found in 
Chapter 4, where all the 38 FI progeny from the STIB 247 x TREU 927 cross were 
sensitive to Pentamidine, suggested that resistance to Pentamidine was conferred by a
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different gene to that determining Cymelarsan resistance. The results obtained from 
allelic deletion and replacement of ORF 4 and subsequent drug assays of the 
transfected cells with Pentamidine show that lack of segregation of Pentamidine 
resistance is not due to the dominance relationships at the same locus, but establish 
that another gene must be responsible.
0RF4 is formally named Tb927.2.2380 (http://www.genedb.org) but is also termed 
25N14.75 (El-Sayed et al., 2003). Translation of the 2.6 kb TREU 927 0RF4 DNA 
sequence predicted an 874 amino acid, 96 kDa protein with an isoelectric point (pi) 
value of 8.72, which is a ‘conserved hypothetical protein’ or ‘T. brucel family 
hypothetical protein’ (El-Sayed et a!., 2003). PIX (Protein Identifier X) analysis 
(www.hqmp.mrc.ac.uk). predicted that there were 4 transmembrane (Tm) domains 
within ORF 4. Of these four domains, however, only one was thought to be a true Tm 
domain as it gave a prediction score of excellent’. The preferred model of orientation of 
this domain, which was predicted by PIX, was from the inside to outside (Fig 6.12). This 
Tm domain is situated close to the N-terminus and starts at amino acid 12 and ends at 
amino acid 32. It may function to anchor the protein in a membrane; however, as this is 
a small Tm domain, spanning only 21 amino acids it is thought unlikely to be a 
transporter. Also, using PIX, it was found that there were no Pfam or prosite hits. Pfam 
is a large collection of multiple sequence alignments covering many common protein 
domains and families. Prosite determines if there are any post-translational 
modifications in common with other protein families. As analysES with these 
programmes were negative, it suggested that ORF 4, a hypothetical protein, has not
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been characterised in any other organism to date in the protein databases nor does it 
contain any common functional domains.
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Fig 6.12: Indicating four predicted transmembrane (Tm) domains for ORF4 using PIX analysis. Of
these four Tm domains only one was a true Tm domain with the quality of the prediction being 
‘excellent (1), whilst the others were either ‘good’ or ‘poor’ (2 - 4). The preferred model of 
orientetion of the Tm domain 1 is from inside to outside (red on graph) which starts at position 
12 and ends at position 32 of the 874 amino acid protein sequence. The position of this domain 
in 0RF4 protein sequence is shown in Fig 6.12.
Database blast searches, using the DNA sequence of ORF 4, were carried out to 
determine any sequence homology to the other chromosomes of T. brucei. This 
revealed that there was some homology to a contig on Chromosome IX, giving 100%
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homology over a 371 bp region. There was also some homology to a T. cruzi clone, 
giving sequence identity of 65% over 234 bp and to Leishmania major chromosome II 
where there was 66% sequence homology over 105 bp. Searches of sequence 
homology to Toxoplasma gondii, Plasmodium falciparum, P. vivax, P. chabaudi, Eimena 
tenella, Theileria annulata and the yeasts Schizosaccharomyces pombe, Candida 
albicans and Saccharomyces cerevisiae revealed no significant homology of any of 
these organisms with ORF 4 from T. brucei. Blast searches were also conducted 
against the human, rat and mouse genomes but again there was no sequence 
homology with ORF 4.
The forward and reverse genetics data show that 0RF4 is heterozygous in TREU 927 
for an allele that determines resistance to Cymelarsan. In order to further test this 
conclusion and screen for polymorphisms that might determine resistance, the entire 
2.6 kb region of ORF 4 for lines STIB 247 and TREU 927 was amplified by PCR and the 
products sequenced to detect any polymorphisims in ORF 4 between STIB 247 and 
TREU 927. Due to the fact that ORF 4 was 2.6 kb in length oligonucleotides were 
designed to produce PCR products spanning the length of ORF 4 (Table 6.3).
Molecular Biology Sequencing Unit (MBSU), Glasgow University, carried out the DNA 
sequencing of STIB 247 and TREU 927 and comparisons were made using the ABI 
Prism software (www. Technelysium.com.au). A single base difference was found when 
the two sequences were aligned, a change from a T in TREU 927 to a C in STIB 247 
that was homozygous in both stocks. It would be predicted that TREU 927 would be 
heterozygous for a base substitution leading to an amino acid change in order to
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account for the genetic analysis of Cymelarsan resistance. On examination, however, of 
the chromatograms derived from sequencing STIB 247 and TREU 927 ORF 4 revealed 
that the base change in TREU 927 was not heterozygous i.e. there was no overlapping 
of this peak with another peak representing a different base (Fig 6.13). This base 
change, therefore, could not be responsible for conferring the resistance phenotype.
TREU 927
STIB 247
Fig 6.13: Chromatograms showing peak profiles generated for of STIB 247 and TREU 927 As can
be observed the polymorphism detected from sequencing ORF 4 in TREU 927 was not 
heterozygous, it was quite clearly homozygous as there was no overlapping with another peak 
(base) (Fig 6.14 A -  0 ) and therefore, could not be used as an infonnative polymorphic marker 
to determine the Cymelarsan resistance phenotype fora population of cells.
By examining the chromatograms, by eye, it was found that there were seven positions 
in the sequence of TREU 927 where the base calling was ambiguous and TREU 927 
could be potentially heterozygous (Fig 6.14 A -  C). This was due to the fact that the
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peaks were overlapping and so discrimination between two bases was difficult. For 
example in Fig 6.14 A 1 -  3, there were three potential heterozygosities in TREU 927, 
where instead of being either (1) C or T, (2) A or I  and (3) G or T, these bases were 
called the bases found at these points in the STIB 247 sequence i.e. C, A and T, 
respectively. There are other points at which overlapping occurs in the figures below but 
these were not thought to be true heterozygosities as the overlap was not very 
pronounced e.g. in Fig 6.14 A2 (red arrow) the overlap where G could be T is not very 
pronounced and so I have not considered it as a possible polymorphism.
Fig 6.14 A -  C : Chromatograms showing peak profiles generated for STIB 247 and TREU 927.
A TREU 927 1 2 3
STIB 247 1
A
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STIB 247
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A) Interpretation of peaks for which TREU 927 could be heterozygous. Due to the fact that the peaks 
indicated (arrow) were overlapping at these points the base could not be defined and were represented 
by N. Chromatogram of the equivalent regions for STIB 247 where the peaks in 1, 2 and 3 are clearly 
distinguishable in comparison to the same peaks in 1, 2 and 3 of TREU 927. The remaining four possible 
regions where TREU 927 could be heterozygous due to overlapping bases are shown in (B) and (0 ) with 
the corresponding region in STIB 247 where no overlap was observed.
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These putative polymorphisms where TREU 927 was heterozygous (Fig 6.15) could, 
however, be attributed to; 1) poor sequencing; 2) the sequences were obtained by direct 
sequencing from a PCR product using Taq polymerase and as there was no proof 
reading activity, these could be ‘jackpot’ mutations. On this basis, the sequencing 
should be repeated using a mix of Taq and pfu (proof reading) polymerases (15:1) 
(Krawchuk and Wahls, 1999). Alternatively, the PCR product could be cloned and 
multiple clones sequenced to define the two alleles from stock TREU 927.
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CTACAATCCACTGCACACTTCTCCACAGTGGTACCATTTCCAAGGGCTTTTGGCATTCTT
TTGCACACAGCCGAAATCATCTTCTTGAGTGCATATCATTCTGCCACTGCGACTTGAGCG
caacccaacatgctgaagaaacgactcgcg / tagag / tcggcgggatccgagtccatatttctc
CACGTGTTTAAGCGCCGCTTCCCCGTCACTTCTCAACCCCCGCGCAGCGTTGGATTGGCC
aaatagcacaaagttcaagcgcaccaaaccccgca / ca / gtcgcgcatccctcactttagagga
CATGTTTGCGACTTTGTTATTACCGCTTGTTCCATTCCCGGCACCTTTTGCGTGGACGAC
AGCTGCAAAAGCAATGGGCTCAGTCGGGGCGTAAAAATCCCAGCCGTGCGTCCACAACCG
CCCCGCAAGTAAAACGGCCTCTTCATCTGGTGTCAGGAAACCCATGTACGGGTCCAGTGG
AACGTGATTCCCAGCATTGCCACTGCTACTATTATTGTGGCTATTTTGGTGGTCTGCTGC
GTCATGCGAGAAATCAAAGAAGGCACCTGCGCGAGTGAAAAGGAAATCTGTGCTTAACCA
CGGTTGCGAAAGTGACGAAGGAAAGCTTTCCTGTCGCCTGCTTCCAAGGCACACCGCATC
ATTCTTCTCATTACACCAATGGATGGGTAGAGGCTCCATATACCGCCGATCGCGCAGGAC
ATATGTGAGGCGGCGCCTGGACTCATATCTCAATTTGAATTTTGCTCCCTCTCCCCCCGA
CACAGTGGCGCTAACGTCCTCCCCATTTTCCACGTTGCCACAACCACTGCTGCCGCCGTC
GCTTTTCGCATCGCACACTTTCCGGCAACCTTCTTCGCTGTGCTGCATCTTTACTGCCAC
ACCACATACGTAGGAGGTGGTGTTTTGTTCACTCATACTTGTCAGCAGTTTCTTACGAAG
TGGTTCACGCAATTTCTTCATCCAATACAATTGGGCACTATTTGGCATCCGGGTTCTCAC
ATTTGGGATCGAGGCTCCGTTTCGCGGGTAGTTGAGAGGTTCTGCTCCAGAGGTTGCTTC
ACCGCCATCTTCCTCTGTGGGAAGTCGGAAAAGGAACTCCACAACATCTTCACTCCCGAA
TCCTCTGGCGCCTTCCGCAGCACTTTCGCCGTTTCCATCCCCCTTCTCTTTGTCCTCCAT
TCCATCGGAACTGTGTAAACGCAGTCCTTCAAGATCGTACAGAGCAGATCCACTCCTTTT
CTTTGAAGGATTTCTCTCGTGAGCTACGTTGAAGTAATCTTCCGTCCCTCCCCTTTCCTT
TCCACGTTGGTCATCACGGAATTGTTGATCCCCATGATCCTTAACCCCTTCATGTCTGTG
accttcattgcttacgtggcggaccacaacttc | tccca / ttgcgcgatgcaccacatc / ttcg
ctgtatgatg ttt / ggccatctgcgagagtataggccgtcgtgacgggagccttagtagcat
GAGCCGCGCTGTCACATCCCATGAGGGCACTAACAACACGCCTGCATTAAGAAACATCAC 
GTATGTTTCGCCGCGATACAGGGCGAGCGTTGCATACCGCTGGGAGGCAATGGAGGTAAA 
GTCACTGAGCCCTCCACTTGCATCACTCCCACTTGAAGCATCCCCATCCCTGTAACCAGC 
ATGCTCGTAGTCGTCCTCAGCTCTTCGACTGCGTGGATTTTCTTTTTTTTCACTCACCTT 
GACGTTACCTTCGCCTCCACCCATATTGCTTCCTTTGCTGTGCCTTCGTGACTTAGCCGA 
CACACGCAGTTGCCGCAGCCGTATGTTGTCCCGTGGACAGAATCCATACCGTTCGGCGCA 
CGTGTGAGACTGATAAGCAACAGGAATACATGGAGACGATGGTGGGAAAGGCCACCGGGA 
CGAGTTGTGACCTCCGCGCCCACCCGATTCCTCAGCCGTCATTACGTCGGGGAGGAACTC 
AACGATACCGGTGAAAATAGCAACTGACCAAAGTGCCGATTCATATAAGTTGTGAACTGT 
CATAGCACACACACTCTCTAGAGAAACAGACCTTCTCATACGAACCAGTGGCGTTTCATG 
GTGCAGAAGACCAACGAAGATACTACCCTCGAGCCCGTAGCCGCGGCGTGCGACATGAGT 
TGGACTCCAGTACGTGTCGGAATGTGTGACATTCTTTATGGAGCCATTGTCCAACCTCTT 
TTCTAACTCATTGTTGAACTTAGGAAGCTGCGTTTCATAGTATTCCAGCAAAATGGCCGC 
GGGCGTTGCATTCGGGGGCAAACCAAACATATCCGTGGCTCCTCCAGCTGCCGCTACTGA 
TGCAGGCATTCCATCAGTTTCCTGGTCCACGAATGCCGTCAATACTGACAGAAGTTTCGT 
GGTAAATGAAAAAACCGCTGGCGAGGCCCGCAAGTTTCCGACCCCTGGCAAACCACCCCG 
AACAGCATGGCTTCCTTCACCAATGTGGCCACCTCTCATTCTGTTTTTACGCTCGCGCGA 
CATAT TAT TCCATAACAAGAAGGTAACCATGACTAAGGCTGGGAGCACCATAT ACATCGG 
GACGGTTATGCAACGCCGGCCCCGACGCCGTGTTTCTGAGCGCAT
Fig 6.15: Sequence of ORF 4 3 - 5 (El-Sayed et al., 2003). The seven polymorphisms that are 
putatively heterozygous for TREU 927 are shown. The bases that are lightly shaded are those, 
which appear in the sequence of ORF 4. Represented in red, blue and black (bold) are the 
altemative bases if TREU 927 was heterozygous at these points. The base in TREU 927 that 
was found to different from STIB 247 but was homozygous for TREU 927 (Fig 6.13) is also 
shown (darkly shaded).
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The protein sequences of STIB 247 and TREU 927 were obtained using Jemboss 
Transeq software available through HGMP (www.hqmD.mrc.ac.uk) and aligned using 
Multalin (http://npsa-Dbil.ibcp.fr/cai-bin/alian multalin.pl). Firstly, the bases in the TREU 
927 sequence for the seven regions at which TREU 927 was putatively heterozygous 
were changed (Fig 6.15). For example in Fig 6.14 A1, in the sequence of ORF 4 (El- 
Sayed et a/., 2003) the position N was defined as C but could be a T, so this was 
changed to T and the same was undertaken for the other six polymorphisms in Fig 6.14 
A -  C. Comparisons revealed four codon differences (two base changes were next to 
each other and were covered by one amino acid change; Fig 6.15) after the seven base 
changes had been made, between the drug sensitive line STIB 247 and the drug 
resistant line TREU 927 at positions (amino acid numbering) 49 91 (two
bases in one codon), 472 and 478 (Fig 6.16). A summary of the results is 
shown in Table 6.4.
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927247Consensus Prim.cons
927247
C o n s e n s u s  
P r im .c o n s
927247
C o n s e n s u s  
P r im .c o n s
LGS
LGS
LGS
LGS
49
CVEGCHYXKWPSKANKQVCGFDDEQTCIMRGSRSSRLGVHQLFSESSRRSGLGYKEVHKLCVEGCHYXKWPSKANKQVCGFDDEQTCIMRGSRSSRLGVHQLFSERSliRSGLGYKEVHKLCVEGCHYXKWPSKANKQVCGFDDEQTCIMRGSRSSRLGVHQLFSErSRRSGLGYKEVHKLCVEGCHYXKWPSKANKQVCGFDDEQTCIMRGSRSSRLGVHQLFSE2SRRSGLGYKEVHKL
91AAEGDSRLGRAANSQGFLVFNLRVLGRRRADRVKSSMNAVKNNGSTGNGAGKAHWAAFAAAEGDSRLGRAANSQGFLVFNLRVLGRLRADRVKSSMNAVKNNGSTGNGAGKAHWAAFAAAEGDSRLGRAANSQGFLVFNLRVLGRrRADRVKSSMNAVKNNGSTGNGAGKAHWAAFAAAEGDSRLGRAANSQGFLVFNLRVLGR2RADRVKSSMNAVKNNGSTGNGAGKAHWAAFA
927 IPETPAYFDWGHTWLRGALLVAEEDPTLFGMYPDLPVHNGANGSSSNNHSNQHDAADHSF24 7 IPETPAYFDWGHTWLRGALLVAEEDPTLFGMYPDLPVHNGANGSSSNNHSNQHDAADHSFConsensus IPETPAYFDWGHTWLRGALLVAEEDPTLFGMYPDLPVHNGANGSSSNNHSNQHDAADHSF Prim.cons IPETPAYFDWGHTWLRGALLVAEEDPTLFGMYPDLPVHNGANGSSSNNHSNQHDAADHSF
927 DFFAGARTFLFDTSLWPQSLSSPFSEQRRSGLCVADNKENCWHIPLPEMYRRDRLVYTLR24 7 DFFAGARTFLFDTSLWPQSLSSPFSEQRRSGLCVADNKENCWHIPLPEMYRRDRLVYTLRConsensus DFFAGARTFLFDTSLWPQSLSSPFSEQRRSGLCVADNKENCWHIPLPEMYRRDRLVYTLR Prim.cons DFFAGARTFLFDTSLWPQSLSSPFSEQRRSGLCVADNKENCWHIPLPEMYRRDRLVYTLR
927 RRSEYRLKFKAGEGGSVTASVDEGNEVNGCGSSGGDSKADCVKRCGEESHQMKVAVGCVY24 7 RRSEYRLKFKAGEGGSVTASVDEGNEVNGCGSSGGDSKADCVKRCGEESHQMKVAVGCVY
C o n s e n s u s  RRSEYRLKFKAGEGGSVTASVDEGNEVNGCGSSGGDSKADCVKRCGEESHQMKVAVGCVY 
P r im . c o n s  RRSEYRLKFKAGEGGSVTASVDEGNEVNGCGSSGGDSKADCVKRCGEESHQMKVAVGCVY
927 STTNQESMSTLLKKRLPERLKKMWYLQASNPMRTRVNPISAGNRPYNLPEAGSTAEGGDE24 7 STTNQESMSTLLKKRLPERLKKMWYLQASNPMRTRVNPISAGNRPYNLPEAGSTAEGGDE
C o n s e n s u s  STTNQESMSTLLKKRLPERLKKMWYLQASNPMRTRVNPISAGNRPYNLPEAGSTAEGGDE 
P r im .c o n s  STTNQESMSTLLKKRLPERLKKMWYLQASNPMRTRVNPISAGNRPYNLPEAGSTAEGGDE
927247
C o n s e n s u s  
P r im .c o n s
927247
C o n s e n s u s  
P r im .c o n s
ETPLRFLFEWDESGFGRAGEAASEGNGDGKEKDEMGDSSHLRLGELDYLASGSRKKSPN
ETPLRFLFEWDESGFGRAGEAASEGNGDGKEKDEMGDSSHLRLGELDYLASGSRKKSPN
ETPLRFLFEWDESGFGRAGEAASEGNGDGKEKDEMGDSSHLRLGELDYLASGSRKKSPNETPLRFLFEWDESGFGRAGEAASEGNGDGKEKDEMGDSSHLRLGELDYLASGSRKKSPN
472 478
REHAVNFYDETGGREKGRQDDRFQQDGHDKVGEHRHGENSVHRVWEERARHWNRQIIN
REHAVNFYDETGGREKGRQDDRFQQDGHDKVGEHRHGENSVHRVWEEWARHWDRQIIN
REHAVNFYDETGGREKGRQDDRFQQDGHDKVGEHRHGENSVHRWVEErARHW#RQIINREHAVNFYDETGGREKGRQDDRFQQDGHDKVGEHRHGENSVHRWVEE2ARHW2RQIIN
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9 2 7  AMQSLIPRRSPLRLLMLRATVDWSPVLLVGANLFMVYTEGRYLALTAYRQSAISTFDSLG
24 7 AMQS LIPRRS PLRLLMLRATVDWS PVLLVGANLFMVYTE GRYLALTAYRQSA I STFDSLG
C o n s e n s u s  AMQS LIPRRS PLRLLMLRATVDWS PVLLVGANLFMVYTEGRYLALTAYRQSAIST FDS LG 
P r im .c o n s  AMQSLIPRRSPLRLLMLRATVDWSPVLLVGANLFMVYTEGRYLALTAYRQSAISTFDSLG
9 2 7  GSADSGSSADGDRYGAHEYDDEARRSRPNEKKESVKVNGEGGGMNSGKSHRRSKASVRLQ
24 7 GSADSGSSADGDRYGAHEYDDEARRSRPNEKKESVKVNGEGGGMNSGKSHRRSKASVRLQ
C o n s e n s u s  GSADS GS SADGDRY GAHEYDDEARRS R PNEKKE SVKVNGE GGGMNS GKS HRR SKASVRLQ 
P r im .c o n s  GSADSGSSADGDRYGAHEYDDEARRSRPNEKKESVKVNGEGGGMNSGKSHRRSKASVRLQ
9 2 7  RLRINDRPCFGYREACTHSQYAVPICPSSPPFPWRSSNHGGRGGSEEATMVDPLFEVIGT
24 7 RLRINDRPCFGYREACTHSQYAVPICPSSPPFPWRSSNHGGRGGSEEATMVDPLFEVIGT
C o n s e n s u s  RLRINDRPCFGYREACTHSQYAVPICPSSPPFPWRSSNHGGRGGSEEATMVDPLFEVIGT 
P r im . c o n s  RLRINDRPCFGYREACTHSQYAVPICPSSPPFPWRSSNHGGRGGSEEATMVDPLFEVIGT
92 7  FIAVSWLASEYLNHVTMACVSELSVSRRMRVLPTEHHLLGVFISGELGYGRRAVHTPSWY
24 7 FIAVSWLASEYLNHVTMACVSELSVSRRMRVLPTEHHLLGVFISGELGYGRRAVHTPSWY
C o n s e n s u s  FIAVSWLASEYLNHVTMACVSELSVSRRMRVLPTEHHLLGVFISGELGYGRRAVHTPSWY 
P r im .c o n s  FIAVSWLASEYLNHVTMACVSELSVSRRMRVLPTEHHLLGVFISGELGYGRRAVHTPSWY
9 2 7  TDSHTVNKISGNDLRKELENNFKPLQTEYYELLIAAPTANPPLGFMDTAGGAAAVSAPMG
24 7 TDSHTVNKISGNDLRKELENNFKPLQTEYYELLIAAPTANPPLGFMDTAGGAAAVSAPMG
C o n s e n s u s  TDSHTVNKISGNDLRKELENNFKPLQTEYYELLIAAPTANPPLGFMDTAGGAAAVSAPMG 
P r im . c o n s  TDSHTVNKISGNDLRKELENNFKPLQTEYYELLIAAPTANPPLGFMDTAGGAAAVSAPMG
9 2 7  DTEQDVFATLVSLLKTTFSFVAPSARLNGVGPLGGRVAHSGEGIHGGRMRNKRERSMNNW
24 7 DTEQDVFATLVSLLKTTFSFVAPSARLNGVGPLGGRVAHSGEGIHGGRMRNKRERSMNNW
C o n s e n s u s  DTEQDVFATLVSLLKTTFSFVAPSARLNGVGPLGGRVAHSGEGIHGGRMRNKRERSMNNW 
P r im .c o n s  DTEQDVFATLVSLLKTTFSFVAPSARLNGVGPLGGRVAHSGEGIHGGRMRNKRERSMNNW
9 2 7  LLFTVMVLAPLVMYMPVTICRRGRRRTESRM
24 7 LLFTVMVLAPLVMYMPVTICRRGRRRTESRM
C o n s e n s u s  LLFTVMVLAPLVMYMPVTICRRGRRRTESRM 
P r im .c o n s  LLFTVMVLAPLVMYMPVTICRRGRRRTESRM
Fig 6.16: Protein sequence alignment ( 3 - 5') of STIB 247 and TREU 927 for ORF 4. There were four
missense mutations t)etween the two lines at amino acid p o s i t io n s 49
and 478 (D -  Aspartic acid, N -  Asparagine, W -  Tryptophan, R -  Arginine, L -  Leucine, 
3 -  Serine) These mutations were located in the middle and end of the sequence away from 
the Tm domain. The Tm domain is highlighted in yellow. The position of the silent mutations are 
also indicated (shaded).
Ser Leu g . j  Arg Trp 472 Arg
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Nucleotide Sequence 
(3’ - 5 ’)
Region on ORF 4 where polymorphisms are located
Base pair position 150 154 175 and 176 1419 1437 1452
TREU 927 Allele 1 CGC6AG GAGCGG CGCAAT cccatg CATCTC TTTGCC
TREU 927 Allele2 cgctag GATCGG CGCcGT cccttg catttc ttggcc
STIB 247 CGCGAG GAGCGG CGCAAT CCCATG CATCTC TTTGCC
Amino Acid 
Sequence (3’ -  S’)
Codon Position 49 51 91 472 478 484
TREU 927 Allele 1 ESS SRR rrr ERA VNR NAM
TREU 927 Allele 2 ERS SRR RLR EWA VDR NAM
STIB 247 ERS SRR RLR EWA VDR NAM
Consensus sequence E rS SRR RrR ErA V#R NAM
Comments 1 2 3A 3B 3B 2
Table 6.4: A summary of the seven putative polymorphblms determined after sequence 
comparisons between TREU 927 and STIB 247 for ORF 4. Indicated are the nucleotide 
polymorphisms between the two lines and their position within ORF 4. Also indicated are the 
amino acid differences from the protein sequence of ORF 4 between the two lines. 1: Only 
one of the five polymorphisms had a restriction enzyme site at codon position 49 There
is a restriction enzyme site with the endonuclease Bfa I in TREU 927 and Hpyl88 III in STIB 
247. 2: There are two silent mutations at codon positions 51 and 484 3A: For the
polymorphisms at positions 175 and 176 bp one amino acid substitution covered both these 
polymorphisms at codon '■®“ 91 but there were no restriction enzyme sites. 3B: There were 
no restriction enzyme sites for the two polymophisms at codons ^ 472 and 478 
None of the amino acid substitutions caused a frame shift. A -  Alanine, D -  Aspartic acid, N -  
Asparagine, W -  Tryptophan, R -  Arginine, L -  Leucine, S -  Serine
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6.4 DISCUSSION
The analysis of the progeny of a genetic cross between a drug sensitive line (STIB 247) 
and a drug resistant line (TREU 927) provided a genetic approach to investigate the 
basis for resistance, which showed that a locus determining drug sensitivity was located 
to a 25 kb segment on T. brucei chromosome II, a segment that contained six ORFs 
(Chapter 5). The model of inheritance predicts that TREU 927 is heterozygous and 
resistance is dominant (Chapter 4). It follows, therefore, that if the resistance allele 
amongst the six ORFs was disrupted (knocked-out) TREU 927 would become sensitive 
to Cymelarsan. As there were a relatively small number of genes within this locus it was 
feasible to conduct a PCR-based allelic deletion strategy to determine if any of these 
genes had an effect on conferring the drug resistance phenotype. Database blast 
searches of these six ORFs revealed no sequence homology to genes in any organisms 
for which sequence was available.
Phenotypic analysis of cells derived after single allele deletion of each ORF in the 
resistant line TREU 927 revealed that there was a significant change in the phenotype 
of populations of cells that had ORF 4 replaced with the neo*^  gene, but this was not 
observed with any of the other five ORFs (Fig 6.5). Six clones from the ORF 4 
transfected cell line were generated and the presence of the neo*^  allele confirmed (Fig 
6.6). Four of these transfectants were sensitive to Cymelarsan. One of the clones, 
however, remained resistant. This could have been attributed to the neo*^  replacing the 
sensitive allele of TREU 927 ORF 4. The clone that gave an intermediate resistant 
phenotype could have arisen as a result of having more than one trypanosome in the 
well at cloning and as such there was a mix of cells containing the insert and cells that
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did not, thus conferring an intermediate phenotype. Those clones that did not have the 
neo insert remained resistant, at the same level as that observed for the naturally 
resistant line (Fig 6.7).
To further investigate this finding, a reverse 'knock-in’ strategy was employed, but 
selecting for resistant transfectants in a drug sensitive (STIB 247) population using 
Cymelarsan to select in vivo. After selection, procyclic forms of the transfected cells 
were grown and cloned. It was found, using the AlamarBiue screening assay, that four 
of the five clones obtained had changed phenotype from sensitive to resistant in the 
presence of Cymelarsan (Fig 6.9).
With the set of clones obtained from allele deletion and replacement analysis, it was 
possible to test if the same results were observed for the other six drugs previously 
used in this study. Drug assays showed that the four transfected clones containing the 
neo'^  gene in place of ORF 4 in the resistant line TREU 927 now had a sensitive 
phenotype to the drugs Melarsoprol, Trimelarsan, Melarsan oxide, Phenylarsine oxide 
and Berenil. For Pentamidine, however, the clones did not change phenotype, which 
suggested that ORF 4 was not responsible for conferring the Pentamidine resistance 
phenotype (Fig 6.10). The four clones obtained as a result of allele replacement of ORF 
4 in STIB 247 with ORF 4 from TREU 927 were all also tested with the same six drugs. 
It was found that for all the drugs except Pentamidine, which remained sensitive, the 
clones had changed phenotype from sensitive to resistant (Fig 6.11).
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As a result of these findings, proof was obtained that ORF 4 conferred the drug 
resistance phenotype. In order to identify the polymorphisms in this gene that could be 
responsible for the phenotype, sequencing of 0RF4 from STIB 247 and TREU 927 was 
carried out. PCR amplification and direct sequencing of ORF 4 initially identified one 
polymorphism between the two lines. On examination of the chromatogram for this 
polymorphism, however, it was found that TREU 927 was homozygous and therefore 
this polymorphism could not be responsible for the resistant phenotype (Fig 6.13). 
However, there were seven candidate polymorphisms found by examining the 
chromatograms derived from the sequencing of ORF 4 in STIB 247 and TREU 927 that 
were potentially heterozygous for TREU 927 (Fig 6.14).
Oligonucleotide primers could, therefore, be designed to regions in the sequence 
flanking these polymorphisms (Fig 6.15). It would then be possible to genotype the 
sensitive and resistant hybrid F1 progeny of the STIB 247 x TREU 927 cross using 
these primers and therefore determine which of the TREU 927 alleles was responsible 
for conferring resistance. The prediction is that the sensitive progeny would have 
inherited one allele from TREU 927 whilst the resistant progeny would have inherited 
the other allele. By simple PCR analysis, therefore, these oligonucleotides would be 
able to detect drug resistant parasites within a population of cells from an infected host. 
Due to time constraints this has not been achieved in this study.
There were four missense mutations in the amino acid sequence (Fig 6.16) found after 
substituting the bases in the ORF 4 sequence where TREU 927 could be heterozygous 
(Fig 6.15). One of these mutations had a restriction site, therefore PCR -  RFLP analysis
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could be carried out on the drug resistant and sensitive lines and any differences in 
banding patterns scored (For example see, Fig 5.2). At amino acid position 49 there 
was a restriction enzyme site for the endonuclease Bfa I in TREU 927 and Hpyl88 in in 
STIB 247. By using either of these restriction endonucleases and conducting PCR -  
RFLP amplification of TREU 927, STIB 247 and the hybrid progeny from the STIB 247 x 
TREU 927 cross, the presence or absence of a band would be observed between the 
Cymelarsan resistant and sensitive lines and could be scored if this mutation was 
involved in conferring the drug resistance phenotype.
The codon differences at positions 91, 472 and 478, did nor alter restriction sites in 
either STIB 247 or TREU 927. Therefore, oligonucleotide primers would have to be 
designed flanking these mutations and PCR amplification of the parental and hybrid 
progeny in order to determine if any of these were involved in conferring the drug 
resistance phenotype. The remaining two single nucleotide polymorphisms (SNPs), at 
codon positions 51 and 484, did not change the amino acid sequence and were 
therefore synonymous (silent) mutations. However, this does not imply that these 
synonymous mutations are non -  functional. A recent study has shown that some 
synonymous mutations in the human dopamine receptor D2 (DRD2) altered the 
predicted mRNA folding and led to a decrease in mRNA stability and translation. Most 
of the mRNA stability elements are generally located in the 5' and 3 ' UTRs of genes, 
however a synonymous mutation in the coding region of DRD2 affected mRNA stability 
(Duan et a/., 2003). In order to determine, therefore, if the three synonymous mutations 
in this study are functional, in vitro translation of ORF 4 mRNAs carrying these 
mutations would have to be investigated to ascertain if any have an effect on gene
2 0 1
Chapter 6 Determination o f  a putative resistance gene using aPC R  based allele deletion and replacement system
expression by comparing the amount of protein synthesis between the wild type and 
mutant cells (Duan et a/., 2003).
The PCR -  RFLP technique has been used in T. gondii gene GRA1, to distinguish 
different strains of T. gondii based on the presence of an A versus a G at a single 
position which changes a Ma HI site to a Mae lU site and so it was possible to type the 
allele at this locus based on this single nucleotide substitution (Sibley et a!., 2002). This 
may be a useful technique to use in future studies to distinguish between alleles of 
sensitive and resistant strains, both laboratory derived lines and more importantly as a 
rapid diagnostic tool for determining resistance in field isolates. Unfortunately, time did 
not allow for analysis of these candidate polymorphic markers for Cymelarsan 
resistance.
These data suggest that ORF 4 has a significant role in conferring drug resistance in T. 
brucei. However, this does not rule out the possibility that there are other mechanisms 
potentially involved in conferring drug resistance, for example transporters and drug 
efflux mechanisms. However, the P2 transporter is unlikely to be involved in conferring 
the Cymelarsan drug resistance in TREU 927 for two reasons which have been 
identified in this study: (1) ORF 4 is located on chromosome II but the P2 transporter is 
on chromosome XI and there is no sequence homology between the two and (2) the 
results show that there was cross resistance between Cymelarsan and Phenylarsine 
oxide and it has been reported that Phenylarsine oxide does not enter the cell through 
the P2 transporter (Carter and Falrlamb, 1993). The roles of different potential 
mechanisms of drug resistance identified in laboratory studies need to be validated by
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analysing field isolates of defined resistant phenotypes. The study reported here 
analyses a ‘natural’ resistant phenotype that was not generated by laboratory selection.
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CHAPTER 7 
DISCUSSION
The aim of this project was to identify the gene/genes involved in conferring resistance 
to the arsenical group of drugs in T. brucei using a classical genetic approach (starting 
with the phenotype and finishing with the identification of the gene). Genetic crosses 
were conducted between the three stocks STIB 247, STIB 386 and TREU 927, which 
were field isolates from Tanzania, The Ivory Coast and Kenya, respectively, and 
showed naturally occurring variation in their susceptibility to Cymelarsan.
Prior to the start of the project crosses had been made between the three stocks in all 
pair-wise combinations and a total of 37 progeny clones isolated that, by marker 
analysis, corresponded to the F1 progeny produced by mating between each pair of 
parental stocks. In order to undertake the genetic analysis of phenotype using these 
crosses, it was necessary to increase the number of independent F1 progeny isolated 
from these crosses in order to statistically test different models of inheritance and 
undertake linkage analysis. A further 42 independent progeny clones were isolated.
The analysis involved four phases aimed at identifying the drug resistance determinant. 
Firstly, the determination of the inheritance of the resistant phenotype leading to a 
genetic model of inheritance, secondly, linkage analysis for each chromosome, thirdly, 
fine scale mapping of a candidate locus and finally screening of the candidate genes 
using a PCR-based allele knock-out and knock-in strategy. Discussion of the results 
obtained in these four phases has been provided at the end of each of the results
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chapters. Therefore, here the main conclusions from this study are discussed, the 
implications in relation to future work considered and the relevance of the results to drug 
resistance in the field.
From the segregation of the resistant phenotype in the F1 progeny, it was postulated 
that resistance is determined by two alleles at a single locus where resistance is 
heterozygous and dominant (Chapter 4). With complete genetic maps available for all 
eleven T. brucei chromosomes (MacLeod et al, in preparation), linkage analysis and 
fine scale mapping were undertaken to localise the resistance determinant to a 25 kb 
region on chromosome II containing six ORFs (Chapter 5). The final part of this study 
was to use a reverse genetic approach to determine if any of the six ORFs were 
involved in conferring the drug resistance trait. This was achieved by using a PCR 
based allele deletion approach in the resistant parental stock. If any of the ORFs 
contained an allele that determined resistance then a change in phenotype would be 
observed when this allele was replaced with the neomycin selectable cassette. Only 
allele knock-out of ORF 4 in TREU 927 gave a change in phenotype in the transfected 
cell lines, and this was confirmed by allele knock-in experiments, transferring the 
resistance allele from the resistant TREU 927 stock into the STIB 247 sensitive stock. 
The clones derived from these transfected cell lines were then tested for cross­
resistance to the arsenicals, MelB, MelOx and MelW, and the diamidine Berenil and the 
same results were observed as those determined for MelCy i.e. allele knock-out clones 
were sensitive and allele knock-in clones were resistant (Chapter 6). Therefore, the
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locus identified (ORF 4) has been named, ard (arsenical and diamidine) resistance 
gene.
The ard gene encodes a hypothetical protein that has a putative signal 
peptide/transmembrane domain near the N-terminus, however, further investigation is 
required to determine the actual function of this domain. Signal peptides and 
transmembrane domains both contain a stretch of hydrophobic amino acids and this 
common feature makes it difficult for bio-informatic analysis to distinguish between the 
two possible functions of such regions. Therefore, the inability to reliably distinguish 
between N-terminal transmembrane domains and signal peptides limits the prediction 
of secretory protein status or transmembrane topology. In light of this problem a 
computational method for discriminating between the two has been established which 
has been used for bacterial analysis and given very promising results (Yuan et al., 
2003). This computational differentiation of N-temninus signal peptides and 
transmembrane domains is one way that may be used in the future to determine which 
is present in the ARD protein.
The finding that the ard gene plays a role in conferring resistance leads to a range of 
future experiments. These would lead to the determination of the features of the gene 
and its products as well as analysing its role in arsenical resistance in the field. There 
are numerous experiments that could be undertaken to improve our understanding of 
the mechanism by which ard confers resistance. These are discussed below.
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The ‘knock-out’ and knock-in’ clones, transfecting 0RF4 have been screened for 
phenotype and compared with TREU 927 and STIB 247 using the AlamarBlue 
screening assay. A comparative study could be undertaken to determine if the same 
effect on resistance occurs in vivo. In order to do this bloodstream form trypanosomes 
would need to be transfected so that either the resistant allele in TREU 927 was 
knocked out or the sensitive allele in STIB 247 was replaced with the resistant allele of 
TREU 927. After electroporation the cells would be allowed to recover for 1hr in 
Cunninghams medium at 37°C and then used to inoculate mice. The knock-out lines 
would require to be selected in vivo with Geneticin. Then, drug resistance analysis of 
the transfected cells in vivo using a single dose of MelCy for each mouse over a range 
of concentrations (described in Chapter 4) could then be determined. The analysis 
would lead to the determination of phenotype of the transfectants and if the results were 
the same as those found in vitro, this would show that the ard gene determines 
arsenical resistance in vivo.
An important question is whether the ard gene is essential? To answer this, gene 
knock-out of both alleles of ard needs to be carried out. This would be carried out 
initially on procyclic forms of the resistant TREU 927 stock. In order to knock-out both 
alleles of ard, sequential replacement of the ard encoding region with selectable 
markers would be required. The two selectable drug resistance markers, for example 
hygromycin and phleomycin, surrounded by ard flanking sequence would then be used 
for transfections into TREU 927 procyclic forms. Following transfections and selection 
for drug resistance, verification by PCR analysis and a northern blot if ard had been
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deleted would be required. If ard is shown to be an essential gene then it would be 
expected that the transfected cells would be unable to proliferate and thus would 
eventually die. It may be necessary to introduce an episomal copy of ard before 
disrupting the second allele. The transformed cells could be cyclically transmitted 
through tsetse flies that would then be allowed to feed on mice thereby obtaining 
bloodstream forms. These bloodstream forms could then be tested in vivo for their 
resistance phenotype.
Definitive proof for the association between the resistance phenotype to the ard gene 
could be achieved by episomal transformation. By using an episomal vector 
transformation this would be independent of the parasite’s genome. Therefore, if the 
resistance phenotype was detected then the activity would be directly attributed to the 
transformed DNA. Extrachromosomal replication of DNA has been observed in 
Trypanosoma cruzi and Leishmania spp. and cosmid vectors have been successfully 
used in these organisms, but these vectors were unable to replicate in T. brucei. A 
number of different episomes have been described, which replicate autonomously after 
introduction into T. brucei procyclic cells by electroporation. One of these, trypanosome 
artifical chromosome (TAG) are stably maintained in the absence of drug pressure, but 
over time the addition of telomeric repeats increase the size of the TACs and so making 
the recovery and analysis of any cloning products difficult (Sommer et a!., 1996). 
However, it has been shown that DNA isolated from T brucei mitochondrial minicircles 
allows plasmid DNA to replicate autonomously in the nucleus of T. brucei (Metzenberg 
and Agabian, 1994). Therefore, this DNA fragment can be transferred into a Bluescript-
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derived T. brucei expression vector, which is the basis for an efficient transfections 
vector for stable, episomal expression of genes in procyclic cells (Sommer ef a/., 1996). 
Confirmation of this would require isolating the episome, therefore the cells would be 
re-transformed to the parental strain. Thus loss of the episomes should result in 
complete reversion to the sensitive phenotype of the untransformed line. The 
transcription levels of episomal ard expression and the chromosomal ard gene should 
also be compared using RT-PCR.
In an alternative approach to determine if ard was responsible for drug resistance, 
procyclic forms of STIB 247 could be transfected with the resistant allele of ard from 
TREU 927 expressing the Tet repressor therefore, expression of resistance would be 
mediated by a tetracycline inducible promoter. The construct used to generate the cell 
lines should also contain a selectable marker for resistance to, for example, 
hygromycin, thus allowing for selection of transformants. After transfections into 
trypanosomes, hygromycin-resistant transformants could be selected in the absence of 
tetracycline. Therefore the inducible promoter would be switched off and it would be 
expected that the cells would remain sensitive. However, by switching the gene on with 
the addition of tetracycline to the culture medium it would be expected that the cells 
would express a resistant phenotype, determined using the AlamarBlue assay.
It would be useful to determine if a transmembrane domain exists as this has 
implications as to the mode of action and target of the drug within the cell. The action of 
any anti-parasitic drug is dependent on the efficiency by which it is taken up by the
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parasite. We already know that the P2 transporter is involved in arsenical and diamidine 
uptake but this study has shown that there is another route involved in drug uptake as 
procyclic forms do not have detectable P2 activity (de Koning, 2001B) yet they are 
susceptible to the drug. Drug uptake can occur by four main routes, passive diffusion, 
endocytosis, receptor-mediated uptake or transporter-mediated uptake (de Koning, 
2001B) and it is possible that the ard gene product is involved in drug uptake. 
Alternatively, the ard gene product could be a specific target or involved in the activation 
of the drug. It is important therefore, to determine whether the ard gene is involved in 
the uptake of arsenicals and diamidines in order to define its function.
An epitope tag system could also be used to determine which region of the protein 
contains the sequence necessary for localisation within the cell. This technique has 
already been used to tag T. brucei genes. Epitope tagging of proteins has become a 
method of choice for the analysis of function, interaction and subcellular localisation of 
proteins (Shen et a/., 2001). A full length copy of the ard gene in TREU 927 procyclic 
forms could be epitope tagged by introducing the Tyl virus like particle from the well 
characterised major structural protein of Saccharomyces cerevisiae (Bastin et a/., 
1996). There are two reasons for using this tag, firstly it is recognised by two different 
monoclonal antibodies (BB2 and TYG5) with overlapping binding sites and secondly, 
Tyl is a linear eiptope with a known amino acid sequence and it is recognised in 
different mutant forms of the protein and therefore it can be recognised in different 
environments (Bastin et a/., 1996).
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In order to determine where ard localises within the cell, the Ty1 epitope would need to 
be introduced within the ard gene followed by cloning the tagged gene into an inducible 
expression vector Transformation of the construct into TREU 927 procyclic forms 
expressing the tetracycline repressor would then be required so that expression of the 
tagged ard gene was dependent on the presence of tetracycline. After cloning the 
resulting transformants, by limiting dilution, the tagged cell lines could then be tested for 
localization within the cell. Cells with the epitope tagged protein, grown in the absence 
of tetracycline should not be detected by immunofluorescence with the antitag antibody 
BB2. However, cells that have been grown in the presence of tetracycline for a week 
then the ARD fusion protein should be detectable by immunofluorescence and should 
show where the ARD protein has localised within the cell.
A follow on investigation from this would be to truncate the ard gene at several points 
and epitope tag each truncated version for cloning and transfection into wild-type drug 
sensitive trypanosomes. Therefore, the truncated proteins would be expressed in the 
presence of the wild-type endogenous ARD. Immunofluorescence of each truncated 
protein would determine which region of ard is necessary for localisation within the cell. 
An example, where this has been successfully achieved is the finding that the region 
between amino acids 514-570 of the paraflagellar rod, PFRA, contained sequence 
necessary but not sufficient for flagellar localisation. This part of the PFRA sequence 
could therefore act as a target signal or be part of a system involving different regions of 
the protein (Bastin et al., 1999). Using these approaches would therefore further 
elucidate on the function of the ard gene.
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An alternative approach would be to raise an antibody to the expressed protein, 
followed by immunolocalisation of the ARD protein. It should also be considered that 
ARD may be associated in a complex with other proteins. As a result, antisera to the ard 
gene product could be produced and immunoprécipitation of the protein extract could be 
used to detect if the ARD protein forms a complex with other proteins in the cell extract. 
If ARD is associated with a complex of proteins, then these could be identified by mass 
spectrometry. As a result this might give important clues as to the function of the gene.
A further approach to the determination of the intracellular target of Cymelarsan might 
be to assay whether the ARD protein binds to the drug. In order to determine this the 
ard gene would need to be expressed as a recombinant protein followed by affinity 
chromatography using cymelarsan immobilized on Sepharose beads (Denise et al., 
1999). A known amount of the ARD recombinant protein could then be run through the 
column and the eluate collected. A measure of the amount of protein washing through 
the column would then be determined and if this was less than the amount originally put 
on then this would be evidence that the protein (from the ard gene product) binds 
Cymelarsan. Thus, these investigations listed above would lead to the determination of 
where the ARD protein localises within the cell and if it binds Cymelarsan, which could 
eventually lead to its determination as a possible drug target.
Determinating which of the four point mutations in ard confers the resistance phenotype 
is required. However, before doing this, these four point mutations need to be 
confirmed, firstly by PCR followed by cloning of both alleles of TREU 927 and finally 
sequencing of the cloned products. After confirmation that the four point mutations are
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true then using the PCR allele knock-in approach will provide a direct means of 
evaluating the role of each point mutation. By transfecting each point mutation from 
TREU 927 into STIB 247, followed by phenotypic analysis of the resulting transfectants 
will determine which point mutation is involved in conferring the drug resistance 
phenotype.
One important question that could be addressed is; what is the relevance of these 
mutations in terms of resistance in the field? In order to achieve this, analysis of the 
levels of MelCy drug resistance in field isolates is required using the AlamarBlue 
screening assay on procyclic forms. Cross resistance patterns could then be 
determined for other arsenicals namely MelB, MelW and MelOx, and also to the 
diamidines Berenil and Pentamidine. Analysis of bloodstream forms should be 
undertaken, using either or both the AlamarBlue assay and the growth inhibition assay 
for all drugs listed above, both in vitro and in vivo using MelCy. A comparison could then 
be made between the resistance patterns from field isolates and the isolates derived 
from this study.
The next step would then be to determine if the point mutations in the ard gene, thought 
to be involved in conferring drug resistance, are present in the field isolates. In order to 
determine this, amplification of the ard gene in the field isolates would be required, 
followed by cloning of both alleles and sequence analysis of the cloned products. As a 
result, the sequence comparisons between the field isolates and the isolates from this 
study would indicate, firstly if there was an association between the mutations found
213
Chapter 7 Discussion
from this study and those found in the field isolates and secondly, if all four mutations 
are present in the field isolates or just some of the mutations. The results would also go 
to prove or disprove the results from the previous investigation as to which of the point 
mutations is involved in conferring resistance in the isolates derived in this study. As a 
result, therefore, a direct comparison could be made between the resistance levels 
found in this study compared to those found from field isolates.
In order to determine if there is any relevance between the level of resistance found in 
this study compared to field isolates I would have needed to analyse field isolates, 
which was beyond the scope of this study. The question, however, would be whether 
the difference in the levels of resistance measures between STIB 247 and 
STIB386/TREU 927 would lead to treatment failure in the field. There are few reliable 
measurements of Melarsoprol levels in the bloodstream or brain of treated humans and 
it is also difficult to correlate the doses administered to humans with those in mice given 
the possible differences in the pharmacokinetics of the drug between man and a murine 
model.
In this context however it is interesting to note a study where 19 individuals with late 
stage T. b. gambiense were treated with melarsoprol to determine if a shorter treatment 
regime was viable. It was found that treatment with ten consecutive doses of 2.6 mg/kg 
melarsoprol was sufficient to eliminate trypanosomes from the bloodstream (Burri et al., 
1993). These doses are similar to those that I have used in mice where 2 - 5  mg/kg 
MelCy was required to clear infection with STIB 386 and TREU 927.
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The cross-resistance observed between the arsenicals and the diamidine Berenil 
suggested that resistance is mediated by the ard gene point mutations and provided 
direct evidence for the important role for this gene in determining susceptibility to these 
drugs. A parallel situation has been found in terms of the ability of mutations in the 
Plasmodium pfcrt gene to confer cross resistance to drugs other than chloroquine 
namely, amodiaquine, quinine, mefloquine and artemisinin, which is also mediated by 
pfcrt point mutations. These finding indicated the need for monitoring resistance, 
including screening for possible additional changes in pfcrt sequence with the increased 
use of antimalaria Is (Sidhu et ai, 2002). Similar screening should be considered for 
trypanocides.
The identification of the P2 adenosine transporter (Carter and Fairlamb, 1993) as a key 
protein in the uptake of the arsenicals and diamidines has led to suggestions that this 
selective uptake pathway could be used to design new drugs that are selectively 
imported into the trypanosome. To date no new drugs of this nature are being 
developed. However, there are ongoing investigations on several novel trypanocides. 
GB-ll-5 and GB-ll-150 have been shown to inhibit the assembly of tubulin, so that cells 
cannot divide, at least in vitro. The I C 5 0  values for these are 0.4pM for GB-ll-5 and 0.05 
pM for GB-ll-150 using bloodstream forms in vitro. No studies have been carried out in 
vivo with GB-115 and GB-ll-150, but these are a new class of tubulin targeted 
antikinetoplastid drugs (Werbovetz et ai, 2003 ASTMH meeting).
215
Chapter 7 Discussion
Another very promising orally available novel compound, DB289, the prodrug of DB75, 
is in phase HA clinical trials. DB289 may be an alternative to Pentamidine as the drug of 
choice for the treatment of early stage T. b. gambiense. This clinical trial is looking very 
promising as only one relapse out of the 21 patients treated has been observed after a 
six month post-treatment evaluation. The treatment regime is 100 mg of DB289 orally 
twice daily for five days. There have been minor side effects reported, headaches and 
intermittent fevers. Despite this, DB289 is a very promising treatment for early stage T. 
b. gambiense (Burri et ai., 2003 ASTMH meeting). One other group of compounds the 
bisphosphonates, have been proposed to possibly target the trypanosomal 
acidocalcisome and show considerable promise. These drugs are already in use for the 
treatment of bone disorders such as osteoporosis, and are well tolerated and achieve 
parasitological cure in rodents (Barrett et a!., 2003), It is clear that there is a major effort 
by the scientific community to firstly understand the pathways involved in drug 
resistance that can lead to the development of novel drugs, and secondly suggests that 
in the near future new drugs may be available for treatment of sleeping sickness.
A good example of the proposed approach for the progression of this study is that of 
the findings of the relevance of the pfcrt genes involvement in resistance in P. 
falciparum. In P. falcipamm mutations in the pfcrt gene, found to confer chloroquine 
resistance, were present in isolates obtained from Asia, Africa and South America. 
Sequence analysis revealed consistent association between pfcrt mutations in 
chloroquine resistant isolates from Asia and Africa for seven of the eight mutations. 
Sequences of pfcrt from South America were also examined and found to contain two of
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the mutations found in the Asian and African isolates, namely K76T and A220S (Fidock 
et ai, 2000). The significance of K76T and A220S in chloroquine resistance has been 
reinforced in a recent clinical trial in West Africa, where these two mutations were found 
in 100% of persisting infections (Djimde et al., 2001). Obviously the identification of the 
pfcrt gene and its role in chloroquine resistance in field isolates and also the fact that it 
has been shown to localise in the digestive vacuole makes it a very worthy candidate for 
drug targeting. Therefore, the sooner field isolates can be screened for the ard 
mutations and localisation investigations carried out the sooner drug targets can be 
determined.
An example of how the determination of the mechanism of resistance has led to the 
identification of a novel drug target is provided by the identification of the involvement of 
the pfcrt gene in chloroquine resistance. Antimalarials are believed to act, in part, by 
complexing with the haem products and it is thought that PfCRT mutations affect 
accumulation by altering drug flux across the digestive vacuole membrane and may 
affect drug haematin binding. The discovery of a possible role of haem binding offers 
alternative strategies for targeting the haemoglobin detoxification pathway for malaria 
treatment (Sidhu et al., 2002).
The results presented in this thesis have led to the identification of a novel gene that 
determines resistance to both the arsenicals and the diamidine Berenil as well as 
establishing the proof of principle that genetic analysis coupled with positional cloning
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can be used in T. brucei to identify genes of importance for the treatment of human 
sleeping sickness.
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Appendix A1
DNA extraction buffer
10 ml of 1M Tris pH 8
2 ml 0.5M EDTA 
4 ml 6M NaCI
Made up to 200 ml with sterile water.
5x TBE electrophoresis buffer
2M Tris
2M Boric acid 
20mM EDTA
Made up to 5 litres in distilled water to pH 8 - 8.3
1 M Tris pH8
Tris 121 g dissolved in 800 ml sterile water and pH adjusted to 8 by adding 42 ml 
concentrated Hydrochloric acid (HCL) and made up to 1 L with sterile water.
1M Phosphate buffered saline (PBS)
lOmM NazHPOa
2mM KHz PO4  
0.136M NaCI 
pH 8
Phosphate buffered saline with glucose (PBSG)
As above with glucose added to make a final concentration of 10mM
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Lysis buffer
50 mM Tris pH 8
100 mM EDTA pH 8 
0.5% SDS
Zimmerman Post Transfusion Buffer
132 mM NaCI 
8 mM KCL 
8 mM Na2HP04 
1.5 mM KH2 PO4 
0.5 mM Mg acetate 
90 pM CaCl
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Table A I A
SDM -  79 (BRUN MEDIUM)
Components______________________ Quantity per litre
Glucose 1 g
Hepes 8 g
MoPS 5g
NaHCOs 2 g
Na pyruvate 100 mg
L-Alanine 200 mg
L - Arginine 100 mg
L -  Glutamine 300 mg
L -  Methionine 70 mg
L -  Phenylalanine 80 mg
L -  Proline 600 mg
L -  Serine 60 mg
L -  Taurine 160 mg
L -  Threonine 350 mg
L -  Tyrosine 100 mg
Adenosine 10 mg
Guanosine 10 mg
Glucosamine -  HCL 50 mg
Folic acid 4 mg
p -  Amino benzoic acid 2 mg
Biotin 0.2 mg
MEM amino acids non-essential (50x) 8 ml
MEM amino acids (100x) 6 ml
MEM* 7g
Medium 199** 2 g
Table A1.A: Composition of SDM-79. * MEM should be with Earles salts, without L- glutamine and 
NaHOH available from Gibco cat no. 072-01700. ** Medium 199 should be with L- 
glutamine and without NaHCOs available from Gibco cat no. 071 -  1 lOO.The pH was 
adjusted to 7.3 and the medium filter sterilized. Before use the medium was supplemented 
with 10% Foetal calf serum and 2% gentamicin.
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Table A1.B
CUNNINGHAMS MEDIUM
Components Quantity per 100 ml
Inorganic Salts
NaH2P04 53 mg
MgCWHzO 304 mg
MgSo4 7HzO 370 mg
KCL (anhydrous) 298 mg
CaClzZHzO 15 mg
Sugars
Glucose 70 mg
Fructose 40 mg
Sucrose 40 mg
Organic Acids
L -  Malic 67 mg
a -  Ketoglutaric 37 mg
Fumaric 5.5 mg
Succinic 6 mg
Amino Acids
3 “  Alanine 200 mg
DL -  Alanine 109 mg
L-Arginine 44 mg
L -  Asparagine 24 mg
L -  Aspartic acid 11 mg
L -  Cysteine HCL 8 mg
L -  Cysteine 3 mg
L -  Glutamic acid 25 mg
L -  Glutamine 164 mg
Glycine 12 mg
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Table A1.B Cont
CUNNINGHAMS MEDIUM (cont)
Components Quantity per 100ml
L -  Histidine 16mg
DL -  isoleucine 9mg
L -  Leucine 9mg
L -  Lysine 15mg
DL -  Methionine 20mg
L -  Phenylalanine 20mg
L -  Pro line 690mg
DL -  Serine 20mg
L-Taurine 27mg
DL-Threonine 10mg
L-Tryptophan lOmg
L -  Tyrosine 20mg
DL -  Valine 21 mg
Vitamin Mixture BME (lOOx) 0.2ml
Indicator Phenol Red (0.5%) 0.4ml
Table A1.B: Components of Cunningham Medium. The compounds were dissolved in double distilled 
water as follows: Inorganic salts in 10 ml except CaCiz, which was in 5 ml. Sugars in 10 ml, 
Organic acids in 5 ml and Amino acids in 65 mi. The Vitamin mixture BME (lOOx) and 
Indicator phenol red was added and made up to 100 ml at pH 7.4. The mixture was filter 
sterilized and stored at -20®C. Foetal calf serum and 2% gen tarn ycin was added at a 
concentration of 30% before use.
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Table A2.A (n vitro cloning of STIB 247 x TREU 927
Markers
Identification CRAM 292 MS42 JS2 PLC Comments
Parental 247 1 -1 5 -5 5 -5 5 -6 5 -5
Parental 927 
Procyclic Cloning 
Cross 247 x 927
Batch 1
3 -4 3 -4 3 -4 3 -4 3 -4
F532/72 pci 1 -118  
Batch 2
1 - 3 - 4 3 - 4 - 5 3 - 4 - 5 3 - 4 - 5 - 6 3 - 4 - 5 Mixed/Trisomic/
Triploid
F532/72 pci 1 - 52 
Batch 3
1 -3 4 - 5 4 - 5 3 -5 4 - 5 1 New Genotype
F532/72 pci 1 - 76 
Batch 4
1 -3 3 - 5 3 - 5 4 - 5 4 - 5 All same 
genotype as 
F532/72 mcl 6
F532/72 pci 1 1 -4 4 - 5 3 - 5 3 - 5 3 - 5 Same as 
F532/72 mcl 1
F532/72 pci 2 1 -4 3 - 5 3 - 5 3 - 5 3 - 5 Replaced with 
F532/72 bsci 1
F532/72 pci 3 1 -4 4 - 5 4 - 5 4 - 6 3 - 5 Same as 
F532/72 mcl 7
F532/72 pci 4 1 -4 3 - 5 3 - 5 3 -5 3 - 5 Replaced with 
F532/72 bsc11
F532/72 pci 5 1 -3 4 - 5 3 - 5 4 - 5 3 - 5 New Genotype
F532/72 pci 6 1 -3 4 - 5 3 - 4 - 5 3 - 6 3 - 4 - 5 Mixed/Trisomic
F532/72 pci 7 1 -4 3 - 5 3 - 5 4 - 6 3 - 5 New Genotype
F532/72 pci 8 1 -3 4 - 5 3 - 5 4 - 6 F New Genotype
F532/72 pci 9 1 -4 3 - 4 - 5 4 - 5 3 - 5 - 6 3 - 5 Mixed/T risomic
F532/72 pci 10 1 -3 3 - 5 3 - 5 4 - 5 4 - 5 Same as 
F532/72 mcl 6
F532/72 pci 11 1 -3 3 - 5 3 - 4 - 5 4 - 6 3 - 5 Mi)©d/Trisomlc
F532/72 pci 12 1 -4 3 - 5 3 - 5 4 - 5 4 - 5 Replaced with 
F532/72 bscI 2
F532/72 pci 13 1 -4 3 - 5 3 - 5 3 -5 3 - 5 Replaced with 
F532/72 bsci 1
F532/72 pci 14 1 -4 3 - 5 3 -5 4 - 5 4 - 5 Replaced with 
F532/72 bsci 2
F532/72pcl 15 1 -4 3 - 5 3 - 5 3 - 5 3 - 5 Replaced with 
F532/72 bsci 1
F532/72 pci 16 1 -4 4 - 5 3 -5 4 - 5 4 - 5 Same as 
F532/72 mcl 2
F532/72 pci 17 1 -4 3 - 5 3 - 5 4 - 5 4 - 5 Replaced with 
F532/72 bsci 2
F532/72 pci 18 1 -4 3 - 5 3 - 5 3 - 5 3 - 5 Replaced with 
F532/72 bsci 1
F532/72 pci 19 1 -4 3 - 5 4 - 5 4 - 5 3 - 5 Same as 
F532/72 mcl 8
F532/72 pci 20 1 -4 3 - 5 3 - 5 3 - 5 3 - 5 Replaced with 
F532/72 bsci 1
F532/72 pci 21 1 -4 4 - 5 4 - 5 4 - 5 3 - 5 Same as 
F532/72 mcl 3
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Table A2.A Cont in vitro cloning of STIB 247 x TREU 927
Markers
Identification CRAM 292 MS42 JS2 PLC Comments
Parental 247 1 -1 5 - 5 5 - 5 5 - 6 5 - 5
Parental 927 
Procyclic Cloning 
Cross 247 x 927
3 - 4 3 - 4 3 - 4 3 - 4 3 - 4
Batch 4 Cont
F532/72 pci 22 1 -4 3 - 5 3 - 5 3 - 5 3 - 5 Replaced with 
F532/72 bsci 1
F532/72 pci 23 1 -4 3 - 5 3 - 5 4 - 5 4 - 5 Replaced with 
F532/72 bsci 2
F532/72 pci 24 1 -3 3 - 5 3 - 5 4 - 5 4 - 5 Same as 
F532/72 mcl 6
F532/72 pci 25 1 -4 3 - 5 3 - 5 3 - 5 3 - 5 Replaced with 
F532/72 bsci 1
F532/72 pci 26 1 -3 3 - 5 3 - 4 - 5 3 - 6 3 - 4 - 5 Mixed/Trisomic
F532/72 pci 27 1 -4 4 - 5 4 - 5 3 - 5 3 - 5 Same as 
F532/72 mcl 5
F532/72 pci 28 1 -4 3 - 5 3 - 5 3 - 5 3 - 5 Replaced with 
F532/72 bsci 1
F532/72 pci 29 1 -3 4 - 5 4 - 5 3 -5 4 - 5 Same as batch 
2, F532/72 pcil
F532/72 pci 30 1 -4 4 - 5 3 - 5 3 - 5 3 - 5 Same as 
F532/72 mcl 1
F532/72 pci 31 1 -4 3 - 5 3 - 5 3 - 5 3 - 5 Replaced with 
F532/72 bsci 1
F532/72 pci 32 1 -4 3 - 5 3 -5 3 -5 3 - 5 Replaced with 
F532/72 bsci 1
F532/72 pci 33 1 -4 3 - 5 3 - 5 4 - 5 4 - 5 Replaced with 
F532/72 bsci 2
F532/72 pci 34 1 -3 3 - 4 - 5 4 - 5 3 - 5 3 - 4 - 5 Mixed/Trisomic
F532/72 pci 35 1 -4 3 - 5 3 - 5 4 - 5 4 - 5 Replaced with 
F532/72 bsci 2
F532/72 pci 36 1 -3 3 - 4 - 5 4 - 5 4 - 6 3 - 4 - 5 Mixed /T risomic
F532/72 pci 37 1 -4 3 - 5 3 - 5 3 - 5 3 - 5 Replaced with 
F532/72 bsci 1
F532/72 pci 38 1 -4 3 - 5 3 - 5 4 - 5 4 - 5 Replaced with 
F532/72 bsci 2
F532/72 pci 39 1 -4 4 - 5 4 - 5 3 - 5 3 - 5 Same as 
F532/72 mcl 5
F532/72 pci 40 1 -4 3 - 5 3 -5 4 - 5 4 - 5 Replaced with 
F532/72 bsci 2
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Markers
Identification CRAM 292 MS42 JS2 PLC Comments
Parental 247 1-1 5 - 5 5 - 5 5 - 6 5 - 5
Parental 927 
Procyclic Cloning 
Cross 247 X 927
3 - 4 3 - 4 3 - 4 3 - 4 3 - 4
Batch 4 Cont
F532/72 pci 41 1 -3 3 - 4 - 5 4 - 5 3 - 5 3 - 5 Mixed/Trisomic
F532/72 pci 42 1 -4 3 - 5 3 - 5 3 - 5 3 - 5 Replaced with 
F532/72 bsci 1
F532/72 pci 43 1 -4 3 - 5 3 - 5 4 - 5 4 - 5 Replaced with 
F532/72 bsci 2
F532/72 pci 44 1 -4 3 - 5 3 - 5 3 -5 3 - 5 Replaced with 
F532/72 bsci 1
F532/72 pci 45 1 -4 3 - 5 3 - 5 4 - 5 4 - 5 Replaced with 
F532/72 bsci 2
F532/72 pci 46 1 -3 4 - 5 3 - 5 3 - 4 - 5 3 - 4 - 5 Mixed/Trisomic
F532/72 pci 47 1 -4 4 - 5 4 - 5 3 - 6 3 -5 Same as 
F532/72 mcl 9
F532/72 pci 48 1 -4 4 - 5 4 - 5 4 - 5 3 -5 Same as 
F532/72 mcl 3
F532/72 pci 49 1 -4 3 - 5 3 - 5 4 - 5 4 - 5 Replaced with 
F532/72 bsci 2
F532/72 pci 50 1 -4 4 - 5 3 - 5 4 - 5 4 - 5 Same as 
F532/72 mcl 2
F532/72 pci 51 1 -4 3 - 5 3 - 5 4 - 6 3 - 5 Same as 
F532/72 pci 7
F532/72 pci 52 1 -4 3 - 5 3 - 5 3 - 5 3 - 5 Replaced with 
F532/72 bsci 1
F532/72 pci 53 1 -3 4 - 5 3 - 5 4 - 5 3 - 5 Same as 
F532/72 pci 5
F532/72 pci 54 1 -4 4 - 5 4 - 5 3 - 6 3 - 5 Same as 
F532/72 mcl 9
F532/72 pci 55 1 -3 3 - 4 - 5 4 - 5 4 - 6 4 - 5 Mixed/Trisomic
F632/72 pci 56 1 -3 4 - 5 4 - 5 3 - 5 4 - 5 Same as batch 
2, F532/72 pci 1
F532/72 pci 57 1 -4 4 - 5 3 - 4 - 5 4 - 5 3 - 4 - 5 Mixed/Trisomic
F532/72 pci 58 1 " 4 3 - 5 3 - 5 4 - 6 3 - 5 Same as 
F532/72 pci 7
F532/72 pci 59 1 -4 4 - 5 3 - 5 3 - 5 3 - 5 Same as 
F532/72 mcl 1
F532/72 pci 60 1 -3 3 - 4 - 5 3 - 5 4 - 6 4 - 5 Mixed/Trisomic
F532/72 pci 61 1 -4 4 - 5 4 - 5 4 - 5 3 - 5 Same as 
F532/72 mcl 3
F532/72 pci 62 1 -4 3 - 5 3 - 5 3 -5 3 - 5 Replaced with 
F532/72 bsci 1
F532/72 pci 63 1 -3 4 - 5 3 - 5 4 - 5 3 - 5 Same as 
F532/72 pci 5
F532/72 pci 64 1 -4 3 - 5 3 - 4 - 5 3 - 6 3 - 4 - 5 Mixed/Trisomic
F532/72 pci 65 1 -4 3 - 5 3 - 5 4 - 5 4 - 5 Replaced with 
F532/72 bsci 2
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Table A2.A Cont in vitro cloning of STIB 247 x TREU 927
Markers
Identification CRAM 292 MS42 JS2 PLC Comments
Parental 247 1 -1 5 - 5 5 - 5 5 - 6 5 - 5
Parental 927 
Procyclic Cloning 
Cross 247 x 927
3 - 4 3 - 4 3 - 4 3 - 4 3 - 4
Batch 4 Cont
F532/72 pci 66 1 -4 4 - 5 3 - 5 4 - 5 4 - 5 Same as 
F532/72 mcl 2
F532/72 pci 67 1 -3 4 - 5 3 - 4 - 5 4 - 6 3 - 4 - 5 Mixed/T risomic
F532/72 pci 68 1 -4 3 - 5 3 - 5 4 - 5 4 - 5 Replaced with 
F532/72 bsci 2
F532/72 pci 69 1 -4 3 - 5 3 - 5 4 - 6 3 - 5 Same as 
F532/72 pci 7
F532/72 pci 70 1 -4 3 - 4 - 5 4 - 5 3 - 5 4 - 5 Mixed/Trisomic
F632/72 pci 71 1 -3 4 - 5 4 - 5 3 - 5 4 - 5 Same as batch 
2, F532/72 pci 1
F532/72 pci 72 1 -4 3 - 5 3 - 5 3 - 5 3 - 5 Replaced with 
F532/72 bsci 1
F532/72 pci 73 1 -3 4 - 5 3 - 5 4 - 5 3 - 5 Same as 
F532/72 pci 5
F532/72 pci 74 1 -4 3 - 5 4 - 5 4 - 6 3 - 4 - 5 Mixed/Trisomb
F532/72 pci 75 1 -4 4 - 5 4 - 5 3 - 6 3 - 5 Same as 
F532/72 mcl 9
F532/72 pci 76 1 -3 3 - 4 - 5 3 - 4 - 5 3 - 5 4 - 5 Mixed/Trisomb
F532/72 pci 77 1 -4 3 - 4 - 5 3 - 5 3 - 6 3 - 5 Mixed/Trisomb
F532/72 pel 78 1 -3 4 - 5 4 - 5 3 -5 4 - 5 Same as batch 
2, F532/72 pci 1
F532/72 pci 79 1 -4 3 - 5 3 - 5 3 - 5 3 - 5 Replaced with 
F532/72 bsci 1
F532/72 pci 80 1 -4 4 - 5 4 - 5 4 - 5 3 - 5 Same as 
F532/72 mcl 3
F532/72 pci 81 1 -4 4 - 5 3 - 5 3 - 4 - 5 3 - 4 - 5 Mixed/Trisomb
F532/72 pci 82 1 -4 3 - 5 4 - 5 4 - 5 3 - 5 Same as 
F532/72 mcl 8
F532/72 pci 83 
Batch 5
1 -4 3 - 5 3 - 5 4 - 5 3 - 4 - 5 Mixed/T risomic
F532/72 p e ll -121 1 -4 3 - 5 3 - 5 3 - 5 3 - 5 All same 
genotype, 
Replaced with 
F532/72 bsci 1
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Table A2.B In vivo cloning STIB 247 x TREU 927
Appendix
Markers
Identification CRAM 292 MS42 JS2 PLC Comments
Parental 247 1 -1 5 - 5 5 - 5 5 - 6 5 - 5
Parental 927 
Bloodstream Cloning 
Cross 247 x 927
3 - 4 3 - 4 3 - 4 3 - 4 3 - 4
F532/72
F532/72 bscl 1 1 -4 3 - 5 3 - 5 3 - 5 3 - 5 New Genotype
F532/72 bscl 2 1 -4 3 - 5 3 - 5 4 - 5 4 - 5 New Genotype
F532/72 bscl 3 1 -4 3 - 4 - 5 3 - 5 3 - 5 3 - 5 Mi)œd/Trisomlc
F532/72 bscl 4 1 -4 4 - 5 3 - 5 3 - 5 3 - 5 Same as 
F532/72 mcl 1
F532/72 bscl 5 1 -3 3 - 5 3 - 5 4 - 5 4 - 5 Same as 
F532/72 mcl 6
F532/72 bscl 6 1 -4 3 - 5 3 - 5 3 - 4 - 5 4 - 5 Mixed/Trisomic
F532/72 bscl 7 1 -4 3 - 4 - 5 3 - 5 4 - 5 3 - 5 Mixed/T risomic
F532/72 bscl 8 1 -3 3 - 5 3 -5 4 - 5 4 - 5 Same as 
F532/72 mcl 6
F532/72 bscl 9 1 -4 3 - 4 - 5 3 - 5 3 - 5 4 - 5 Mixed/Trisomic
F532/72 bscl 10 1 -4 4 - 5 3 - 4 - 5 3 - 5 4 - 5 Mixed/Trisomic
F532/72 bscl 11 1 -4 3 - 5 3 - 5 3 - 5 3 - 5 Same as 
F532/72 bscl 1
F532/72 bscl 12 1 -4 3 - 5 3 - 5 3 -5 3 - 5 Same as 
F532/72 bscl 1
F532/72 bscl 13 1 -4 3 - 4 - 5 3 - 5 3 - 5 4 - 5 Mixed/Trisomic
F532/72 bscl 14 1 -3 3 - 4 - 5 3 - 5 3 - 5 3 - 5 Mixed/Trisomic
F532/72 bscl 15 1 -4 3 - 5 3 - 5 4 - 5 - 6 3 - 5 Mixed/Trisomic
F532/72 bscl 16 1 -4 3 - 5 3 - 5 4 - 5 4 - 5 Same as 
F532/72 bscl 2
F532/72 bscl 17 1 -4 3 - 5 3 - 5 3 - 5 3 - 5 Same as 
F532/72 bscl 1
F532/72 bscl 18 
Batch 1 F124/28
1 -4 3 - 5 3 - 5 3 - 5 3 - 5 Same as 
F532/72 bscl 1
FI 24/28 bscl 1 1 -3 4 - 5 3 - 5 4 - 6 3 - 5 New Genotype
F I24/28 bscl 2 1 -4 4 - 5 4 - 5 4 - 5 - 6 4 - 5 Mixed/Trisomic
F124/28 bscl 3 1 -3 3 - 5 4 - 5 4 - 5 4 - 5 New Genotype
F124/28 bscl 4 3 - 4 3 - 4 3 - 4 3 -4 3 - 4 Parental
F124/28 bscl 5 1 -4 3 - 5 4 - 5 3 - 5 4 - 5 New Genotype
F124/28 bscl 6 
Batch 2 F124/28
1 -3 4 - 5 3 - 5 4 - 6 3 - 5 Same as 
F I24/28 bscl 1
F I24/28 bscl 1 1 - 3 - 4 4 - 5 3 - 4 - 5 3 - 4 - 5 4 - 5 Mixed/Trisomic
F I24/28 bscl 2 1 - 3 - 4 3 - 4 - 5 3 - 4 - 5 3 - 4 - 5 4 - 5 Mixed/Trisomic
F124/28bscl3 1 -4 4 - 5 3 - 4 - 5 3 - 4 - 5 4 - 5 Mixed/T risomic
F I24/28 bscl 4 1 -3 3 - 4 - 5 3 - 4 - 5 3 - 4 - 5 3 - 4 - 5 Mixed/Trisomic
F124/28 bscl 5 1 -4 3 - 4 - 5 3 - 4 - 5 3 - 4 - 5 3 - 4 - 5 Mixed/Trisomic
F I24/28 bscl 6 1 -4 3 - 4 - 5 3 - 4 - 5 3 - 4 - 5 4 - 5 Mixed/Trisomic
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Table A2.B Cont In vivo cloning STIB 247 x TREU 927
Appendix
Markers
Identification CRAM 292 MS42 JS2 PLC Comments
Parental 247 1 -1 5 -5 5 -5 5 -6 5 -5
Parental 386 1 -2 1 -2 1 -2 1 -2 1 -2
Parental 927 
Bloodstream Cloning 
Cross 247 x 927
3 -4 3 -4 3 -4 3 -4 3 -4
Batch 2 F I24/28
F124/28bscl7 1 -3 3 - 4 - 5 3 - 4 - 5 3 - 4 - 5 4 - 5 Mixed/T risomic
F124/28bscl8 1 -4 3 - 4 - 5 3 - 4 - 5 3 - 4 - 5 3 - 4 - 5 Mixed/Trisomic
F124/28 bscl 9 1 -4 3 - 5 3 - 5 3 - 6 3 - 5 New Genotype
F124/28 bscl 10 1 -3 3 - 4 - 5 3 - 4 - 5 3 - 4 - 5 3 - 5 Mixed/Trisomic
F124/28 bscl 11 1 -3 4 - 5 3 - 5 4 - 6 3 - 5 Same as Batch 
1 FI 24/28 bscl 1
F124/28 bscl 12 1 -4 3 - 5 3 - 5 4 - 6 3 - 5 New Genotype
F124/28bscl13 1 -3 3 - 5 3 - 5 4 - 6 3 - 5 New Genotype
F124/28 bscl 14 1 -4 3 - 5 4 - 5 3 - 5 3 - 5 New Genotype
F124/28 bscl 15 1 -3 4 - 5 4 - 5 4 - 5 4 - 5 New Genotype
F124/28 bscl 16 1 -3 3 - 4 - 5 3 - 4 - 5 4 - 6 3 - 4 - 5 Mixed/T risomic
F I24/28 bscl 17 1 -4 3 - 4 - 5 3 - 4 - 5 3 - 4 - 5 3 - 5 Mixed/Trisomic
F I24/28 bscl 18 1 -4 3 - 5 4 - 5 4 - 6 4 - 5 Same as 
F I24/28 bscl C5
F124/28 bscl 19 1 -4 3 - 5 4 - 5 4 - 6 4 - 5 Same as 
F I24/28 bscl C5
F I24/28 bscl 20 1 -3 3 - 5 3 - 5 4 - 5 F New Genotype
F124/28 bscl 21 1 -3 3 - 4 - 5 3 - 4 - 5 4 - 5 4 - 5 Mixed/Trisomic
F124/28 bscl 22 1 -4 4 - 5 4 - 5 4 - 5 4 - 5 New Genotype
F124/28 bscl 23 1 -4 3 - 4 - 5 3 - 4 - 5 3 - 4 - 5 3 - 4 - 5 Mixed/Trisomic
F124/28 bscl 24 1 -4 3 - 4 - 5 3 - 4 - 5 3 - 4 - 5 3 - 4 - 5 Mixed/Trisomic
F I24/28 bscl 25 1 -3 3 - 4 - 5 3 - 4 - 5 3 - 4 - 5 3 - 4 - 5 Mixed/Trisomic
F I24/28 bscl 26 1 -4 3 - 4 - 5 3 - 4 - 5 3 - 4 - 5 3 - 4 - 5 Mixed/Trisomic
F124/28 bscl 27 1 -4 3 - 5 4 - 5 3 - 5 4 - 5 Same as Batch 
1 F124/28 bscl 5
F I24/28 bscl 28 
F974/78
1 -4 4 - 5 4 - 5 4 - 5 4 - 5 Same as 
F124/28 bscl 22
F974/78 bscl 1 3 - 4 3 - 4 3 - 4 3 -4 3 - 4 Parental
F974/78 bscl 2 3 - 4 3 - 4 3 - 4 3 -4 3 - 4 Parental
F974/78 bscl 3 1 -4 4 - 5 3 - 5 4 - 5 4 - 5 New Genotype
F974/78 bscl 4 3 - 4 3 - 4 3 - 4 3 -4 3 - 4 Parental
F974/78 bscl 5 3 - 4 3 - 4 3 - 4 3 -4 3 - 4 Parental
F974/78bscl6 1 - 3 4 - 5 4 - 5 4 -6 3 - 5 New Genotype
F974/78 bscl 7 1 -4 3 - 5 3 - 5 4 - 5 4 - 5 New Genotype
F974/78 bscl 8 1 -4 4 - 5 3 - 5 4 - 5 4 - 5 Same as 
F974/78 bscl 3
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Table A2.B Cont In vivo cloning STIB 247 x TREU 927
Markers
Identification CRAM 292 MS42 JS2 PLC Comments
Parental 247 1 -1 5 -5 5 -5 5 -6 5 -5
Parental 927 
Bloodstream Cloning 
in vivo
Cross 247 x 927 
F974/78 Cont
3 -4 3 -4 3 -4 3 -4 3 -4
F974/78 bscl 9
Re-cloning of F532/72 
bscl 15
1 -3 4 - 5 4 - 5 4 - 6 3 - 5 Same as 
F974/78 bscl 6
F532/72 bscl 15/IB 1 -4 3 - 5 3 - 5 3 -5 3 - 5 Same as 
F532/72 bscl 1
F532/72 bscl 15/2B 1 -3 3 - 5 3 - 5 4 - 5 4 - 5 Same as 
F532/72 mcl 6
F532/72 bscl 15/3B 1 -4 3 - 5 3 - 5 4 - 5 4 - 5 Same as 
F532/72 bscl 2
F532/72 bscl 15/4B 1 -4 3 - 5 3 - 5 3 -5 3 - 5 Same as 
F532/72 bscl 1
F532/72 bscl 15/5B 1 -3 3 - 5 3 - 5 4 - 6 3 - 5 New Genotype
F532/72 bscl 15/6B 1 -4 3 - 5 3 - 5 3 -5 3 - 5 Same as 
F532/72 bscl 1
F532/72 bscl 15/7B 1 -3 3 - 5 3 - 5 4 - 6 3 - 5 Same as 
F532/72 bscl 
15/5B
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Table A2.C in vivo cloning STIB 247 x STIB 386
Appendix
Markers
Identification CRAM 292 MS42 JS2 PLC Comments
Parental 247 1 -1 5 -5 5 -5 5 -6 5 -5
Parental 386 
Bloodstream 
Cloning
Cross 247 x 386 
F9/41
1 -2 1 -2 1 -2 1 -2 1 -2
F9/41 bscl 1 1-1 2 - 5 2 - 5 1 -6 1 -5 New Genotype
F9/41 bscl 2 1-1 1 -5 1 -5 1 -6 1 -5 New Genot^e
F9/41 bscl 3 1-1 1 -5 1 -5 1 -6 1 -5 Same as F9/41 
bscl 2
F9/41 bscl 4 1 - 1 2 - 5 2 - 5 1 -6 1 -5 Same as F9/41 
bscl 1
F9/41 bscl 5 1 -2 2 - 5 2 - 5 1 -5 2 - 5 New Genotype 1
F9/41 bscl 6 1 -2 2 - 5 2 - 5 1 - 2 - 5 - 6 1 - 2 - 5 Mixed/Trisomic
F9/41 bscl 7 1 -2 2 - 5 2 - 5 1 -5 1 -5 New Genotypè"®
F9/41 bscl 8 1-1 2 - 5 1 - 5 1 - 5 1 - 5 New Genotype
F9M1 bscl 9 1 - 1 1 -5 1 -5 2-6 2 - 5 New Genotype
F9/41 bscl 10 1-2 2 - 5 2 - 5 1 -5 1 -5 Same as F9/41 
bscl 7
F9M1 bscl 11 
FI 9/31
1 -2 1 -5 1 -5 1 -5 2 - 5 New Genotype
F19/31 bscl 1 1-2 2 - 5 1 -5 1 -6 1 -5 New Genotype
F19/31 bscl 2 1 -2 1 - 2 - 5 1 - 5 1 - 6 2 - 5 Mixed/Trisomic
F I9/31 bscl 3 1 -2 1 -5 1 -5 2-6 2 - 5 Same as F19/31 
bscl 10
FI 9/31 bscl 4 1 -2 2 - 5 1 -5 1 -6 1 -5 Same as F19/31 
bscl 1
F19/31 bscl 6 1 -1 1 -5 1 -5 1 -6 2 - 5 New Genotype
FI 9/31 bscl 6 1 -1 1 -5 1 -5 1 -6 2 - 5 Same as F19/31 
bscl 5
F I9/31 bscl 7 1 -2 2 - 5 1 -5 1 -6 1 -5 Same as F19/31 
bscl 1
F I9/31 bscl 8 1-2 1 -5 1 -5 2 - 5 2 - 5 New Genotype
FI 9/31 bscl 9 1 - 1 1 -5 1 -5 1 -6 2 - 5 Same as F19/31 
bscl 5
F19/31 bscl 10 1 -2 1 -5 1 -5 2-6 2 - 5 New Genotype
F19/31 bscl 11 1-1 1 -5 1 -5 1 -5 2 - 5 New Genotype
F19/31 bscl 12 1 - 1 1 -5 1 -5 1 -6 2 - 5 Same as F19/31 
bscl 5
FI 9/31 bscl 13 1 -2 1 -5 1 -5 2-6 2 - 5 Same as F19/31 
bscl 10
FI 9/31 bscl 14 1 -2 1 -5 1 -5 2 - 5 2 - 5 Same as F19/31 
bscl 8
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Table A2.C Cont In  v iv o  cloning STIB 247 x STIB 386
Markers
Identification CRAM 292 MS42 JS2 PLC Comments
Parental 247 1 -1 5 -5 5 -5 5 -6 5 -5
Parental 386 
Bloodstream Cloning 
Cross 247 x 386
1 -2 1 -2 1 -2 1 -2 1 -2
F28/46
F28/46 bscl 1 1 - 1 1 -5 1 -5 2 - 5 1 -5 New Genotype
F28/46 bscl 2 1 - 1 1 -5 1 -5 2 - 5 1 -5 Same as F28/46 
bscl 1
F28/46 bscl 3 1 - 1 1 -5 1 -5 2 - 5 1 -5 Same as F28/46 
bsd 1
F28/46 bscl 4 1 -2 1 -5 1 -5 2-6 2 - 5 New Genotype
F28/46 bscl 5 1 -1 1 -5 1 -5 2 - 5 1 -5 Same as F28/46 
bscl 1
F28/46 bscl 6 1 -2 1 -5 1 -5 2 - 5 2 - 5 New Genotype
F28/46 bscl 7 1-1 2 - 5 1 -5 2 - 5 1 -5 New Genotype
F28/46 bscl 8 1 -2 2 - 5 2 - 5 2-6 2 - 5 New Genot^e
F28/46 bscl 9 1 -2 2 - 5 2 - 5 2-6 2 - 5 Same as F28/46 
bscl 8
F28/46 bscl 10 1 -2 1 -5 1 -5 2 - 5 2 - 5 Same as F28/46 
bscl 6
F28/46 bscl 11 
F29/46
1 -2 2 - 5 2 - 5 2 - 5 2 - 5 New Genotype
F29/46 bscl 1 1-1 2 - 5 1 -5 1 -5 1 -5 New Genotype
F29/46 bscl 2 1 -1 1 -5 1 -5 2-6 2 - 5 New Genotype
F29/46 bscl 3 1-1 1 -5 1 -5 2-6 2 - 5 New Genotype
F29/46 bscl 4 1-1 1 -5 1 -5 2-6 1 -5 New Genotype
F29/46 bscl 5 
F57/40
1 - 1 1 -5 1 -5 2-6 2 - 5 Same as F29/46 
bscl 3
F57/40 bscl 1 1 -2 1 -2 1 -2 1 -2 1 -2 Parental
F57/40 bscl 2 1-2 1-2 1 -2 1 -2 1-2 Parental
F57/40 bscl 3 1 -2 1 -2 1 -2 1 -2 1 -2 Parental
Table A2.A-C: Minisateliite analysis of all trypanosome clones derived from genetic crosses. (A)
Cross STIB 247 x TREU 927 procyclic clones (pci). (B) Cross STIB 247 x TREU 927 
bloodstream clones (bscl). (C) Cross STIB 247 x STIB 386 bloodstream clones (bscl). 
Column 1 indicates the hybrid clone identification number used throughout this study. 
Columns 2 -6  give the results of the mini- and microsatellite analysis. Alleles are 
numbered 1-5 for the minisatellites CRAM, 292, MS42 and PLC, and 1-6 for the 
microsatellite JS2. Column 7 gives the interpretation of the result for each clone. All 
clones that are genotypically unique are shaded. Clones exhibiting three band patte ms 
for one or more markers were considered either a mix or trisomie.
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